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• 'dicial District Court - Bannock 
ROAReport 
Case: CV-2009-0003869-PI Current Judge: Robert C Naftz 
Judy Nield vs. Pocatello Health Services, Inc. 
User: DCANO 
Judy Nield vs. Pocatello Health Services, Inc. 
Date 
10/1/2009 
10/26/2009 
11/12/2009 
1/16/2009 
i/19/2009 
12012009 
1412009 
18/2009 
Code 
LOCT 
NCPI 
SMIS 
COMP 
ATTR 
ATTR 
HRSC 
HRSC 
User 
DCANO 
DCANO 
DCANO 
DCANO 
DCANO 
JANA 
CAMILLE 
MEGAN 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
NICOLE 
NICOLE 
DCANO 
CR 
New Case Filed-Personal Injury 
Summons Issued 
Verified Complaint and Demand for Jury Trial 
Filed 
Judge 
Peter D. McDermott 
Peter D. McDermott 
Peter D. McDermott 
Peter D. McDermott 
Filing: A - All initial civil case filings of any type not Robert C. Naftz 
listed in categories B-H, or the other A listings (Magistrate) 
below Paid by: cooper and larsen Receipt 
number: 0036486 Dated: 10/1/2009 Amount: 
$88.00 (Check) For: 
Plaintiff: Nield, Judy Attorney Retained Reed W Peter D. McDermott 
Larsen 
Affidavit of return; srvd on Pocatello Health Robert C Naftz 
services inc. thru Gard Skinner on 10-16-09 
Filing: 11 - Initial Appearance by persons other Robert C Naftz 
than the plaintiff or petitioner Paid by: Hall Farley 
Oberrecht & Blanton P.A. Receipt number: 
0041727 Dated: 11/12/2009 Amount: $58.00 
(Check) For: Pocatello Health Services, Inc. 
(defendant) 
Def Pocatello Health services, inc Pocatello care Robert C Naftz 
and Rehabilitation centers Answer to Plntts 
Verified complaint and demand for Jury Trial; 
aty Keely Duke for def Pocatello Health 
Defendant: Pocatello Health Services, Inc. Robert C Naftz 
Attorney Retained Keely E Duke 
Notice of service - Def Pocatello Health services, Robert C Naftz 
Inc. dba Pocatello care and rehabilitation centers 
first set of Interrog. and requests for production of 
documents to plntt: aty Keely Duke for def 
Notice of Depo of Judy Nield on 1-12-2010 @ Robert C Naftz 
9am: aty Chris Comstock for def 
Order for submission of information for Robert C Naftz 
scheduling Order; Plntt shall submit to the court, 
within 14 days of the date of this Order, a 
Stipulated statement: J Naftz 11-19-09 
Notice of sevice - Plntts First set of Discovery to Robert C Naftz 
Def Pocatello Health Services, Inc. aty Reed 
larsen for plntt 
Stipulated Statement; aty Reed Larsen for plntt Robert C Naftz 
Hearing Scheduled (Jury Trial 11/16/201009:00 Robert C Naftz 
AM) 10-12 days requested 
Hearing Scheduled (Jury Trial 02/15/2011 09:00 Robert C Naftz 
AM) 10 - 12 days requested 
Scheduling Order, Notice of Trial Setting and 
Initial Pretrial Order 
Robert C Naftz 
UCHI:'. 01 I ,,"',,"U I r 
Time: 09:36 AM 
Page 2 of 10 
.htdicial District Court· Bannock User: DCANO 
ROAReport 
Case: CV-2009-0003869-PI Current Judge: Robert C Naftz 
Judy Nield vs. Pocatello Health Services, Inc. 
Judy Nield vs. Pocatello Health Services, Inc. 
Date Code User 
12/14/2009 CAMILLE 
12/21/2009 CAMILLE 
12/29/2009 CAMILLE 
12/30/2009 CAMILLE 
1/4/2010 CAMILLE 
1/8/2010 CAMILLE 
4/21/2010 CAMILLE 
6/212010 CAMILLE 
6/10/2010 CAMILLE 
6/11/2010 CAMILLE 
6/16/2010 CAMILLE 
6/29/2010 CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
Judge 
Notice of service - Plntfs Discovery Responses to Robert C Naftz 
Def Pocatello Health Care: aty Reed larsen for 
plntf 
Notice Vacating Depo of Judy Neild; aty Keely Robert C Naftz 
Duke for defs 
Amended Notice of Depo of Judy Nield on Robert C Naftz 
2-18-2010: aty Chris Comstock 
Notice of service - Answers to Plntfs First set of Robert C Naftz 
Interrog and REq for Production of Documents wi 
this notice of service: aty Keely Duke for defs 
Notice of Service - Plntfs Supplemental Discovery Robert C Naftz 
Responses to Def Pocatello Health Services, Inc; 
aty Reed Larsen for pInt 
Second Amended Notice of Depositoin; set for Robert C Naftz 
2-24-2010 @ 9am: aty Chris Comstock 
Plaintiffs witness Disclosures; aty Reed Larsen Robert C Naftz 
for Plaintiff 
Notice of service - Plntfs Second Supplemental Robert C Naftz 
Discovery Responses to def Pocatello Care & 
Rehabilitation Centers First set of Interrog and req 
for production of Documents to plntf: aty Reed 
Larsen for plntf 
Stipulation to Amend Scheduling Order; aty Robert C Naftz 
Keely Duke for Def Pocatello Health Service 
Notice of Service - Plntfs Third Supplemental Robert C Naftz 
Discovery Responses to Defendant Pocatello 
Health Services, Inc. and this Notice: aty 
Reed Larsen for p Intf 
Order granting Stipulation to Amend Scheduling Robert C Naftz 
Order; sl Judge Naftz 6-16-2010 
Notice of Deposition of Mary Akina on 7-12-2010 Robert C Naftz 
@ 8:30 am: aty Reed Larsen for plntf 
Notice of Deposition of Melody Lee on 7-12-2010 Robert C Naftz 
@ 10:30 am: aty Reed Larsen for plntf 
Notice of Deposition of Wendy Sneddon on Robert C Naftz 
7-12-2010 @ 1:30 pm: aty Reed Larsen 
Notice of Deposition of DAna Camphouse on Robert C Naftz 
7-12-2010 @ 3:30 pm: aty Reed Larsen fo 
rplntf 
Notice of Deposition of Lachelle Pratt on Robert C Naftz 
7-13-2010 @ 8:30 am: aty Reed Laren for plntf 
Notice of Deposition fo Jill Schuette on 7-13-2010 Robert C Naftz 
@ 10:30 am: aty Reed Larsen for plntf 
Notice of Deposition of TAra Tanner on Robert C Naftz 
7-13-2010 @ 1:30 pm: aty Reed Larsen for plntf 
Notice of DepOSition of Connie Funk on Robert C Naftz 
7-13-2010 @ 3:30 pm: aty Reed Larsen for plntf 
Udlt::. 01 ILILU I I 
Time: 09:36 AM 
Page 3 of 10 
:SIxth .1·'(1IcI81 District Court - Bannock 
ROAReport 
Case: CV-2009-0003869-PI Current Judge: Robert C Naftz 
Judy Nield vs. Pocatello Health Services, Inc. 
User: DCANO 
Judy Nield VS. Pocatello Health Services, Inc. 
Date Code User 
6/29/2010 CAMILLE 
7/212010 CAMILLE 
7/8/2010 CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
7/22/2010 CAMILLE 
7/26/2010 CAMILLE 
CAMILLE 
CAMILLE 
3/412010 HRSC NICOLE 
3/6/2010 CAMILLE 
3/20/2010 HRVC NICOLE 
Notice of Depositon of Debra Cheatum on 
7-14-2010 @8:30 am: aty Reed Larsen 
Judge 
Robert C Naftz 
Notice of service - First Supplemental Answers to Robert C Naftz 
Plntfs First set of Interrog and requests for 
Production of Documents and this Notice: aty 
Keely Duke 
Amended Notice of Deposition of connie Funk on Robert C Naftz 
7-13-2010 @ 1pm: aty Reed Larsen for plntf 
Amended Notice of Deposition of Debra Robert C Naftz 
Cheatum; set for 7-13-2010 @ 2pm: aty Reed 
larsen for plntf 
Amended Notice of Deposition of Melody Lee on Robert C Naftz 
7-13-2010 @ 3pm: aty Reed Larsen for plntf 
Amended Notice of Deposition of Lachelle Pratt Robert C Naftz 
on 7-14-2010 @ 8am: aty Reed Larsen for plntf 
Amended Notice of Deposition of Dana Robert C Naftz 
Camphouse on 7-14-2010 @ 9am: aty Reed 
Larsen for plntf 
Amended Notice of Deposition of Mary Akina on Robert C Naftz 
7-14-2010 @ 10am: aty Reed Larsen for plntf 
Amended Notice of Deposition of Wendy Robert C Naftz 
Sneddon on 7-14-2010 @ 11am: aty Reed 
Larsen for plntf 
Amended Notice of Deposition of Jill Schuette on Robert C Naftz 
7-14-2010 @ 1:30 pm: aty Reed Larsen for plntf 
Amended Notice of Deposition of Tara Tanner on Robert C Naftz 
7-14-2010 @ 2:30 pm: aty Reed Larsen for plntf 
Defendants Pocatello care and Rehabilitation Robert C Naftz 
Centers expert witness disclosure: aty Keely 
Duke 
Motion for stay of Proceedings; aty Reed Larsen Robert C Naftz 
for plntf 
Affidavit of Reed Larsen in Support of Motion to Robert C Naftz 
Stay Proceedings; aty Reed Larsen for pltnf 
Notice of service - Def Pocatello I-iEtalth services Robert C Naftz 
Inc. Pocatello Care and Rehabilitation Centers 
Answers to Plntfs First set of Interog. aty Keely 
Duke for def 
Hearing Scheduled (Motion for Summary 
Judgment 09/13/201001:30 PM) 
Robert C Naftz 
Notice of Hearing; set for Plntfs Motion for Stay Robert C Naftz 
of Proceedings: on 8-23-2010 @ 1 :30 pm: aty 
Reed Larsen for plntf 
Hearing result for Motion for Summary Judgment Robert C Naftz 
held on 09/13/201001:30 PM: Hearing Vacated 
upon request of Defendant 
• __ .. _. V, , .... ,"-V I I 
Time: 09:36 AM 
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»IAUI ,",UUICliU UIStfict c.;ourt - Bannock User: DCANO 
ROAReport 
Case: -LUU~-UUL'.jtjC::>~-11"'1 Current Judge: Robert C Naftz 
Judy Nield vs. Pocatello Health Services, Inc. 
Judy Nield vs. Pocatello Health Services, Inc. 
Date Code 
8/2012010 HRVC 
8/23/2010 HRVC 
8/24/2010 HRSC 
10/8/2010 
10/21/2010 CO NT 
10/28/2010 
11/15/2010 
User 
NICOLE 
CAMILLE 
NICOLE 
CAMILLE 
NICOLE 
CAMILLE 
CAMILLE 
CAMILLE 
DCANO 
NICOLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
Hearing result for Motion held on 08/23/2010 
01 :30 PM: Hearing Vacated Motion for Stay of 
Proceedings upon request of Plaintiff 
Stipulation to Vacate; aty Reed Larsen for plntf 
Judge 
Robert C Naftz 
Robert C Naftz 
Hearing result for Jury Trial held on 11/16/2010 Robert C Naftz 
09:00 AM: Hearing Vacated 10-12 days 
requested 
Order granting Stipulation to Vacate Trial; sl Robert C Naftz 
Judge Naftz 8-20-2010 (this matter shall be reset 
to 2-15-28, 2011) 
Hearing Scheduled (Motion for Summary 
Judgment 11/08/201001:30 PM) 
Robert C Naftz 
Defendant Pocatello Health services, Inc DBA Robert C Naftz 
Pocatello care and rehabiltation centers Motin for 
Summary Judgment; aty Keely Duke for def 
Memorandum in Support of Def Pocatello Health Robert C Naftz 
Services, Inc DBA Pocatello Care and 
Rehabilitation Centers Motion for summary 
Judgment; aty Keely Duke 
Affidavit of Keely Duke in Support of Defendant Robert C Naftz 
Pocatello care and Rehabilitation centers Motion 
for Summary Judgment; aty Keely Duke for def 
Affidavit of Thomas J. Coffman, MD, in Support of Robert C Naftz 
Defendant Pocatello Health Services, Inc. D/B/A 
Pocatello Care and Rehabilitation Centers Motion 
for Summary Judgment; Keely E. Duke, Attys for 
Dfdts. 
Continued (Motion for Summary Judgment Robert C Naftz 
12/13/2010 01 :30 PM) Defendant's Motion upon 
request of defense 
Notice of Deposition of Laree Dun on 11-9-2010 Robert C Naftz 
@ 9am: aty Javier Gabiola 
Notice of Deposition of Joyce Maxfield on Robert C Naftz 
11-9-2010 @ 1pm: aty Javier Gabiola for plntf 
Notice of Deposition of Thomas Coffman MD: Robert C Naftz 
on 11-11-2010 @ 9:30am: aty Javier Gabiola 
for plntf 
Notice of Deposition Derick Glum on 11-16-2010 Robert C Naftz 
@ 9:30 am: aty Javier Gabiola for plntf 
Notice of Depositon of Marji Brim on 11-19-2010 Robert C Naftz 
@ 1 :30pm: aty Javier Gaboiola for plntf 
Stipulation to vacate trial and amend scheduling Robert C Naftz 
order; aty Keely Duke 
Amended Notice of Deposition of Thomas J Robert C Naftz 
Coffman, MD: (11-19-20109am) aty Javier 
Gabiola for plntf 
uate: til12/2011 
Time: 09:36 AM 
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I'ldicial District Court - Bannock 
ROAReport 
Case: CV-2009-0003869-PI Current Judge: Robert C Naftz 
Judy Nield vs. Pocatello Health Services, Inc. 
User: DCANO 
Judy Nield vs. Pocatello Health Services, Inc. 
Date Code 
11/15/2010 
11/18/2010 
11/29/2010 
11/30/2010 HRSC 
12/112010 
21212010 
User 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
NICOLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
Judge 
Amended Notice of Deposition of Joyce Maxfield; Robert C Naftz 
set for Joyce Maxfield on 11-17-2010 1 pm): aty 
Javier Gabolia for plntt 
Amended Notice of Deposiiton of Derrick Glum; Robert C Naftz 
on 11-16-2010 @ 8:30 am: atyJavier Gabolia 
for plntt 
Amended Notice of hearing; set for 12-13-2010 Robert C Naftz 
@ 1 :30 pm: aty Keely Duke for Def. 
Defendant Pocatello care and rehabilitation Robert C Naftz 
centers first supplemental expert witness 
disclosure; aty Keely Duke 
Amended Notice of Deposition ofTaree Dunn on Robert C Naftz 
11-17-2010 @ 9am: aty Javier Gabiola for p Intt 
Memorandum in support of Plaintiffs Motion to Robert C Naftz 
Strike the Affidavit of Dr. Coffman: aty Reed 
Larsen for plntt 
Motion to continue hearing on Summary Robert C Naftz 
Judgment or in the Alternative Additional time to 
suppplement the record: aty Reed Larsen for 
plntt 
Memorandum in support of pints motion to Robert C Naftz 
continue hearing on summary judgment or in the 
alternative additional time to supplement the 
record; aty Reed Larsen for plntt 
Memorandum in opposition to defendants motion Robert C Naftz 
for summary judgment; aty Reed Larsen for 
plntt 
Affidavit of Reed Larsen in support of plntts Robert C Naftz 
opposition to defs motion for summary judgment; 
aty Reed Larsen for plntt 
Hearing Scheduled (Motion 12/13/201001:30 Robert C Naftz 
PM) Motion to Strike Affidavit of Dr. Coffman 
Affidavit of Suzanne Frederick; aty Suzann 
Frederick for plntt 
Robert C Naftz 
Motion to strike the Affidavit of Dr. Coffman; aty Robert C Naftz 
Reed Larsen for plntt 
Affidavit of Javier Gabiola in support of plntts Robert C Naftz 
motion to continue hearing on summary judgment 
or in the alternative additional time to 
supplemental the record: aty Reed Larsen for 
plntt 
Affidavit of Hughes Selznick, MD; aty Reed Robert C Naftz 
Larsen for plntt 
Affidavit of Sidney Gerber; Robert C Naftz 
Notice of hearing; set for 12-13-2010 @ 1:30 Robert C Naftz 
pm: aty Reed Larsen for plntt 
ualt::. 0/ I,{,U II 
Time: 09:36 AM 
Page 6 of 10 
s icia' District Court - Bannock User: DCANO 
ROAReport 
Case: CV-2009-0003869-PI Current Judge: Robert C Naftz 
Judy Nield vs. Pocatello Health Services, Inc. 
Judy Nield vs. Pocatello Health Services, Inc. 
Date Code User 
12/6/2010 CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
218/2010 CO NT NICOLE 
CAMILLE 
2/9/2010 CINDYBF 
CINDYBF 
CINDYBF 
U17/2010 CAMILLE 
21/2011 HRVC NICOLE 
Judge 
Motion to strike portions of the affidavit s of Hugh Robert C Naftz 
Selznick, MD Suzanne Frederick and Sidney 
Gerber; aty Keely Duke for def 
Memorandum in Opposition to plntfs Motion to Robert C Naftz 
continue hearing on summary Judgment or in the 
Alternative Additional time to supplement the 
record: aty Keely Duke for def 
Motion to Shorten Time Regarding Motin to Strike Robert C Naftz 
Portions of the Affidavits of Hugh Selznick, MD 
Suzanne Frederick and Sidney Gerber; aty 
Keely Duke for def 
Notice of Hearing regarding motion to strike Robert C Naftz 
portions of the affidavit s of Hug Selznick, MD 
Suzann Frederick and Sidney Gerber: aty 
KeelyDuke for def 
Memorandum in Opposition t oplntf to plntfs Robert C Naftz 
motion to strike the affidavit of Dr. Coffman; aty 
Keely Duke for def 
Reply Memorandum in support of def pocatello Robert C Naftz 
Health services, Inc DBA Pocatello care and 
rehabiliation centers motion for summary 
judgment. aty Keely Duke for Def 
Memorandum in support of motion to strike 
portions of the affidavit of Hugh Selznick, MD 
Suzanne Frederrick and Sidney Gerber; aty 
Keely Duke 
Continued (Jury Trial 10/25/2011 09:00 AM) 
10-12 days requested; 9 scheduled 
Robert C Naftz 
Robert C Naftz 
Order granting stipulation to amend scheduling Robert C Naftz 
order; sl Judge Naftz 11-22-2010 
Reply Memorandum in Support of Plaintiffs Robert C Naftz 
Motion to Continue Hearing on Summary 
Judgment or in the Alternative Additional Time to 
Supplement the Record- by PA Larsen. 
Reply Memorandum in Support of Plaintiffs Robert C Naftz 
Motion to Strike the Affidavit of Dr. Coffman- by 
PA Larsen. 
Memorandum in Opposition to Defendant's Robert C Naftz 
Motion to Strike Portions of the Affidavits of Hugh 
Selznick, MD, Suzanne Frederick and Sidney 
Gerber- by PA Larsen. 
Notice of service - Plaintiffs Second set of Robert C Naftz 
Discovery to Defendant: aty Javier Gabiola for 
plntf 
Hearing result for Motion held on 12113/2010 Robert C Naftz 
01 :30 PM: Hearing Vacated Motion to Continue 
Hearing on Summary Judgment; withdrawn by 
Plaintiff 
Time: 09:36 AM 
Page 7 of 10 
";IALII ""'UI'->Ii:U UI5trlCt lOOUn - t:5annock 
Case: Current Judge: Robert C Naftz 
Judy Nield VS. Pocatello Health Services, Inc. 
User: DCANO 
Judy Nield VS. Pocatello Health Services, Inc. 
Date Code User 
1/21/2011 DCHH NICOLE 
DCHH NICOLE 
CAMILLE 
2/412011 CAMILLE 
CAMILLE 
2/8/2011 HRSC NICOLE 
2/9/2011 CAMILLE 
2/18/2011 CAMILLE 
212412011 STIP DCANO 
U25/2011 CO NT NICOLE 
CAMILLE 
11312011 OR DR DCANO 
128/2011 INHD BRANDY 
1312011 HRVC BRANDY 
CAMILLE 
Hearing result for Motion held on 12/13/2010 
01 :30 PM: District Court Hearing Held 
Court Reporter: Stephanie Davis 
Number of Transcript Pages for this hearing 
estimated: less than 100 pages 
Motion to Strike Affidavit of Dr. Coffman 
Judge 
Robert C Naftz 
Hearing result for Motion for Summary Judgment Robert C Naftz 
held on 12/13/201001:30 PM: District Court 
Hearing Held 
Court Reporter: Stephanie Davis 
Number of Transcript Pages for this hearing 
estimated: less than 100 pages 
Defendant's Motion 
Memorandum Decision and Order; Defendants Robert C Naftz 
Motion for Summary Judgment is hereby 
GRANTED: sl Judge Naftz 1-21-2011 
Plaintiffs motion for reconsideration; aty Reed Robert C Naftz 
Larsen for plntf 
Memorandum in support of Plaintiffs Motion for Robert C Naftz 
Recosnsideration; aty Reed Larsen for plntf 
Hearing Scheduled (Motion 02/28/2011 01 :30 Robert C Naftz 
PM) Motion for Reconsideration (Plaintiff) 
Notice of hearing; set for plntf motion for Robert C Naftz 
reconsideration on 2-28-2011 @ 1 :30 pm: aty 
Javier Gabiola for plntf 
Pocatello Health services, inc dba Pocatello care Robert C Naftz 
and rehabilitation centers Memorandum in 
opposition to plntfs motion for reconsideration; 
aty Keely Duke for def 
Stipulation to Vacate Hearing on Motion for Robert C Naftz 
Reconsideration; Keely E. Duke, Atty for Dfdts. 
Continued (Motion 03/28/2011 01 :45 PM) Robert C Naftz 
Motion for Reconsideration (Plaintiff) per stipulatin 
Reply Memorandum in support of plaintiffs motion Robert C Naftz 
for reconsideration; aty Reed Larsen 
Order Granting Stipulation to Vacate Hearing on Robert C Naftz 
Plaintiffs Motion for Reconsideration; Javier L. 
Gabiola, Atty for Plntfs. 
Hearing result for Motion held on 03/28/2011 Robert C Naftz 
01 :45 PM: Interim Hearing Held Motion for 
Reconsideration (Plaintiff) 
Hearing result for Jury Trial held on 10/25/2011 Robert C Naftz 
09:00 AM: Hearing Vacated 10-12 days 
requested; 9 scheduled 
Memorandum Decision and Order; Plaintiffs 
Motion for rexonsideration is hereby DENIED; 
court will prepare judgment: sl Judge Naftz 
Robert C Naftz 
Udlt::. O/ILlLU II 
Time: 09:36 AM 
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.hldicial District Court - Bannock r ...... _'I .. User: OCANO 
ROAReport 
Case: CV-2009-0003869-PI Current Judge: Robert C Naftz 
Judy Nield vs. Pocatello Health Services, Inc. 
Judy Nield vs. Pocatello Health Services, Inc. 
Date 
5/3/2011 
5/12/2011 
5/17/2011 
5/18/2011 
5/19/2011 
5/24/2011 
5/25/2011 
3/26/2011 
Code 
JDMT 
CSTS 
APSC 
NOTC 
MISC 
HRSC 
CSTS 
MISC 
User 
CAMILLE 
CAMILLE 
NOELIA 
DCANO 
DCANO 
DCANO 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
CAMILLE 
NICOLE 
NICOLE 
DCANO 
CAMILLE 
CAMILLE 
CAMILLE 
Judge 
Judgment; court DENIED the plntf Motion for Robert C Naftz 
reconsideration, court is hereby ordered and 
adjudged that all of the plntfs claims against the 
def in this matter are dismissed withprej: sl 
Judge Naftz 5-3-2011 
Case Status Changed: Closed Robert C Naftz 
Filing: L4 - Appeal, Civil appeal or cross-appeal to Robert C Naftz 
Supreme Court Paid by: Larsen, Reed W 
(attorney for Nield, Judy) Receipt number: 
0016659 Dated: 5/12/2011 Amount: $101.00 
(Check) For: Nield, Judy (plaintiff) 
Appealed To The Supreme Court Robert C Naftz 
Notice of Appeal: Javier L. Gabiola, Atty for Robert C Naftz 
Plaintiff 
Received Check #27668 for $101.00 filing fee on Robert C Naftz 
Appeal and Check # 27669 for $100.00 for 
Deposit of Clerk's Record. 
Pocatello Health Services, Inc. dba Pocatello care Robert C Naftz 
and rehabilitation centers motion for costs; aty 
Keely Duke for Oef. 
Pocatello Health services, Inc dba Pocatello care Robert C Naftz 
and rehailitation centers verified Memorandum of 
costs; aty Keely Duke for def 
Affidavit of ocunsel in support of Memorandum for Robert C Naftz 
fees and costs; aty Keely Duke for def 
Pocatello Health services, Inc's Memorandum in Robert C Naftz 
support of Motion to amend Judgment; aty Keely 
Duke for def 
Pocatello Health services, Inc's Motion to Amend Robert C Naftz 
Judgment; aty Keely Duke 
Hearing Scheduled (Motion 06/13/2011 02:00 Robert C Naftz 
PM) Motion for Costs 
Motion to Amend Judgment 
Case Status Changed: Closed pending clerk Robert C Naftz 
action 
CLERK'S CERTIFICATE OF APPEAL: Signed Robert C Naftz 
and Mailed to Counsel and SC on 5-24-11. 
Notice of hearing; aty Keely Duke for def 
Defendant Pocatello Health services, Inc's 
requests for additions to the clerks record; aty 
Keely Duke 
Robert C Naftz 
Robert C Naftz 
Plaintiff's Memorandum i n Opposition to Def Robert C Naftz 
Pocatello Health services, Inc. dba Pocatello care 
and rehabilitation centers motion to amend 
judgment and motion for costs; aty Reed larsen 
Udlt::. O/ILILU"I"1 Sixth "'dicial District Court - Bannock Cou User: DCANO 
Time: 09:36 AM ROAReport 
Page 9 of 10 Case: CV-2009-0003869-PI Current Judge: Robert C Naftz 
Judy Nield vs. Pocatello Health Services, Inc. 
Judy Nield vs. Pocatello Health Services, Inc. 
Date Code User Judge 
5/27/2011 CAMILLE Affidavit of Javier Gabiola in support of plaintiffs Robert C Naftz 
Memorandum in opposition to defs pocatello 
health services, Inc dba pocatello care and 
rehabilitation centers motion to amend judgment 
and motion for costs; aty Reed larsen 
6/2/2011 MISC DCANO IDAHO SUPREME COURT; Notice of Appeal Robert C Naftz 
received in SC on 5-26-11. Docket Number # 
38823-2011. Clerk's Record and Reporter's 
Transcripts must be filed in SC on 8-3-11. 
(6-30-11 5 weeks prior). The following Transcritps 
to be lodged: Motion for Summary Judgment 
12-13-10 and Reconsideration 3-28-11. 
DCANO IDAHO SUPREME COURT; Clerk's Certificate Robert C Naftz 
filed with SC. Examine Title of Cert. if any 
corrections contact Dist. Clerk. Title in the Cert. 
must appear on all documents filed with SC. 
6/9/2011 DCANO Pocatello Health Services, Inc. dba Pocatello Robert C Naftz 
Care and Rehabilitation Center's Reply 
Memorandum in Support of Motion for Costs; 
Keely E. Duke, Atty for Defendants. 
DCANO Defendant Pocatello Health Services, Inc.'s Robert C Naftz 
Second Request for Additions to the Clerk's 
Record.! Keely E. Duke, Atty for Defendants. 
DCANO Pocatello Health Services, Inc.'s Reply Robert C Naftz 
Memorandum in Support of Motion to Amend 
Judgment; Keely E. Duke, Atty for Defendants. 
DCANO Pocatello Health Services, Inc. dba Pocatello Robert C Naftz 
Care and Rehabilitation Center's Amended 
Verified Memorandum of Costs; Keely E. Duke, 
Atty. for Defendants. 
6/10/2011 CAMILLE Affidavit of counsel in support of Pocatello health Robert C Naftz 
services, inc. dba Pocatello care and 
rehabilitation centers reply memorandum in 
support of motion for costs: aty Keely Duke for 
def 
3/16/2011 CAMILLE Plaintiffs request for additions to clerks record; Robert C Naftz 
aty Reed Larsen 
3/17/2011 DCHH NICOLE Hearing result for Motion held on 06/13/2011 Robert C Naftz 
02:00 PM: District Court Hearing Held 
Court Reporter: Stephanie Davis 
Number of Transcript Pages for this hearing 
estimated: less than 100 pages 
Motion for Costs 
Motion to Amend Judgment 
:;/20/2011 CAMILLE Minute Entry and Order; Plntfs Motion to Amend Robert C Naftz 
Judgment and Motion for costs are DENIED: 
sl Judge Naftz 6-20-2011 
Time: 09:36 AM 
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I'~dicial District Court - Bannock 
ROAReport 
Case: CV-2009-0003869-PI Current Judge: Robert C Naftz 
Judy Nield vs. Pocatello Health ~ervices.Jnc. 
User: DCANO 
Judy Nield vs. Pocatello Health Services, Inc. 
Date Code User 
7/7/2011 MISC DCANO 
7/26/2011 DCANO 
8/12/2011 MISC DCANO 
Judge 
IDAHO SUPREME COURT; Documents filed in Robert C Naftz 
SC. Defendant Pocatello Helath Serivces, Inco's 
Request for Additions to the Clerk's Record and 
Defendant Poctello Haelth Service, Inc.'s Second 
Request for Additions to the Clerk's Record. 
REPORTER'S TRANSCRIPTS received in Court Robert C Naftz 
Records on 7-26-11 from Stephanie Davis for the 
following hearings: Dfdts. Motn Summary Judge, 
Motion to Strike, Plntts Motion to Strike and Motn 
to Continue held 12-13-10. Pltnfs. Motion to 
Reconsider held 3-28-11. 
CLERK'S RECORD RECEIVED IN Court Robert C Naftz 
Records on 8-12-11. 
Keely E. Duke 
ISB #6044; ked@hallfarley.com A!4 
Chris D. Comstock .t';IO: 0 I 
ISB #6581; cdc@hallfarley.com 
HALL, FARLEY, OBERRECHT & BLANTON, P. 
702 West Idaho, Suite 700 
Post Office Box 1271 
Boise, Idaho 83701 
Telephone: (208) 395-8500 
Facsimile: (208) 395-8585 
W:\4\4-568.! \Pleadings\MSJ-HFOB Noh.doc 
Attomeys for Defendant Pocatello Health Services, Inc. d/b/a Pocatello Care and Rehab 
IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE 
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK 
JUDY NIELD, 
Plaintiff, 
vs. 
POCATELLO HEALTH SERVICES, INC., a 
Nevada corporation, d/b/a POCATELLO 
CARE AND REHAB, and JOHN DOES I-X, 
acting as agents and employees of 
POCATELLO HEALTH SERVICES, INC., 
d/b/a Pocatello Care and Rehab, 
Defendants. 
Case No. CV 09 3869 PI 
NOTICE OF HEARING 
ORIGINAL 
PLEASE TAKE NOTICE, defendant Pocatello Health Services, Inc., d/b/a Pocatello 
Care and Rehab ("Pocatello Care and Rehab"), by and through its counsel of record, has set 
before this Court to be heard a Motion for Summary Judgment. Said motion shall be heard on 
the 8th day of November, 2010 at the hour of 1 :30 p.m. before the Honorable Robert c. Naftz. 
NOTICE OF HEARING - 1 
448 
DATED this 113, day of October, 2010. 
HALL, FARLEY, OBERRECHT & 
BLANTON, P.A. 
I, 
BY:-p-:M4qpt:..-¥--=_~~~ ___ _ 
K ely E. uke - 0 the Firm 
Chris D. Comstock - Of the Firm 
Attorneys for Defendant Pocatello Health 
Services, Inc. d/b/a Pocatello Care and Rehab 
CERTIFICATE OF SERVICE 
I HEREBY CERTIFY that on the }"fJ. day of October, 2010, I caused to be served a 
true copy of the foregoing NOTICE OF HEARING, by the method indicated below, and 
addressed to each of the following: 
Reed W. Larsen 
COOPER & LARSEN, CHARTERED 
151 North 3 rd Avenue, 2nd Floor 
P.O. Box 4229 
Pocatello, ID 83205-4229 
Fax: (208) 235-1182 
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Keely E. Duke 
ISB #6044; ked@hallfarley.com 
Chris D. Comstock 
ISB #6581; cdc@hallfarley.com 
HALL, FARLEY, OBERRECHT & BLANTON, P.A. 
702 West Idaho, Suite 700 
Post Office Box 1271 
Boise, Idaho 83701 
Telephone: (208) 395-8500 
Facsimile: (208) 395-8585 
W:\4\4-568.1 \Discovery\Defendant's Expert Disclosure.First Supplemental.doc 
Attorneys for Defendant Pocatello Health Services, Inc. d/b/a Pocatello Care and Rehabilitation 
Center 
IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE 
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK 
JUDY NIELD, 
Plaintiff, 
vs. 
POCATELLO HEALTH SERVICES, INC., a 
Nevada corporation, d/b/a POCATELLO 
CARE AND REHABILITATION CENTER, 
and JOHN DOES I-X, acting as agents and 
employees of POCATELLO HEALTH 
SERVICES, INC., d/b/a POCATELLO CARE 
AND REHABILITATION CENTER, 
Defendants. 
Case No. CV 09 3869 PI 
DEFENDANT POCATELLO CARE 
AND REHABILITATION CENTER'S 
FIRST SUPPLEMENTAL EXPERT 
WITNESS DISCLOSURE 
COMES NOW defendant Pocatello Health Services, Inc., d/b/a Pocatello Care and 
Rehabilitation Center ("the Center") by and through its counsel of record Hall, Farley, Oberrecht 
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-& Blanton, P.A., and hereby makes the following disclosures pursuant to Rule 26(b)(4) of the 
Idaho Rules of Civil Procedure related to experts who may be called to testify at trial: 
SUPPLEMENTAL DISCLOSURES 
Without waiving such objections, and subject to such reservations, the Center makes the 
following supplement to its Expert Disclosure provided on July 21, 2010: 
Thomas J. Coffman, M.D. 
125 E. Idaho Suite 203 
Boise, Idaho 83712 
• Dr. Coffman may testify regarding causation of Ms. Nield's left below knee 
amputation. Specifically, Dr. Coffman may testify that Ms. Nield's comorbidities 
including but not limited to: poorly controlled diabetes; chronic non healing 
ulcers caused by leukocytoclastic vasculitis and severe neuropathy of the left 
lower extremity may have eventually required a below left knee amputation 
regardless of whether or not she was MRSA colonized. 
• Dr. Coffman may testifY that Ms. Nield's left leg below knee amputation was 
more likely required as a result of her leukocytoclastic vasculitis as opposed to 
her MRSA colonization. Dr. Coffman will testify regarding the characteristics, 
causes, symptoms and effects of leukocytoclastic vasculitis and the effect Ms. 
Nield's leukocytoclastic vasculitis had on her. Dr. Coffman will explain how Ms. 
Nield's leukocytoclastic vasculitis interacted with her MRSA colonization. 
• Dr. Coffman will testify that if Ms. Nield had contracted MRS A in the Center, it 
would be expected that she would have contracted a hospital acquired strain of 
MRSA, as opposed to a community acquired strain. Dr. Coffman will testify that 
the strain of MRSA Ms. Nield was identified with is a mixture of hospital 
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acquired and community acquired MRSA, that is more closely associated with 
community rather than hospital acquired MRS A based upon an antibiotic 
susceptibility profile. 
ARTICLES 
Literature upon which Dr. Coffman may rely or testify concerning: 
• Methicillin-Resistant Staphylococcus aureus Disease in Three Communities, NEW 
ENG. J. MED. 2005; 352:1436-1444 
• The Role of Nasal Carriage in Staphylococcus aureus Infections, THE LANCET 
INFECTIOUS DIS. 2005, 5: 751-62 
• Methicillin-Resistant Staphylococcus aureus: An Evolutionary, Epidemiologic, 
and Therapeutic Odyssey, CLINICAL INFECTIOUS DISEASES 2005; 40:562-73 
• Throat Swabs Are Necessary to Reliably Detect Carriers of Staphylococcus 
aureus, CLINICAL INFECTIOUS DISEASES 2007; 45:475-7 
• Methicillin-Resistant Staphylococcus aureus (MRSA) Nares Colonization at 
Hospital Admission and Its Effect on Subsequent MRSA Infection, CLINICAL 
INFECTIOUS DISEASES 2004; 39:776-82 
• Predicting the Staphylococcus aureus Nasal Carrier State: Derivation and 
Validation of a "Culture Rule ", CLINICAL INFECTIOUS DISEASES 2004; 39:806-11 
• Community-Associated Methicillin-Resistant Staphylococcus aureus: The Way to 
the Wound Is through the Nose, THE JOURNAL OF INFECTIOUS DISEASES 2006; 
193:169-71 
• Predicting the Staphylococcus aureus Nasal Carrier State: Derivation and 
Validation of a "Culture Rule ", CLINICAL INFECTIOUS DISEASES 2004; 39:806-
11. 
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Discovery in this matter is still underway, and the Center reserves the right to supplement 
these opinions based upon its experts' review of depositions in this case that have not yet been 
taken and any other additional discovery, including additional documents that are provided to 
them. 
DATED this {"'~ay of November, 2010. 
HALL, FARLEY, OBERRECHT & 
BLANTON, P.A. 
By.~~~~~~~~ ____ _ 
Keely E. Duke - Of the Firm 
Chris D. Comstock - Of the Firm 
Attorneys for Defendant Pocatello Health 
Services, Inc. d/b/a Pocatello Care and 
Rehabilitation Center 
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CERTIFICATE OF SERVICE 
I HEREBY CERTIFY that on the Ib;-day of November, 2010, I caused to be served a 
true copy of the foregoing POCATELLO CARE AND REHABILITATION CENTER'S 
FIRST SUPPLEMENTAL EXPERT WITNESS DISCLOSURE, by the method indicated 
below, and addressed to each of the following: 
Reed W. Larsen 
COOPER & LARSEN, CHARTERED 
151 North 3rd Avenue, 2nd Floor 
P.O. Box 4229 
Pocatello, ID 83205-4229 
Fax: (208) 235-1182 
Attorneys for Plaintiff 
o U.S. Mail, Postage Prepaid 
o Hand Delivered 
o Overnight Mail 
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t Keely E. Duke 
DEFENDANT POCATELLO CARE AND REHABILITATION CENTER'S FIRST SUPPLEMENTAL EXPERT WITNESS 
DISCLOSURE -5 
454 
From the Division of Bacterial and Mycotic 
Diseases (S.K.F.) and Division of Health· 
care Quality Promotion U.C.H., M.M., 
J.A.J.), National Center for Infectious Dis· 
eases, Centers for Disease Control and Pre· 
vention, Atlanta; Emory University School 
of Medicine and the Veterans Affairs Med· 
ical Center, Atlanta (M.M.,J.A.J., M.M.F.); 
Johns Hopkins University Bloomberg 
School of Public Health, Baltimore (L.T.S., 
L.H.H.); and the Minnesota Department 
of Health, Minneapolis (K.C.·S., KH., 
R.L.). Address reprint requests to Dr. Frid· 
kin at the CDC, NCID, DBMD, MDB, MS 
C·09, 1600 Clifton Rd., NE, Atlanta, GA 
30333, or at skfO@cdc.gov. 
N Engl J Med 2005;352:1436·44. 
Copyright © 2005 Mass.,husens Medical Society. 
1436 
The NEW ENGLAND JOURN 
I~I _________________ O __ R_I_G_I_N_A __ L_A_R_._T_I_C_L_E ________________ ~II 
Methicillin-Resistant Staphylococcus aureus 
Disease in Three Communities 
Scott K. Fridkin, M.D., Jeffrey C. Hageman, M.H.S .. Melissa Morrison, M.P.H., 
Laurie Thomson Sanza. R.N., Kathryn Como·Sabetti, M.P.H., 
John A.Jernigan, M.D., Kathieen Harriman, Ph.D., Lee H. Harrison, M.D., 
Ruth Lynfield, M.D., and Monica M. Farley. M.D., for the /\ctivc Bacterial Core 
Surveillance Program oftne Emerging Infections Prograrn Network 
ABSTRACT 
BACKGROUND 
Methicillin-resistant Staphylococcus aureus (MRSA) infection has emerged in patients who 
do not have the established risk factors. The national burden and clinical effect of this 
novel presentation of MRS A disease are unclear. 
METHODS 
We evaluated MRSA infections in patients identified from population-based surveillance 
in Baltimore and Atlanta and from hospital-laboratOly-based sentinel surveillance of 
12 hospitals in Minnesota. Information was obtained by interviewing patients and by 
reviewing their medical records. Infections were classified as community-acquired 
MRSA disease if no established risk factors were identified. 
RESULTS 
From 2001 through 2002, 1647 cases of community-acquired MRSA infection were re-
ported, representing between 8 and 20 percent of all MRSA isolates. The annual disease 
incidence varied according to site (25.7 cases per 100,000 population in Atlanta vs. 
18.0 per 100,000 in Baltimore) and was significantly higher among persons less than 
two years old than among those who were two years of age or older (relative risk, 1.51; 
95 percent confidence interval, 1.19 to 1.92) and among blacks than among whites in 
Atlanta (age-adjusted relative risk, 2.74; 95 percent confidence interval, 2.44 to 3.07). 
Six percent of cases were invasive, and 77 percent involved skin and soft tissue, The in-
fecting strain of MRSA was often (73 percent) resistant to prescribed antimicrobial 
agents. Among patients with skin or soft-tissue infections, therapy to which the infect-
ing strain was resistant did not appear to be associated with adverse patient-reported 
outcomes. Overall, 23 percent of patients were hospitalized for the MRSA infection. 
CONCLUSIONS 
Community-associated MRSA infections are now a common and serious problem. 
These infections usually involve the skin, especially among children, and hospitaliza-
tion is common. 
N ENGl J MED 352;14 WWW.NEJM.ORG APRil 7,2005 
Downloaded from www.nejm.org at ST LUKES MEDICAL LIBRARY on July 22, 2010 . 
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N THE UNITED STATES, STAPHYLOCOCCUS 
aureus is the most common cause of skin and 
soft-tissue infections, as well as ofinvasive in-
fections acquired in hospitals.1,2 Treatment of seri-
ous S. aureus infections can be challenging, and the 
associated mortality rate remains 20 to 25 percent 
despite the availability of highly active antimicrobial 
agents. 3,4 However, most antistaphylococcal agents 
are ineffective against methicillin-resistant S. aureus 
(MRSA), which was first identified as a hospital-
acquired pathogen in the 1960s.2,3,5,6 
Over the past 40 years, MRSA infections have 
become endemic in most U.S. hospitals1,2 and hos-
pitals worldwide,7 striking, with rare exception, 
only patients with established risk factors. 8,9 More 
recently, however, MRSA infections have been de-
scribed in patients without established risk factors 
who are living in the community.10-19 The current 
approach to suspected cases of community-asso-
ciated (also referred to as community-acquired) 
S. aureus infections (suggested by findings offurun-
c1es, abscesses, or cellulitis) commonly includes 
empirical treatment with f3-lactam antibiotics. This 
approach may need to be reconsidered if commu-
nity-associated MRSA becomes a clinically signifi-
cant pathogen. 
The Centers for Disease Control and Prevention 
(CDC) and three sites participating in the Emerg-
ing Infections Program began a specialized MRSA 
surveillance project in 2001 using the Active Bacte-
rial Core Surveillance program, a population-based 
surveillance component of the Emerging Infections 
Program Network designed to study the epidemio-
logic features of invasive bacterial disease and to 
track drug resistance in the United States. We used 
these data to evaluate the incidence of endemic 
community-associated MRSA infection, racial dis-
parities in the incidence, patterns of antimicrobial 
susceptibility, and clinical outcomes in several areas 
in the United States. 
METHODS 
SURVEILLANCE POPULATION 
The MRSAActive Bacterial Core Surveillance project 
monitored all MRSA isolates from all body sites 
from patients in 11 Baltimore hospitals serving a 
population of700,000; Health District 3 in greater 
Atlanta, comprising eight counties with a total pop-
ulation of 3.3 million; and 12 sentinel hospital-
based laboratories representative of the state in 
Minnesota (6 rural and 6 urban, representing 16 
percent of the licensed hospital beds in the state). 
Laboratories served both outpatient clinic networks 
and hospital inpatients; sites in Atlanta included 
several referral laboratories serving predominant-
ly ambulatory care settings. Surveillance was per-
formed consecutively for 12 months in Baltimore 
(beginning February 2002), 18 months in Atlanta 
(beginning July 2001), and 24 months in Minne-
sota (beginning January 2001). In Baltimore, 1 of 
12 eligible hospitals declined to participate in the 
MRSA study; however, this omission would be un-
likely to have a substantial effect. The laboratory in 
that hospital historically reports only about 5 per-
cent of the cases ofinfections with other pathogens 
under surveillance as part of the Active Bacterial 
Core Surveillance system in Baltimore. 
CASE DEFINITIONS AND ASCERTAINMENT 
A community-associated MRSA isolate was defined 
as an MRSA isolate recovered from a clinical cul-
ture from a patient residing in the surveillance area 
who had no established risk factors for MRSA in-
fection. Established risk factors included the isola-
tion of MRSA two or more days after hospitaliza-
tion; a history of hospitalization , surgery, dialysis, 
or residence in a long-term care facility within one 
year before the MRSA-culture date; the presence of 
a permanent indwelling catheter or percutaneous 
medical device (e.g., tracheostomy tube, gastros-
tomy tube, or Foley catheter) at the time of culture; 
or previous isolation of MRSA. We reviewed the 
medical records of patients with suspected commu-
nity-associated MRSA isolates to identifY risk fac-
tors for infection. We attempted to interview by tele-
phone all patients for whom no risk factors were 
identified to confirm the absence of established 
risk factors and to obtain a brief history of the clin-
ical outcome. At least 15 attempts were made, after 
which suspected community-associated MRSA iso-
lates were classified as confirmed in the case of 
patients who were successfully interviewed and con-
firmed to have no established risk factors or as 
probable in the case of patients who were not inter-
viewed but who had no established risk factors on 
a review of medical records. The remaining isolates 
were classified as either health care-associated 
when established risk factors were identified or in-
determinate if no information on the patient could 
be obtained. 
A case of community-associated MRSA disease 
was defined as illness compatible with staphylococ-
cal disease in a patient residing in the surveillance 
N ENGl J MED 352;14 WWW.NEJM.ORG APRil 7. 2005 
Downloaded from www.nejm.org at ST LUKES MEDICAL LIBRARY on July 22. 2010. 
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areas and isolation of community-associated MRSA 
from a clinically relevant site. Only a subgroup of 
patients with community-associated MRSA isolates 
had actual disease and achieved case status. 
To identifY cases, surveillance personnel routine-
ly contacted all clinical microbiology laboratories 
serving residents of each catchment area regarding 
MRSA isolated from clinical cultures (infection-
control surveillance cultures were excluded). Period-
ic audits oflaboratory records were conducted by 
surveillance personnel to identifY any unreported 
cases and ensure the completeness of reporting. 
Surveillance personnel collected information on pa-
tients using a standardized questionnaire that in-
cluded demographic and isolate data on all MRSA 
isolates; information on antimicrobial-suscepti-
bility testing (with results characterized as suscep-
tible, intermediate, or resistant) and clinical char-
acteristics were obtained from available medical 
records (e.g., emergency room, primary care, or 
hospital) only for patients with confirmed or prob-
able community-associated MRSA isolates. The col-
lection of additional data on disease outcome, 
employment status, household structure, socioeco-
nomic status, and level of education was limited to 
patients with confirmed cases of community-asso-
ciated MRSA disease. 
The study was approved by the appropriate in-
stitutional review boards at the participating sites, 
including all participating Baltimore hospitals, the 
Maryland Department of Health and Mental Hy-
giene, lohns Hopkins University Bloomberg School 
of Public Health, the Georgia Department ofHu-
man Resources, Emory University School ofMedi-
cine, the Minnesota Department of Health, and the 
CDC. Oral informed consent was obtained from all 
those who were interviewed. 
STATISTICAL ANALYSIS 
Statistical analysis was conducted with SAS soft-
ware (SAS Institute). Annual cumulative incidence 
rates were calculated, after adjustment for the study 
period at each site, with the use of projections of 
the 2001 and 2002 population from the Census Bu-
reau. Initial therapy was categorized as active if the 
patient received an antimicrobial agent with activity 
against S. aureus and to which the MRSA was sus-
ceptible in vitro. Therapy was categorized as inac-
tive if initial therapy consisted of antimicrobial 
agents to which the isolate had intermediate resis-
tance on testing or was resistant in vitro. If the re-
sults of susceptibility testing were not available for 
a prescribed agent or the patient received no anti-
microbial agents, the patient was excluded from 
analyses correlating inactive therapy and outcomes. 
The Mantel-Haenszel chi-square test was used to 
compare the incidence according to race and other 
categorical data, and the t-testwas used for contin-
uous data. All comparisons were initially stratified 
according to the reporting area, and rate ratios were 
pooled if there were no significant differences be-
tween areas according to the Breslow-Day test for 
homogeneity of the rate ratios. 
RESULTS 
SURVEILLANCE 
During the study period, 12,553 patients with 
MRSA isolates were reported. Of these patients, 
9972 (79 percent) were immediately classified as 
having health care-associated MRSA infection and 
did not require interviews. Interviews were attempt-
ed with 2581 patients with suspected cases of com-
munity-associated MRSA infection; 1063 of these 
patients (41 percent) were interviewed, allowing 280 
(11 percent) to be reclassified as having health care-
associated MRSA. Among the remaining patients 
with suspected cases of community-associated 
MRSA infection, 2107 (17 percent) were classified 
as having confirmed or probable community-asso-
ciated MRSA isolates (Atlanta, 1590 of7819 [20 per-
cent); Minnesota, 370 of 3714 [12 percent); and 
Baltimore, 147 of1720 [8 percent); P<O.OOl). MRSA 
isolates in 196 patients were classified as indeter-
minate (2 percent). 
The overall incidence of invasive MRSA infection 
(i.e., MRSA recovered from a normally sterile site), 
regardless of whether the infection was acquired in 
the community or at a health care facility, was 19.3 
infections per 100,000 population in Atlanta and 
40.4 infections per 100,000 in Baltimore. 
Of the 2107 confirmed or probable isolates of 
community-associated MRSA, 1647 (78 percent) 
were associated with clinical illness and were clas-
sified as cases of community-associated MRSA 
disease. Among these cases, the confirmed and the 
probable community-associated MRSA isolates 
were obtained from similar body sites and dem-
onstrated similar susceptibilities to antimicrobial 
agents with one exception, i.e., there was variable 
sensitivity to erythromycin (details are provided in 
the Supplementary Appendix, available with the full 
text of this article at www.nejm.org). The annual 
incidence of community-associated MRSA disease 
N ENGL) MED 352;14 WWW.NEJM.ORG APRIL 7. 2005 
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in the two areas that performed population-based 
surveillance was 25.7 cases per 100,000 in Atlanta 
and 18.0 per 100,000 in Baltimore (rate ratio, 0.70; 
95 percent confidence interval, 0.58 to 0.85) (Fig. 
1). In both surveillance areas, the incidence was 
significantly higher among persons who were less 
than two years old than among those who were two 
years of age or older (unadjusted relative risk, 1.51; 
95 percent confidence interval, 1.19 to 1.92) (Fig. 
1). Incidence rates were significantly higher 
among blacks than whites in Atlanta among all age 
groups (age-adjusted relative risk, 2.74; 95 percent 
confidence interval, 2.44 to 3.07); racial differenc-
es in incidence were not significant in the Balti-
more population, even in the youngest age group 
(relative risk, 2.58; 95 percent confidence interval, 
0.31 to 21.5). 
CLINICAL CHARACTERISTICS 
The type ofinfection varied slightly among the sur-
veillance areas (Table 1); of the 1647 patients with 
community-associated MRSA disease, most (1266 
[77 percent]) were categorized as having skin or 
soft-tissue infections. Specific types included ab-
scess in 751 patients (59 percent), cellulitis in 528 
patients (42 percent), folliculitis in 88 patients 
(7 percent), and impetigo in 33 patients (3 percent). 
Among the other types of infection reported, 103 
(6 percent) were invasive, including bacteremia, 
septic arthritis, and osteomyelitis; 157 were in 
wounds (10 percent); and 31 were pneumonia 
(2 percent) (Table 1). 
Most patients (1333 [81 percent)) were treated 
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with antimicrobial agents; specific antimicrobial 
agents were documented for 1297 patients (97 per-
cent). Among these 1297 patients, 757 (58 percent) 
received f3-lactam antibiotics alone, 199 (15 percent) 
received a f3-lactam with a non-f3-lactam agent, 
and 341 (26 percent) received only non-f3-lactam 
therapy. Among the patients whose antibiotic regi-
mens were documented, significantly more of the 
1099 patients with skin infections than of the 198 
patients with other types of infection received 
f3-lactam agents alone (64 percent vs. 28 percent, 
P<O.OOI). 
Antimicrobial susceptibilities were obtained 
from the medical records of 1345 of the 1647 pa-
tients with community-associated MRSA disease 
(82 percent). With-few exceptions, the patterns of 
susceptibility were similar among the study areas. 
However, isolates from patients in Atlanta and Bal-
timore were significantly less likely than those from 
Minnesota to be susceptible to erythromycin and 
ciprofloxacin (Table 2). Susceptibility data and doc-
umented information on empirical therapy were 
available for most patients who received empirical 
therapy (1215 of1297 [94 percent)); 884 (73 per-
cent) received inactive therapy. 
Limited information on the effect of the disease 
was available from the medical records; 506 patients 
(31 percent) were hospitalized, including 371 (23 
percent) who were hospitalized specifically for 
MRSA disease (Table 1). For these 371 patients, 
hospitalization was unlikely to be the result of the 
clinician's receiving the MRSA-culture report. The 
interval between specimen collection and admis-
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Figure 1. Incidence of Community· Associated MRSA Disease in Atlanta and Baltimore, According to Race and Age Group. 
The horizontal line in each graph is the overall site-specific annual incidence. Race was determined in most cases by 
study person nel. 
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Table 1. Infections and Outcomes Associated with Community-Associated MRSA Disease, 2001-2002. 
Atlanta Baltimore Minnesota Total 
Variable (N=1267) (N=llS) (N=265) (N = 1647) PValue* 
Invasive infections - no. (%)1' 
Bacteremia 30 (2) 7 (6) 6 (2) 43 (3) 0.66 
Meningitis 1 (<1) 1 (1) 0 2 (<1) 0.84 
Osteomyelitis 11 (1) 6 (5) 7 (3) 24 (1) <0.01 
Bursitis 12 (1) 0 7 (3) 19 (1) 0.04 
Arthritis 13 (1) 0 2 (1) 15 (1) 0.52 
Other infections - no. (%)t 
Skin and soft tissue 973 (77) 95 (83) 198 (75) 1266 (77) 0.71 
Wound 136 (11) 8 (7) 13 (5) 157 (10) <0.01 
Pneumonia 23 (2) 4 (3) 4 (2) 31 (2) 0.97 
Urinary tract 57 (4) 4 (3) 3 (1) 64 (4) 0.01 
Sinus 60 (5) 0 1 (<1) 61 (4) <0.01 
Underlying illness - no. (%) 594 (47) 70 (61) 80 (30) 744 (45) 0.08 
Hospitalization - no. (%) 339 (27) 72 (63) 95 (36) 506 (31) 0.68 
MRSA disease primary reason- 251/339 (74) 41/72 (57) 79/95 (83) 371/506 (73) 0.62 
no./total no. (%) 
Intensive care unit stay - no./total no. (%) 26/339 (8) 7/72 (10) 4/95 (4) 37/506 (7) 0.14 
Discharged from hospital- no./total no. (%) 323/339 (95) 71/72 (99) 86/95 (91) 480/506 (95) 0.Q7 
Median stay - days 5 5 3 4 0.20 
* P values were determined by means of the Cochran-Mantel-Haenszel summary statistic and indicate significant differ-
ences in infection rates among sites. 
'i' Patients could have more than one infection. 
Table 2. Number of Community. Associated MRSA Isolates That Were Susceptible to Selected Antimicrobial Agents, 
2001-2002.* 
Agent Tested Atlanta Baltimore Minnesota Total PValuei' 
no. of susceptible isolates/total no. (percent) 
Ci profloxaci n 408/648 (63) 6/31 (19) 146/182 (80) 560/861 (65) <0.001 
Clindamycin 840/970 (87) 78/92 (85) 211/239 (88) 1129/1301 (87) 0.58 
Erythromycin 98/907 (11) 11/94 (12) 110/235 (47) 219/1236 (18) <0.001 
Gentamicin 429/444 (97) 66/71 (93) 184/188 (98) 679/703 (97) 0.59 
Rifampin 682/694 (98) 6/9 (67) 179/184 (97) 867/887 (98) 0.21 
Tetracycline 726/814 (89) 43/70 (61) 163/179 (91) 932/1063 (88) 0.44 
Vancomycin:~ 1016/1017 (100) 95/96 (99) 232/232 (100) 1343/1345 (100) 0.88 
Linezolid 13/13 (100) 11/12 (92) 0 24/25 (96) 0.30 
Trimethoprim- 912/943 (97) 30136 (83) 236/239 (99) 1178/1218 (97) 0.32 
sulfamethoxazole 
,~ Results were obtained at local facilities. 
'i' P values were determined by means of the Cochran-Mantel-Haenszel summary statistic. 
:~ Two isolates were nonsusceptible with the use of automated testing methods. but these results were not confirmed with 
the use of recommended methods.'o.21 
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sion was less than one day for 226 of the 371 pa-
tients (61 percent), one to two days for 115 (31 per-
cent), and more than two days for 22 (6 percent) 
(2 percent had missing data). A total of37 patients 
(10 percent) required hospitalization in the intensive 
care unit. Hospitalization lasted a median of four 
days, and only 1 of the 37 patients who died during 
hospitalization had documentation that the com-
munity-associated MRSA was causal or contribu-
tory to the death. 
Information on other outcomes associated with 
community-associated MRSA infection was avail-
able for 575 patients with confirmed cases (i.e., in-
terviewed patients). Among these patients, 560 (97 
percent) received some antimicrobial agents, 136 
(24 percent) were hospitalized, 226 (39 percent) 
underwent incision and drainage, and 176 (31 per-
cent) required a follow-up visit with their physician. 
To assess the relationship between inactive anti-
microbial therapy and outcome more closely, we 
attempted to identifY a homogeneous group of 
patients in which to compare clinical outcomes on 
the basis of empirical antimicrobial treatment. We 
limited further analysis to 453 patients with con-
firmed cases of community-associated MRSA dis-
ease involving skin or soft-tissue infections who 
received antimicrobial therapy at the time of the 
isolation of community-associated MRSA and for 
whom information on initial treatment and clinical 
outcome was available from the interview. Neither 
initial incision and drainage nor initial antimicro-
bial therapy that was inactive was significantly asso-
ciated with an increased frequency of the following 
patient-reported outcomes after the initial evalua-
tion for illness: follow-up visits to a health care pro-
vider, subsequent incision and drainage, or subse-
quent change in antimicrobial therapy (Table 3). 
Also, among the subgroup of patients who did 
not initially undergo incision and drainage, there 
were no significant differences in outcomes ac-
Table 3. Effect oflnitial Therapy on Selected Outcomes among 453 Patients with Confirmed Skin or Soft-Tissue 
Infections Due to Community-Associated MRSA, 2001-2002.* 
New Anti-
Incision and microbial Agent 
No. of Follow-up Visit Drainage on Prescribed on 
Initial Therapy Patients to Health Care Provider Follow-up Visit Follow-up Visit 
2:1 Times 2:2 Times 
Incision and drainage 
Yes-no. (%) 196 54 (28) 30 (15) 19 (10) 45 (23) 
No-no. (%) 257 69 (27) 43 (17) 14 (5) 66 (26) 
Rate ratio (95% CI) 1.01 (0.80-1.29) 0.94 (0.70-1.27) 1.37 (1.00-1.87) 0.92 (0.71-1.18) 
Inactive therapy 
Yes-no. (%) 254 59 (23) 35 (14) 15 (6) 55 (22) 
No-no. (%) 199 64 (32) 38 (19) 18 (9) 56 (28) 
Rate ratio (95% CI) 0.81 (0.66-1.00) 0.83 (0.65-1.07) 0.80 (0.54-1.17) 0.85 (0.69-1.05) 
Incision and drainage 
Inactive therapy - no. (%) 108 20 (19) 11 (10) 8 (7) 16 (15) 
Active therapy - no. (%) 88 34 (39) 19 (22) 11 (12) 29 (33) 
Rate ratio (95% CI) 0.60 (0.41-0.87) 0.63 (0.39-1.02) 0.75 (0.43-1.28) 0.58 (0.39-0.88) 
No incision and drainage 
Inactive therapy - no. (%) 146 39 (27) 24 (16) 7 (5) 39 (27) 
Active therapy - no. (%) III 30 (27) 19 (17) 7 (6) 27 (24) 
Rate ratio (95% CI) 0.99 (0.78-1.26) 0.98 (0.73-1.31) 0.87 (0.51-1.49) 1.05 (0.83-1.34) 
" The outcomes were reported during the interview with each patient. Only patients who were interviewed were included 
in the analysis. Initial therapy was categorized as active if the patient received an antimicrobial agent with activity against 
S. aureus and to which the MRSA was susceptible in vitro. Therapy was categorized as inactive if initial therapy included 
only antimicrobial agents to which the isolate had intermediate susceptibility on testing or was resistant in vivo. The rate 
ratio is the ratio of the rate of the outcome among the exposed group to the rate of the outcome among the group that 
was not exposed. CI denotes confidence interval. 
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cording to whether the initial therapy was inactive coccal disease among Pacific Islanders, American 
(Table 3). Indians, and Alaskan Natives.16,18,22,23 Black race 
POTENTIAL EXPOSURES TO MRSA 
Although none of the established risk factors for 
MRSA infection were documented in any patient, 
744 patients (45 percent) had underlying conditions 
or factors that were associated with skin infections 
or suggested some contact with the health care 
system. Among the 1250 patients whose age was 
known to be at least 18 years, 653 (52 percent) 
reported 1249 underlying conditions, including 
smoking (35 percent), previous skin infections (21 
percent), diabetes (19 percent), asthma (12 percent), 
infection with the human immunodeficiency virus 
(HIV) (9 percent), intravenous drug use (7 percent), 
alcohol abuse (6 percent), and coronary vascular 
disease (5 percent). Among 345 patients who were 
younger than 18 years old, 76 (22 percent) reported 
90 preexisting conditions, including skin disease 
(42 percent), asthma (35 percent), and smoking 
(7 percent). Among the 575 patients with confirmed 
community-associated MRSA disease, detailed in-
formation on household characteristics and em-
ployment status was obtained from the interview, 
and several points of contact with the health care 
system exclusive of established risk factors for 
MRSA infection were identified (Table 4). 
DISCUSSION 
In this study, 8 to 20 percent of all MRSA isolates 
collected as part of prospective population-based 
surveillance were not associated with traditional risk 
factors and were classified as community-associat-
ed MRSA. Most of these isolates were associated 
with clinically relevant infections that required treat-
ment. The most common infections involved skin 
and soft tissues; however, 6 percent were consid-
ered invasive. Attributable mortality was low, but 
23 percent of patients were hospitalized for these 
infections. 
The incidence of clinically relevant community-
associated MRSA disease varied between the Atlanta 
surveillance area (25.7 per 100,000) and the Balti-
more surveillance area (18.0 per 100,000), and we 
found marked disparity in the incidence of com-
munity-associated MRSA disease between blacks 
and whites in Atlanta but not in Baltimore, even 
among the youngest age group. Several reports have 
highlighted the increased incidence of staphylo-
was associated with increased rates of invasive 
S. aureus disease in 1998 in one population-based 
study in Connecticuf4 and in other studies evalu-
ating invasive pneumococcal disease. 25-28 The in-
creased prevalence of certain underlying diseases 
(e.g., diabetes and HIV infection), differences in 
immune response, or differences in other socio-
economic factors (e.g., crowding in the household 
or decreased access to medical care), which are 
correlated with black race, may contribute to these 
findings.29 
The differences observed in incidence rates be-
tween Baltimore and Atlanta can probably be ex-
plained on the basis of the different populations 
under surveillance. The lower overall incidence of 
community-associated MRSA disease in Baltimore 
suggests that this surveillance population may be 
more likely to have established risk factors for 
MRSA infection. The incidence may also be falsely 
low, since 1 of12 eligible laboratories declined to 
participate in the study. However, it is unlikely that 
the Baltimore surveillance underreported cases from 
the remaining laboratories, since the rates of in-
vasive MRSA disease (regardless of whether the 
infection was acquired in the community or at a 
health care facility) were higher in Baltimore (40 
per 100,000) than Atlanta (19 per 100,000). The 
Atlanta surveillance area encompassed an eight-
county urban and suburban area and included a 
large referral laboratory; the Baltimore surveillance 
area was limited to urban hospital-based labora-
tories likely to serve persons with more frequent 
contact with the hospitals. 
Our large, prospective series of community-
associated MRSA infections identified with the use 
of standardized methods to measure rates of en-
demic disease allows for an accurate description of 
the clinical course and effect of these infections. In a 
manner consistent with previous reports from out-
breaks and smaller surveillance studies, we found 
that most patients who were treated empirically re-
ceived f3-lactam antimicrobial agents. Measuring 
the effect ofinactive therapy on these infections has 
been difficult owing to the small numbers of cas-
es and imprecise outcome measurements.30-35 Al-
though we relied on self-reported measures, our 
data suggest that patients with community-associ-
ated MRSA skin or soft-tissue disease who initially 
receive inactive antimicrobial therapy have out-
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comes similar to those among patients who are 
treated with antimicrobial agents to which the or-
ganism is susceptible in vitro. Prospective evalua-
tions with more objective measurements are need-
ed to clarifY whether the addition of active systemic 
therapy to topical agents or surgical drainage in-
creases the beneficial effect in patients with com-
munity-associated MRSA infections involving the 
skin and soft tissues. 
Our report reflects the results of one to two 
years of active surveillance in three large and diverse 
geographic areas. However, certain limitations 
should be borne in mind. First, we were unable to 
perform population-based estimates in Minnesota, 
where sentinel surveillance was conducted. How-
ever, the descriptive data probably reflect the pa-
tient mix in that state. Second, our surveillance re-
quired isolation of MRSA from a clinically relevant 
culture; since S. aureus skin disease is often treated 
empirically without a diagnostic test, our results 
probably underestimate the true burden of disease. 
Some caution must be taken in generalizing our 
findings to the U.S. population. First, we were able 
to interview only 41 percent of eligible patients, 
eliminating a majority of patients from the outcome 
analysis. Second, although there were rarely signif-
icant differences among the reporting areas, the 
majority of cases were reported in the Atlanta area. 
Also, patients who could not be interviewed may 
have been misclassified as having community-
associated MRSA infection, since no interview data 
were available. However, we believe pooling the pa-
tients with probable and confirmed cases of com-
munity-associated MRSA disease was justified on 
the basis of the similarities between both patients' 
and isolates' characteristics, reflecting a pattern 
typically seen in previously reported outbreaks of 
community-associated MRSA infection.10,1l,15,36-38 
To avoid clinical complications from commu-
nity-acquired MRSA infections, clinicians should 
now consider MRSA as a potential pathogen in pa-
tients with suspected S. aureus infections in the 
community setting. Clinicians should obtain ap-
propriate material for bacterial culture; should fol-
low up on the results of susceptibility testing of all 
S. aureus isolates, since by definition MRSA organ-
isms are not susceptible to l3-lactam antibiotics; 
and should recommend surgical drainage ofinfec-
tions when feasible. The choice of appropriate anti-
microbial agents for suspected S. aureus infections 
of skin and soft tissue in patients in the community 
Table 4. Frequency of Characteristics Potentially Related to Infection 
among 575 Patients with Confirmed Community-Associated MRSA Disease, 
2001-2002.* 
Potential Risk Factor 
Any visit to a physician's office in past yr 
Receipt of any antimicrobial agents in past yr 
Chronic noninfectious skin disease 
No. of Patients (%) 
357 (62) 
Stayed >2 wk in non-health care high-risk setting in past 
5 yr"j 
Health care-related employment in past 5 yr 
Health care provider or direct care 
Health care-delivery support services 
Other type of health care 
Acute care or skilled-nursing facility 
Clinic or ambulatory care facility 
Crowded household (>1 person/bedroom»),: 
",1 Household member ,;;2 yr old 
",1 Household member >60 yr old 
",1 Household member with established risk factor for 
MRSA infection 
Job in the health care setting 
Attendance at day care~ 
History of MRSA infection 
Receipt of home care services 
Self-reported annual income, 
<$20,000 
$20,000--$50,000 
>$50,000 
Receipt of public assistance 
* The categories are not mutually exclusive. 
224 (39) 
190 (33) 
10 (2) 
69 (12) 
23 (4) 
26 (5) 
46 (8) 
30 (5) 
12 (2) 
121 (51) 
132 (23) 
109 (19) 
92 (16) 
69 (12) 
52 (9) 
35 (6) 
17 (3) 
144 (29) 
178 (36) 
173 (35) 
92 (16) 
l' A high-risk setting was defined as a department-of-corrections facility or mili-
tary barracks. 
),: Data on crowding were available for 236 of the 575 interviewed patients. 
§ Day-care attendance among household members was for a median of20 hours 
per week (range, 20 to 60). 
, Data on income were available for 495 interviewed patients. 
must now take into account the emergence of 
community-associated MRSA; providers should 
be aware that several available antimicrobial agents 
should be effective in treating these infections. 
Supported by the CDC Emerging Infections Program. (The use of 
product names in this article does not imply their endorsement by 
the Public Health Service or the Department of Health and Human 
Services.) 
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The role of nasal carriage in Staphylococcus aureus infections 
Heiman F I. Wertheim, Damian C Me/les, Margreet C Vas, Wit/em van l.eelJwen, Alex van BelkulTI, Henri A Verbrugh,Jan L Nouwen 
Staphylococcus aureus is a frequent cause of infections in both the community and hospital. Worldwide, the increasing 
resistance of this pathogen to various antibiotics complicates treatment of S aureus infections. Effective measures to 
prevent S aureus infections are therefore urgently needed. It has been shown that nasal carriers of S aureus have an 
increased risk of acquiring an infection with this pathogen. The nose is the main ecological niche where S aureus resides 
in hurnan beings, but the determinants of the carrier state are incompletely understood. Eradication of S aureus from 
nasal carriers prevents infection in specific patient categories-eg, haemodialysis and general surgery patients. 
However, recent randomised clinical trials in orthopaedic and non-surgical patients failed to show the efficacy of 
eliminating S aureus from the nose to prevent subsequent infection. Thus we must elucidate the mechanisms behind 
S aureus nasal carriage and infection to be able to develop new preventive strategies. We present an overview of the 
current knowledge of the determinants (both human and bacterial) and risks of S aureus nasal carriage. Studies on the 
population dynamics of S aureus are also summarised. 
Introduction 
Staphylococcus aureus is both a human commensal and a 
frequent cause of clinically important infections 
(figure 1).' Although the prevalence of me tic ill in-resistant 
S aureus (MRSA) is still very low in northern European 
countries,' there is a worldwide increase in the number of 
infections caused by MRSA. Vancomycin is one of the last 
therapeutic options available for MRSA infections. TIle 
recent isolation of vancomycin-resistant MRSA strains in 
the USA is a major cause for concern: Therefore, the 
prevention of staphylococcal infections and reduction of 
the spread and emergence of MRSA are essential. 
The association between S aureus nasal carriage and 
staphylococcal disease was first reported by DanboIt in 
1931, who studied furunculosis.4 The increasing incidence 
of penicillin-resistant S aureus hospital infections since 
1947 emphasised the need for a better understanding of 
the pathogenesis of staphylococcal disease. Subsequently, 
numerous studies confirmed Danbolt's finding."") A 
causal relation between S aureus nasal carriage and 
infection is supported by the fact that the nasal S aureus 
strain and the infecting strain share the same phage type 
or genotype."'" Furthermore, nasal application of an 
antistaphylococcal drug temporarily decolonises the nose 
and other body sites, which prevents infection.ll 
Our knowledge of the mechanisms, risks. and treatment 
of S aureus nasal carriage has greatly expanded over the 
past decade. Table 1 presents an overview of major events 
in S aureus research. Here, we focus on the latest insights 
into the determinants of S aureus nasal carriage and the 
risks of infection associated with S aureus nasal carriage. 
Most studies were done in western cotmtries, so 
conclusions drawn can not always be generalised. 
Determinants of nasal carriage of S aureus 
5 aureus nasal carriage patterns 
S aureus colonises the skin and mucosae of human beings 
and several animal species. I Although multiple body sites 
can be colonised in human beings, the anterior nares of 
Lhe nose is the most frequent carriage site for S aureus.; 
include the skin, perineum, and pharynxY<-1S Other 
carriage sites including the gastrointestinal tract, \," 
vagina.'7 and axi1lae"""" harbour S aureus less frequently 
(figure 2). 
Most studies on S aureus nasal carriage have used a 
cross-sectional design with a single nasal culture to 
Pneumonia 
HaemotogenotJs 
spread/sepsis 
Endocarditis 
Extra-nasal sites that typically harbour the organism Figllfel: Large diversity in 5 aurellS infections 
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I Review 
Vear Event 
1880 Alexander Ogston identities micrococci in putulent infections" 
1931 Association between nasal (olonisation and furunculosis di5covered~ 
1934 Popularisation of the coagulase test for the identification of S aureus' 
1944 Introduction of phage typing" 
1947 Penicillin-resistant 5 aureus reported" 
1951 As~ociation between nasal colonisation of S l1ureus and infection with the same stram 
determined by phage typing"'" 
1961 Meticillin-resistant S aureus (MRSA) reported" 
1991 Pulsed field gel electrophoresi' "sed for genotyping 5 aur'tls" 
1994 Identification of microbial surface components recognising adhesive matrix molecules 
(MSCRAMMs)" 
2000 Mukilocus sequence typing developed for studying clon.lity of 5 aureus'" 
2001 Whole genome of 5 aureus sequenced" 
2001 80% of bacteraerni( S aureus isolates are endogenousll 
2001 Increase in cornmunity~onset MRSA infections" 
2002 Van(Qmycin~resistant Saureus reported)) 
Table 1: Major events in S aureus research 
General population 
classifY an individual as a carrier or not. However. 
longitudinal studies distinguish at least three S aureus 
nasal carriage patterns in healthy individuals: persistent 
carriage. intermittent carriage. and non-carriage.',6.1l",!O 
Some studies make a further distinction between 
occasional and intermittent carriers.'''''! Therefore, a 
patient classified as a carrier in cross-sectional studies 
could either be a persistent or an intermittent carrier. This 
distinction is important because persistent carriers have 
higher S aureus loads and a higher risk of acquiring 
5 aureus nasal carriers 
Figure 2: 5 aurevs carriage rates per body site in adults 
There is all increase in carriage rates at extra-nasal sites within nasal S aureus carriers. The mentioned rates are 
approximations using data from the literature cited in the text 
752 466 
S aureus infection.n.ll Likewise. non-carriers in a cross-
sectional study may actually be intermittent carriers. 
TIle definition of persistent carriage varies from study to 
study. There is no general consensus on how many 
cultures should be taken and how many cultures should 
be positive to define persistence. One study concludes that 
a "cUlture rule" that combines qualitative and quantitative 
results of two nasal swabs taken with a week interval can 
accurately classifY S aureus nasal carriage." Since 
adequate. internationally accepted definitions are needed. 
the so-called culture rule is an improvement for those 
studying determinants and risks of S aureus nasal 
carriage. 
Longitudinal studies show that about 20% (range 
12-30%) of individuals are persistent S au reus nasal 
carriers, approximately 30% are intermittent carriers 
(range 16-70%). and about 50% (range 16-69%) non-
carriers"·""·lI The very wide ranges found in the 
proportions of intermittent and non-carriers are the result 
of the use of different culture techniques. different 
populations being studied. and the use of different 
interpretation guidelines.'" Although at least seven nasal 
swab cultures are necessary to segregate non-carriers from 
intermittent carriers. the more nasal cultures are analysed. 
the higher the chance of identifYing an intermittent 
carrier." 
Children have higher persistent carriage rates than 
adults.21.J637 Rates vary substantially with age, falling from 
approximately 45% during the first 8 weeks to 21% by 
6 months.JS More than 70% of newborn babies have at 
least one positive nasal culture with S aureus.18 There is a 
transition from persistent carriage to intermittent or non-
carriage states during adolescence (figure 3)Y' Cross-
sectional surveys of healthy adult populations have 
reported S aurcus nasal carriage rates of approximately 
27% since 2000?')!'>-l(, This rate is much lower than the 
earlier reported prevalence 005%, which included studies 
since 1934.(' Plotting the carriage rates of either healthy 
populations or a general hospital population clearly 
illustrates a substantial decline in the S aureus nasal 
carriage rate in time (figure 4. patient categories with 
known higher S aureus nasal carriage rates, like dialysis 
patients. were excluded). Explanations for this decline 
include improved personal hygiene. changes in 
socioeconomic class.n and smaller families.'" 
Determinants of S aureus nasal carriage 
Although the reasons remain unknown. the basic 
determinants of persistent and intermittent carriage are 
thought to be different. Persistent carriers are often 
colonised by a single strain of S aureus over long time 
periods. whereas intermittent carriers may carry different 
strains over time."''''''! Furthermore. the load of S aureus is 
higher in persistent carriers. resulting in increased 
dispersal and a higher risk of infection. H." Nasal caniers 
who are also perineal carriers have higher S aureus loads 
and disperse more S aureus.'·21 ... 
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The mechanisms leading to S aureus nasal carriage are 
multifactorial. A recent study in which volunteers (non-
carriers and persistent carriers) were artificially inoculated 
with a mixture of S aureus strains showed that non-
carriers quickly eliminated the inoculated S aureus strains, 
whereas most persistent carriers selected their original 
resident S aureus strain from the inoculation mixture.'o 
The investigators concluded that host characteristics 
substantially co-determine the S aureus carrier state and 
that an optimal fit between host and bacteria seems to be 
essential. so 
This view is further supported by the fact that S aureus 
carriage rates vary between different ethnic groups, with 
higher rates in white peoples", and in men,s . .,.S} and depend 
on age. lJ•l •• " Patients with diabetes mellitus (both insulin 
dependent and non-insulin dependent);" patients 
tmdergoing haemodialysis"'5S or continuous peritoneal 
dialysis for end stage renal disease,l" patients with end 
stage liver disease;,7." patients with HIV;"'''' patients with 
S aureus skin infections and skin disease (eg, eczema or 
psoriasis),"}-('} and obesity and a history of cerebrovascular 
accident" have been shown to have higher S aureus nasal 
carriage rates. Most studies are hospital or outpatient-
clinic based and need confirmation from community-
based surveys. In one community-based study, Boyko and 
co-workers'A found similar S aureus carriage rates in 
diabetics and non-diabetics, by contrast with an earlier 
clinic-based study." 
Nasal colonisation of S aureus can be seen as the net 
result of repellent and attracting forces. There are four 
prerequisites to becoming a nasal carrier of S aureus. First, 
the nose has to come in contact with S aureus. Second, 
S aureus needs to adhere to certain receptors in the nasal 
niche. Third, S aureus needs to overcome the host 
defences. Finally, S aureus should be able to propagate in 
the nose. We will discuss these issues separately (table 2). 
How does S aureus reach the nose? 
S aureus cells can survive for months on any type of 
surface."" Hands are the main vector for transmitting 
S aureus from surfaces to the nasal niche-eg, nose 
picking.'" S aureus cells are principally found in the 
anterior nares (vestibulum nasi or "nose picking area"), 
and S aureus nasal carriage and hand carriage are strongly 
correlated.' Some studies find higher carriage rates more 
proximal in the nose, but these studies are rare and 
probably reflect a chance finding.,·7 S aureus may also reach 
the nose directly through the air, but this probably occurs 
less frequently."" However, airborne transmission is 
important for the dispersal of staphylococci to many 
different reservoirs, from where, via the hands, they can 
reach the nose. S aureus nasal carriers with rhinitis can 
disperse high loads of S aureus into the environment and 
may be the source of an outbreak of S aureus infections-
the so called "cloud" individual.'" 
Environmental factors can also influence the S aureus 
nasal carriage state. Hospitalisation, for example, has been 
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Figure 3: Rates of 5 aur.us nasal carriage according to age 
shown to be an important risk factor.7o Furthermore, it 
seems that S aureus carriers can "impose" their carrier 
state upon other household members. Recently, Peacock 
and colleagues" found concordant carrier states between 
mothers and their children. Also, Bogaert and co-workers" 
found large households (;;.five members) to be positively 
assodated with S aureus nasal carriage. Most mothers 
carry the same strain as their children. indicating that 
carriage strains are transmitted to close contacts.]" A study 
among an elderly population demonstrated that not only 
persistent but also non-carriage or intermittent S aureus 
nasal carrier states are shared among household 
members.71 Up to 65% of people with positive cultures 
living within one household shared genotypically identical 
strains.71 Intrafamilial spread of MRSA from and to 
health-care workers has also been shown to be an 
10 
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Figure 4: Reported S aureus nasal carriage rates through the years 
There is a Significant negative correlation between the year of reporting and the 
reported carriage rate (correlation coefficient -0·55; p<O·OOl). 
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important risk factor for the re-introduction of MRSA into 
hospitals.71 Furthermore. Herwaldt and colleagues71 
demonstrated that in 21% of patients receiving 
continuous peritoneal dialysis. the source of newly 
acquired nasal S aureus strains were their respective 
family members. 
Activities leading to skin lesions are also correlated with 
higher S aureus nasal carriage rates. These include river 
rafting." football." and (pig-)farming,7(. Repeated skin 
ptmctures in drug users and diabetics were thought to 
explain higher S aureus nasal carriage rates." However. 
recent studies do not support this theory: intravenous 
drug users have a lower prevalence of S aureus nasal 
carriage compared with drug users on an oral methadone 
programme,?' and S aureus nasal carriage rates are not 
different between diabetic patients injecting insulin and 
those using oral glucose-lowering medication."·M 
There is no relation between carriage rate and season-
ality, temperature, or relative humidityY'" A population-
based cohort of children and adolescents showed that 
active cigarette smoking is associated with a lower S aureus 
nasal carriage rate. whereas passive smoking is associated 
with a higher S aureus nasal carriage rate," The 
aetiological basis of this observation is unknown. 
How does 5 aureus withstand and evade the host immune 
response? 
Nasal secretions have a prominent role in the innate host 
defence. Components of nasal secretions that contribute 
to the innate immune response include immunoglobulin 
A and G, lysozyme, lactoferrin, and antimicrobial 
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peptides."" S aureus nasal carriers may have a 
dysregulation of these innate humoral factors in their 
nasal secretions." Such people have raised concentrations 
of the alpha-defensins (eg, human neutrophil peptide 
[HNP] 1, 2, and 3) and human beta-defensin 2 (HBD2), 
indicative of the presence of both neutrophil-mediated 
and epithelial-mediated inflammation." lipoteichoic acid, 
present in the S aureus cell wall, is a strong stimulus for 
neutrophil recruitment."' Therefore, this inflammatory 
response could be induced by S aureus colonisation, 
However, studies have shown that HNPl, 2, and 3, and 
HBD2 are not microbicidal against S aureus in vitro, 
suggesting that the host response is ineffective and 
insufficient to prevent S aureus nasal carriage.'" The role of 
the cellular response is unclear. The previously 
established relation between glycaemic control and 
S aureus carriage rate in diabeticslJ could be seen as the 
result of hyperglycaemia-related reduced phagocytic 
activation." 
Several studies have found that certain antimicrobial 
peptides have no or little activity against S aureus or that 
other peptides are needed to enhance their activity, .. ··1 
The inability of nasal antimicrobial peptides to clear 
S aureus from the nose may be explained by (1) the 
anatomy of the nose in relation to S aureus nasal carriage 
and (2) resistance of S aureus to many antimicrobial 
peptides.'o .•• S aureus predominantly colonises an area in 
the vestibulum nasi that is devoid of cilia and relatively 
free from nasal mucous secretions that contain 
antimicrobial peptides and immunoglobulins.'" It is 
nevertheless possible that the innate immune response 
prevents S aureus from invading the mucosa and 
causing more extensive forms of colonisation or even 
infection. 
In-vitro studies have shown that S aureus is able to resist 
certain cationic antimicrobial peptides by reducing the net 
negative charge of its cell wall and cell membrane. or 
perhaps by using efflux pumps or by releasing proteases."· 
S aureus has several mechanisms-including 
staphylokinase87 and membrane lipid modification88-
through which it can withstand an attack by cationic 
antimicrobial peptides, including defensins and 
cathelicidins, which are present in nasal secretions.""'" 
Whether the resistance of S aureus to defensins and other 
cationic antimicrobial peptides is a determinant of 
S ~u1"eus nasal carriage is currently not known. 
Cathelicidin can synergistically work with defensins to 
exert a bactericidal effect on S aureus." Furthermore. all 
S aureus strains are lysozyme resistant since they possess 
the peptidoglycan-specific O-acetyltransferase.'!tI 
The presence of S aureus in the nose elicits a subclinical 
immune response, as shown in a study where 
seroconversion occurred after carriage was established.''' 
S aureus produces protein A that binds the Fc region of 
iillI11unoglobulins, thereby inactivating tllem." It is clear 
that S aureus has a wide arsenal of strategies to evade the 
host immune response. Further studies are needed to 
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identifY all the components of the immWle response 
towards S aureus in the nose. 
How does 5 aureus adhere to, and propagate in, the 
anterior nares? 
The vestibulum nasi is limited laterally by the interior of 
the wing of a nostril and medially by a mucous fold (limen 
nasi) . behind which the nasal cavity with mucosal lining 
begins (figure 5) ." TIle epithelial inner wall of a nostril is 
fully keratinised and includes apocrine sweat glands. 
sebaceous glands. and hair follicles of the vibrissae:" Most 
studies on determinants of S aureus nasal carriage focus 
on mucosal and mucin binding.''''''' Considering the 
anatomy of the vestibulum nasi. this focus should be 
changed. 
Bibel and colleagues" demonstrated the importance of 
keratinised epithelial cells in binding S aureus. In addition 
to the nose. S aureus can also multiply independently in 
the area of the perineum.'7 Both the vestibulum nasi and 
the perineum contain large apocrine sweat glands. which 
is an important clue in studying determinants of S aureus 
nasal carriage. but has not been studied thoroughly.'" 
Since S aureus binding to mucosa or mucin probably has a 
transient nature. we propose that: (1) intermittent carriers 
are actually "mucosal carriers" and (2) persistent carriers 
use a special niche. such as an apocrine gland. where 
S aureus cells can multiply to high numbers. 
S aureus adherence may also be non-specifically 
mediated via physicochemical forces. including 
hydrophobic interactions.' Alternatively. adherence may 
be more specifically accomplished through binding of 
certain bacterial cell surface moieties (adhesins) to defined 
structural receptors in the membranes of the host cells ." 
S aureus has a greater affinity for nasal epithelial cells 
sampled from carriers than from non-carriers:" and the 
bacterium adheres better to nasal epithelial cells from 
patients with eczema than to cells from patients without 
eczema." 
Recent experiments have shown that clumping factor B 
(ClfB) and the S aureus surface protein G (SasG) bind to 
nasal epithelial cells ..... ·' clm specifically binds human 
cytokeratin type 10 and SasG to an unknown ligand of 
desquamated nasal epithelial cells." Also. cell wall teichoic 
acid is essential for S aureus nasal carriage!'lOU Microbial 
surface components recognising adhesive matrix 
molecules (MSCRAMMs) can bind to fibronectin. 
fibrinogen. and collagen related polysaccharides." 
MSCRAMMs probably have a role in the binding of 
staphylococci to sites where the mucosal lining is 
breached. exposing these matrix molecules.'" Differences 
in the expression of genes coding for these factors. 
depending on the ecological niche. and other putative 
adhesins and receptors may provide clues to the true 
determinants of S aureus nasal carriage or non-carriage. 
Bacterial interference has been postulated to be a major 
determinant of the S aureus carrier state. or rather. non-
carrier state. When an ecological niche is already occupied 
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Figure 5: Anatomy of the nostril 
Adapted from reference 92. 
by certain bacteria. other bacteria do not seem to have the 
means to replace this resident bacterial population.'o, The 
resident flora must be reduced or eliminated before other 
bacteria can successfully "interfere" with the resident 
bacterial population.'''' Cross-inhibition of the expression 
of various virulence factors by the accessory gene regulator 
(agr) and staphylococcal accessory regulator (sar) may be 
one mechanism by which one strain excludes others from 
colonising sites including the anterior nares. W ! although a 
large S aureus population genetic analysis failed to 
confirm this suggestion."" Still. bacterial interference can 
be seen as a determinant of S aureus nasal carriage. 
although it does not appear to be the ultimate 
determinant." 
Bacterial interference by active colonisation using a non-
pathogenic S aureus strain (S02A) was successful in 
nurseries during outbreaks of S aureus infections in the 
1960s and for treatment of patients with recurrent 
furunculosis .""·1fI1 The early practice of artificial 
inoculation with S aureus S02A was abandoned after 
alleged complications"" and the advent of newer 
antistaphylococcal antibiotics in the early 1970s. 
Bacterial population dynamics 
To understand S aureus nasal carriage and the relation 
with subsequent disease. we need to define the population 
structure of S aureus. Several techniques have been used 
to describe the natural population structure of S aureus. 
including multilocus enzyme electrophoresis.,o7 pulsed-
field gel electrophoresis."'" multilocus sequence typing 
(MLST).'" "" and amplified fragment length polymorphism 
(AFLP)."() These studies have revealed that S aureus is 
highly clonal. by contrast with other pathogenic species 
such as Streptococcus pneumoniae.'" Most recent studies 
have assessed the population structure of S aureus using 
MLST.'9.109 This molecular typing method characterises 
bacterial isolates on the basis of the sequence of internal 
fragments of seven housekeeping genes that represent the 
stable "core" of the bacterial genome. These MLST studies 
have placed most S aureus isolates (colonising as well as 
invasive isolates of meticillin-sensitive S aureus [MSSAJ 
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and MRSA) in five major clusters-clonal complex (CC) 8, 
CC30, CC5, CC22, and CC45."I'J·"Ull MRSA isolates were 
found in several major clonal complexes, indicating that 
meticillin resistance has developed in most distinct 
phylogenetic sub-populations of S aureus.,,0,1l4m The 
pandemic penicillin-resistant S aureus clone in the 1950s, 
now known as CC30, is currently re-emerging as a 
pandemic MRSA clone.
'
''''''7 
Most population structure studies of S aureus were 
biased by the use of mostly clinical isolates and collections 
of nosocomial MRSA.II~, I I ' Recently, the population 
structure of S aureus isolated from the nose of people 
living in the community was analysed by AFLP .110 AFLP is 
a whole genome typing method, documenting the 
contribution of "accessory genetic elements" as well as 
genome-core polymorphisms. This study revealed the 
existence of three major (I. II, III) and two minor (IVa and 
IVb) genetic clusters of S aureus (figure 6). AFLP clusters 
II and III-identical to MLST CC30 and CC45, 
respectively-account for almost half (47%) of all carriage 
isolates, suggesting that these two clonal complexes have 
evolved to be very successful in colonising human 
beings, 11 11 Melles and co-workers"o identified the same 
major clusters as the MLST studies (Oxford database, UK; 
http://www.mlst.net). Apparently, these clonal clusters 
have spread successfully worldwide. 110 
There is controversy as to whether all S aureus strains 
have equal disease invoking potential or whether invasive 
disease is associated with particularly virulent genotypes. 
Feil and co-workers!'" fOlmd no significant differences in 
the disuibution of genotypes between strains isolated 
from carriers and those from patients with invasive 
.' ,#- . . _, 44%. of t..1mage Isolates 
(.. ~;ery heterogeneous) 
• I 
= Carnage l50lates (children) 
.. Carriage i,olates (elderly) 
- Invasive isolates (chijdren) 
- Invasive isolates (elderly) 
-Impetigo 
-MRSA 
- Reference strains 
Figur. 6: Principal component analysis of 1056 5 aureus strains reveals genetic dusters of hypervirulent 
dones1l1J,ll' 
The diff.rent boxes, plotted here in a three· dimensional space and coloured according to their source, represent 
each S allrells strain analysed in the study. The five circles indicate the three major (I. II, and III) and two minor (IVa 
and IVb) different phylogenetic clusters identified by AFLP, Although strains from each of the genetic dusters are 
essentially able to cause invasive disease, some clusters contain proportionally more invasive isolates, 
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disease. There was, therefore, no evidence for the 
existence of hyper-virulent S aureus clones. By contrast, 
subclusters of strains with differential degrees of 
pathogenicity were observed in the study by Melles and 
colleagues,"U who identified subclusters with an over-
representation of bacteraemia isolates. Furthermore, 
expansion of multidrug-resistant clones or clones 
associated with skin disease (impetigo) were observed, 
Some clones have been shown to be more virulent than 
others; however, given the appropriate clinical conditions 
each and every strain of S aureus can become a life-
threatening pathogen. Another study found that invasive 
S aure:us strains belonging to a clonal complex are 
associated with a higher in-hospital mortality rate, 
indicating co-evolution of S aureus virulence and spread 
among human beings."9 This study also concluded that 
(major) CC45 was significantly under· represented among 
invasive strains (odds ratio [OR] 0·2, 0.04-0.6), which 
corroborated earlier findings.IIO,1I9 Furthermore, Peacock 
and colleagues! '" provided evidence of considerable 
horizontal transfer of virulence-associated genes in a 
clonal background. In summary, S aureus will remain an 
important clinical challenge and, apparently, some strains 
will present challenges that are more vigorous than others. 
It remains to be seen whether the possibility of identifying 
the more pathogenic clones of S aureus in the laboratory 
can be translated into a reliable diagnostic tool with 
clinical relevance in the future. 
Risks of S aureus nasal carriage 
Community-acquired infections 
Most-studies regarding the risks of acquiring S aureus 
infections in the community concern skin and soft tissue 
infections. Several, mostly older, studies investigated the 
relation between S aureus nasal carriage and skin 
infections, '" including furunculosis,1Zl,!lJ impetigo,'" 
sycosis barbae,!lI,m,,,; and stye.116 On average, 80% (range 
42-100%) of those with skin lesions were S aureus nasal 
carriers, and 65% (range 29-88%) had the same phage 
type in the nose and lesion. 
In one large prospective population-based study among 
elderly people there was no relation between persistent 
S aureus nasal carriage and all-cause mortality, a surrogate 
end-point for serious staphylococcal disease.7' Earlier 
retrospective cohort or case-control studies have 
demonstrated increasing age, male sex, alcoholism, lung 
disease, cancer, diabetes mellitus, end stage renal failure, 
and dialysis to be risk factors for community-acquired 
S aureus infections necessitating hospital admission.l17-119 
These factors have also been identified earlier as 
determinants of S aureus nasal carriage in case-control or 
cross-sectional studies.' 
The spectrum of commtmity S aureus disease is rapidly 
changing with the advent and spread of community-onset 
MRSA strains.7·,,'IC,,1l0,1l' Overall MRSA carriage rates in the 
community are stilllow,W,ll! but seem to be rising rapidly 
in certain parts of the world. uO,m In the only prospective 
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study done so far on nasal carriage of community-onset 
MRSA and risk of infections in soldiers, Eliis and co-
workers'" found a relative risk on· 1 (95% CI 1· 5-6·5) for 
nasal MRSA carriers to acquire a MRSA infection (eg, 
cellulitis, abscesses) in the commtmity. In a retrospective 
study concerning community-onset MRSA skin infections 
among professional football players, Kazakova and 
colleagues7\ did not find any MRSA in nasal swabs or 
environmental cultures, although 42% were nasal carriers 
of MSSA strains. Apart from these highly selected 
populations, it remains questionable whether the results 
from these studies can be extrapolated to the general 
population.'" We need more community-based studies to 
better understand the ecology, pathophysiology, and 
epidemiology of S aureus nasal carriage and infections in 
the community and to develop and target preventive 
measures. 
Nosocomial infections 
S aureus (MSSA as well as MRSA) ranks as the second 
most common cause of hospital-acquired (nosocomial) 
bloodstream infections. About 20% of patients 
undergoing surgery acquire at least one nosocomial 
infection. leading to increased morbidity. mortality, 
hospital stay. and costs.l!·~"'J Hospital treatment usually 
requires that first line barriers for pathogens--of which 
the skin is an important one--are intentionally breached. 
resulting in an increased risk of infection. Most of these 
nosocomial S aureus infections are caused by the patient's 
own S aureus cells, which were already present on the skin 
or mucosal membranes before hospital admission in at 
least 800/0 of the casesY It could well be that more 
infections are of endogenous origin, since 10% of the 
nasal S aureus carriers have more than one genotype or 
phage type in their nose. S,"" 
5 aureus nasal carriage has been identified as a risk 
factor for the development of nosocomial infections in 
general hospital populations.''' surgical patients 
(general.',(,,9 orthopaedic.''' thoracic surgery,'" and 
children'''), patients on haemodialysis or continuous 
peritoneal dialysis,w,,.,14,,J4(, patients with liver cirrhosis and 
after liver transplantation.'8,147-'" HIV-infected patients.'"'''' 
and patients admitted to intensive care units.'· .... ,\] In a 
recent study there was a threefold increased risk for non-
surgical patients who were S aureus nasal carriers to 
acquire a nosocomial S aureus bacteraernia versus non-
carriers.' Also nasal carriers among surgical patients have 
a higher risk (OR 4·0) for nosocomial S aureus 
bacteraemia compared with controls.';' 
Second to coagulase-negative staphylococci,S aureus is 
the most prevalent organism causing intravascular device-
associated bacteraemia.','37,'" Pujol and colleagues"'" 
looked at bacteraemia in an intensive care unit. Most of 
the 5 aureus bacteraemias had an intravascular device as a 
source. In this study. carriers of S aureus had a relative risk 
of 12·4 for the development of S aureus bacteraemia. "" In 
a study by Wertheim and co-workers,' the source of 
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bacteraemia was device related in more than 50% of the 
cases. Interestingly, the mortality rate from S aureus 
bacteraemia is higher in non-carriers compared with 
carriers.' Since bacteraemia is usually endogenous in 
carriers. partial immunity may have an important role 
here. This finding needs confirmation and the underlying 
medlanism resolved. 
In HIV-positive patients, increased rates of S aureus 
bacteraemia and deep soft tissue infections have been 
observed. which frequently recur. Even higher infection 
rates are fotmd in patients with AIDS compared with 
HIV-positive asymptomatic patients. Nguyen and 
colleagues" found that nasal carriage is an important risk 
factor in this patient population (OR 5 ·1). Other risk 
factors for infection in this study were presence of a 
vascular catheter (OR 4·9), low CD4 cell count 
«100 cells/f.l.L; OR 3·5), and neutropenia. The risk for 
developing an S aureus infection was approximately 10% 
for every 6 months in patients who were nasal carriers of 
S aureus and had CD4 cell counts ofless than 100 cells/ f.l.L. 
It should be noted that S aureus nasal carriage was more 
common in patients who were not receiving co-
trimoxazole prophylaxis for prevention of Pneumocystis 
jiroveci pneumonia. 
In haemodialysis patients. S aureus is the most 
frequently found pathogen in infections at the vascular 
access site and in bacteraemia. The infection rate is higher 
in carriers on haemodialysis, with relative risks varying 
from 1· 8 to 4· 7.',,",14\,146';" S aureus isolates are usually 
identical to the one previously isolated from the patient's 
nose."" In a study by Nielsen and colleagues,1\', the relative 
risk for S aureus bacteraemia was 26·2 (6·1-113) when 
S aureus was colonising the insertion site, and 
3·3 (0·74-15·1), in the case of only S aureus nasal 
carriage. However, multiple studies have demonstrated 
that long-term eradication of S aureus nasal carriage by 
(repeated) application of mupirocin effectively prevents 
S aureus infections among patients who are receiving 
dialysis. thereby decreasing complications and costS.1I7-'60 
Additional application of a local antibiotic ointment to exit 
sites is also important in preventing infections.'M 
In patients on continuous peritoneal dialysis, S aureus is 
the leading cause of continuous peritoneal dialysis-related 
infections, often leading to catheter loss. S aureus nasal 
carriage has been found to be a major risk factor for 
infections in patients on continuous peritoneal dialysis, 
mainly associated with exit site and tunnel 
infections. ;1.10,"2-"'" Intervention studies consistently 
demonstrated a substantial reduction in the incidence of 
exit site infections, but not a consistent reduction in the 
incidence of continuous peritoneal dialysis-related 
peritonitis.\4,'66-"o Two studies did not find a correlation 
between S aureus nasal carriage and the development of 
5 aureus exit site infections.''',17l In a recent study it was 
demonstrated that only continuous peritoneal dialysis 
patients who are persistent S aureus nasal carriers are at 
increased risk of acquiring continuous peritoneal dialysis-
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Search strategy and selection criteria 
We searched Pubmed with the following search terms: 
"Staphylococcus aureus", "colonisation", "carriage", "nose", 
"nasal", "vestibulum nasi", "mucosa", "nasal", "nosocomial", 
"epidemiology", "determinants", "risk factor", "treatment", and 
"infection". The following limits were used: English language, 
abstract, and human studies. We identified additional articles 
by searching the reference lists of existing articles. 
related S aureus infections. n Intermittent nasal carriers of 
S aureus have the same risk of S aureus infection as non-
carriers .... Targeting interventions to prevent continuous 
peritoneal dialysis-related infections is thus possible, 
thereby eliminating unnecessary prophylactic and 
therapeutic antibiotic use and resistance development. l7J 
The nasal strain and the infectious strain are clonally 
related in most patients on continuous peritoneal dialysis 
with S aureus infection.I •. B •56 
Studies in the 1950s and 1960s show that with 
increasing numbers of staphylococcal bacteria in the nose, 
as in persistent carriers, S aureus skin carriage rates 
increase proportionally. in parallel with a rise in risk of 
S aureus surgical site infections.'·u.l74.m The more recent 
observation that patients carrying S aureus in their nose as 
well as perineal (or rectal) skin are at a higher risk for 
subsequent S aureus infections when compared with only 
perineal or nasal carriers can probably also be explained by 
a higher S aureus load.'" Presumably people who carry 
S aureus in their nose contaminate their hands, then 
transferring the organism to other sites on their bodies.'"' 
The number of staphylococcal cells needed to cause 
infection decreases dramatically at the site of a suture, 
compared with healthy skin."" 
Although S aureus nasal carriage is unanimously 
accepted as one of the most important risk factors for 
nosocomial and surgical site infections today and studies 
using historical controls have reported substantial 
reductions of surgical site infections among patients 
receiving mupirocin.1JI •. m -'7') randomised controlled trials 
uniformly failed to confirm these results.,·,so.'81 Perl and 
colleagues') could only demonstrate a significant effect 
(48% risk reduction, p=0· 02) on the rate of nosocomial 
S aureus infections after surgery among S aureus nasal 
carriers before surgery. The 37% reduction in S aureus 
surgical site infections was not statistically significant 
(p=0·15): Wertheim and colleagues"" and Kalmeijer and 
co-workers'" did not find a significant effect of eradication 
of S aureus nasal carriage in a general hospital and 
orthopaedic patient population, respectively. In the study 
of Perl and co-workers; 53% of S aureus surgical site 
infections occurred in the non-carrier group, and 15% of 
the S aureus surgical infections in carriers was caused by a 
strain other than their resident strain. These infections 
probably result from exogenous transmissions from the 
hospital environment or undetected extra-nasal S aureus 
472 
carriage sites. Health-care workers can be important 
sources of transmission of S aureus and cross-infection.'" 
Conclusions 
Many studies have been published on S aureus nasal 
carriage--a Pubmed search with the terms 
"Staphylococcus aureus" and "nasal" gives 1383 hits. 
Based on these studies and the results of contradicting 
twin studies""'" a simple Mendelian trait probably does 
not explain the different S aureus nasal carrier states. ".41< 
The repeated exposure to S aureus in the (household) 
environment is considered to be an important 
determinant of S aureus nasal carriage, probably more 
important than the genetic background of individuals. 
In general, a multifactorial genesis underlies S aureus 
nasal carriage. 
We now need to identifY which factors of S aureus and 
the nasal niche are of importance in adherence. Recent in-
vitro and in-vivo studies in rats have begun to elucidate 
these factors, which is an important step forward ..... "" 
Furthermore, we may need to change the focus from 
mucosal adherence to adherence to more prevalent 
epitopes present in the anterior nares. The real 
importance of these factors needs to be confirmed in a 
human colonisation model. Only then may we find new, 
effective ways of decolonising the nares and other body 
sites.-So far there is limited evidence that decolonisation of 
the anterior nares to prevent staphylococcal disease is only 
effective in dialysis and surgical patients. Recent clinical 
trials in non-surgical and orthopaedic patients did not 
show any positive effect.''''·,·, Focusing only on at-risk 
patients-eg, persistent carriers-may improve the 
outcome of an intervention. Also the decolonisation of 
extra-nasal sites needs to be improved." 
So far, there has been concem only for the increased risk 
of S aureus nasal carriers for acquiring S aureus infections. 
However, studies have shown that non-carriers who 
acquire exogenous S aureus bacteraemia have a fourfold 
increased mortality rate compared with S aureus nasal 
carriers.7 Thus, the immunological mechanisms of 
S aureus nasal carriage need to be resolved. In non-
carriers, preventing the acquisition of S aureus strains 
deserves more attention. 
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Methicillin-Resistant Staphylococcus au reus: 
An Evolutionary, Epidemiologic, 
and Therapeutic Odyssey 
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Methicillin-resistant Staphylococcus au reus, first identified just over 4 decades ago, has undergone rapid evo-
lutionary changes and epidemiologic expansion. It has spread beyond the confines of health care facilities, 
emerging anew in the community, where it is rapidly becoming a dominant pathogen. This has led to an 
important change in the choice of antibiotics in the management of community-acquired infections and has 
also led to the development of novel antimicrobials. 
HISTORICAL BACKGROUND 
AND EPIDEMIOLOGY 
It was only 1 year after an Oxfordshire constable, Albert 
Alexander, became the first recipient of penicillin, that 
Rammelkamp reported the identification of isolates of 
Staphylococcus aureus resistant to this miracle drug [1]. 
Infections caused by penicillin-resistant S. aureus were 
initially limited to hospitalized patients and were only 
later detected in the community, where they eventually 
became common [2]. In an historical reprise, the iden-
tification of methicillin-resistant S. aureus (MRSA) was 
reported within 1 year after the 1960 introduction of 
this semisynthetic penicillin, and once again, an or-
ganism that was initially present only in hospitals later 
became prevalent in the community [2, 3]. The spread 
of MRSA from the hospital to the community was a 
predictable event. The emergence in the past decade of 
novel strains of MRSA in the community that are ge-
netically distinct from MRSA strains originating in the 
hospital was perhaps less anticipated. 
MRSA is currently the most commonly identified 
antibiotic-resistant pathogen in US hospitals [4, 5]. Al-
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though 25.9% of S. aureus strains isolated from out-
patients were methicillin resistant [5], most of these 
strains were recovered from individuals who were likely 
to have acquired them in the health care environment 
[6, 7J. Their association with health care may, however, 
have been indirect; household contacts of individuals 
with hospital-acquired MRSA (HA-MRSA) are at sig-
nificantly increased risk for MRSA colonization [8]. In 
a recent and dramatic evolutionary development, how-
ever, infection with novel community-acquired strains 
of MRSA (CA-MRSA) in previously healthy individuals 
without either direct or indirect association with health 
care facilities has emerged as a new and important pub-
lic health problem [9-11]. 
In-some community settings, CA-MRSA have be-
come the prevalent form of S. aureus isolated from 
cutaneous infections, especially among children. At a 
Houston pediatric hospital, 74% of community-ac-
quired S. aureus strains isolated since 2001 have been 
resistant to methicillin [12]. Clusters and outbreaks in 
adolescents and adults have been reported to occur in 
Native Americans [13], homeless youth [14], men who 
have sex with men [9], jail inmates [10], military re-
cruits [15], children in child care centers [16], and 
competitive athletes [17]. Although most infections 
have involved skin and skin structures, potentially lethal 
invasive infections have also occurred. The report in 
1999 of the deaths of 4 previously healthy children in 
Minnesota and North Dakota who did not have pre-
vious contact with health care facilities unequivocally illustrated 
the potential dangers presented by CA-MRSA [18). 
Reversing and completing an epidemiologic cycle, CA-MRSA 
are now being introduced from their site of origin in the com-
munity into the hospital [19,20). At some hospitals, CA-MRSA 
are displacing classic hospital-associated strains of S. aureus, 
which is consisitent with the hypothesis that the former may 
be more fit [21). 
MOLECULAR EPIDEMIOLOGY OF METHICILLIN 
RESISTANCE 
The mechanism of resistance to methicillin was uncovered in 
1981 with the the identification of reduced-affinity penicillin-
binding proteins in MRSA [22). The altered protein, PBP2a 
(PBP2' in the United Kingdom), retains effective transpeptidase 
activity while having reduced affinity for penicillin and other 
available /3-lactam antibiotics. PBP2a exhibit both a reduced 
rate-constant for acylation by /3-lactams and elevated dissoci-
ation constants [23). These 2 factors, acting together, prevent 
acylation of PBP2a and thus result in /3-lactam resistance [23). 
PBP2a is encoded by the mecA gene (for a glossary of genetic 
terms, see Appendix) [24). The mobile mecA gene complex is 
comprised of mecA together with its regulator genes, mecI and 
mecR, and resides within a genomic island, the staphylococcal 
cassette chromosome mec (SCCmec) that constitutes 1%-2% 
of the -2.9 million-bp S. aureus chromosome [24-26) (figure 
1). SCCmec also contains the insertion sequence, IS431 mec, as 
well as recombinases necessary for site-specific integration and 
excision. Some SCCmec types also contain various additional 
genetic elements, such as Tn554 (which encodes resistance to 
macrolides, clindamycin, and streptogramin B) and pTl81 
(which encodes resistance to tetracyclines) [2). 
The expression of PBP2a is induced by the binding of /3-
lactam antibiotics to a cytoplasmic membrane sensor-trans-
ducer receptor encoded by the mecRl gene, triggering a signal 
leading to the proteolytic release of the mecI repressor from 
the operator region of the mecA gene [27, 28). Phenotypic 
resistance to methicillin is variably expressed, and population 
analysis demonstrates that each MRSA strain has a character-
istic growth profile at each concentration of methicillin ex-
amined [29). In contrast to this heterogeneously expressed re-
sistance to methicillin, homogeneous resistance requires the 
interaction of additional factors, such as the femA-F genes that 
are involved in peptidoglycan synthesis [30). 
MOLECULAR EVOLUTIONARY HISTORY 
Although PFGE is commonly used in hospitals to determine 
the relatedness of isolates for epidemiologic purposes, this 
method is insufficiently discriminatory for evolutionary studies 
[31). The overall genetic background of S. aureus isolates is 
unambiguously determined through multiJocus sequence typ-
.'lnwcRI IS43lm,,,, 
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Figure 1. Diagram showing the staphylococcal cassette chromosome 
mec type IV (SCCmec type IV) (adapted from [24)). SCCmec type IV lacks 
antibiotic resistance elements directed at non-/3-lactam antibiotics that 
are present in SCCmec types characteristic of hospital-acquired methi-
cillin-resistant Staphylococcus aureus. ccrA2and ccrB2designate cassette 
chromosome recombinases. viS 1272designates IS431mec insertion se-
quences. mecA encodes PBP2a. orfX indicates an open reading frame. 
t:.mecRl is a signal transducer gene whose activation by /3-lactam an-
tibiotics inactivates the mecl repressor gene product. allowing expression 
of mecA. 
ing by determination of the sequence of portions of 7 house-
keeping genes [25). The mobile SCCmec elements, on the other 
hand, are classified by analysis of their cassette chromosome 
recombinase (cer) and mecA gene complexes [32). SCCmec 
types also differ with regard to their acquisition of resistance 
determinants acquired as the result of integration of plasmids 
and transposons [32). At least 5 SCCmec types (types I-V), 
varying in size from -20 kb to 68 kb, have been identified [33) 
(table 1). The smallest of these-SCCmec types I, IV, and V-
contain only recombinase genes and the structural and regu-
latory genes for resistance to methicillin and lack the trans-
posable elements and genes encoding resistance to non-/3-lac-
tam antibiotics carried by types II and III [33, 35). SCCmec 
types I-IV contain alleles of cerA and cerE, whereas type V, 
which has to date been identified in a small number of Aus-
tralian CA-MRSA isolates, contains a novel cerdesignated ccrC 
[33). Two possible additional SCCmec types have recently been 
identified among Australian CA-MRSA strains [36). 
Genetic evolutionary analyses have demonstrated that the 
mecA gene has been transferred into methicillin-susceptible S. 
aureus (MSSA) on *20 occasions, having emerged in *5 phy-
logenetically d~stinct lineages (as well as reemerging within ind-
vidual lineages) [25, 31, 37J. It has been suggested that the 
emergence of PBP2a initially resulted from a recombination 
event involving the genes encoding an existing PBP and an 
inducible /3-lactamase [38). The donor strains that became the 
source of PBP2a are likely to have been coagulase-negative 
staphylococci, with Staphylococcus sciuri identified as a prime 
candidate [39). A recent study of 44 methicillin-resistant Staph-
ylococcus epidermidis isolates from the blood of patients with 
prosthetic valve endocarditis from 1973 to 1983 found that 2% 
carried SCCmec type I, 34% carried type II, 28% carried type 
III, and 36% carried type IV [40). The introduction of mecA 
from the putative donor species into MSSA strains that are 
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Table 1. Characteristics of staphylococcal cassette chromosome mac ISCCmec) types I-V. 
SCCmec SCCmec 
type size. kb 
34 
Other 
antibiotic-resistant 
elements (gene) on SCCmec 
Origin of 
S. aureus isolatates 
carrying the specified 
SCCmec type 
Presence of 
Panton-Valentine 
leukocidin in 
S. aureus isolates 
carrying the specified 
SCCmec type" 
II 
III 
IV 
V 
53 
67 
21-24 
28 
PUB110 (aadO)b. Tn554 (ermA!" 
PUB110 (aadO)b. PT181 (tetK)d 
Hospital 
Hospital 
Hospital 
Infrequent 
Infrequent 
Infrequent 
Frequent 
Unknown 
Community 
Community 
NOTE. Data is adapted from 140J and 11551. PVL. Panton-Valentine leukocidin; S. aureus. Staphylococcus aureus. 
a In general. <5% of 5. aureus strains that carry SCCmec types I-III also carry the PVL gene; with some exceptions. 
40%-90% of S. aureus strains that carry SCCmec type IV carry the PVL gene. 
b Encodes resistance to tobramycin and kanamycin. 
C Encodes resistance to macrolide-lincosamide-streptogramin antibiotics. 
d Encodes resistance to tetracycline. 
already successfully adapted to hospital environments and to 
the community have, in turn, created successful epidemic HA-
MRSA and CA-MRSA clones [31, 35, 41, 42]. 
Evidence indicates that the ancestral MRSA genotype, ST250-
MRSA, is a strain originating in Denmark and possessing 
SCCmec type I, most extant isolates of which were obtained in 
the 1960s [37]. (By convention, strains are named by their 
sequence type [ST] and the presence or absence of methicillin 
resistance. Thus, this strain is a methicillin-resistant S. aureus 
of a sequence type designated as 250). ST250-MRSA arose as 
the consequence of the acquisition of the mec gene by the 
methicillin-susceptible strain ST250-MSSA, which had itself 
arisen from ST8-MSSA by a chromosomal point mutation [37). 
ST250-MRSA is no longer a major cause of epidemic MRSA 
infections, but ST247-MRSA (the "Iberian clone"), which 
evolved from ST250-MRSA by a single point mutation, remains 
an important hospital pathogen in Europe and has been re-
ported to have caused an outbreak in a New York City hospital 
[43]. As indicated above, there have since been multiple intro-
ductions of mec into S. aureus [31]. The emergence of CA-
MRSA strains, in particular, has repeatedly occurred as a result 
of the introduction of SCCrnec type IV into a variety of genetic 
MSSA backgrounds [41). In the United States, one of the re-
sultant clones, ST8-MSSA (USA 300) has proven increasingly 
successful [44]. 
EPIDEMIOLOGIC SUCCESS AND VIRULENCE 
OF CA-MRSA 
CA-MRSA strains differ in a number of important ways from 
the 6 major pandemic clones of MRSA that account for nearly 
70% of epidemic HA-MRSA strains [45]. These differences are 
found in the composition of the gene cassette coding for meth-
icillin resistance, in the carriage of plasmids encoding resistance 
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to antibiotics of other classes (as well as resistance to heavy 
metals), and in their associated virulence factors. 
The earliest strain of MRSA in which SCCmec type IV has 
been identified was isolated in 1981 [32]. Despite this appar-
ently recent emergence, an analysis of a large number of MRS A 
isolates detected SCCrnec type IV in twice as many clones as 
any of the other types, suggesting its greater promiscuity and 
successful persistence [26]. This may be the result of greater 
efficiency of transfer and/or a lesser fitness cost to the recipient 
clone, possibly because of its smaller size and lack of the" excess 
baggage" included in other SCCmectypes [26,35,41]. Although 
HA-MRSA has been reported to replicate more slowly than 
MSSA [46], a CA-MRSA clinical isolate harboring SCCmectype 
IV has been demonstrated to replicate more rapidly than HA-
MRSA isolates with other SCCmec types [41, 42J. In contrast, 
transformation of an SCCrnec type I element into S. aureus 
strains yielded highly oxacillin-resistant transformants with a 
reduced growth rate [47]. This relatively greater fitness ofCA-
MRSA strains carrying SCCrnec type IV may account for its 
remarkable success in displacing other MRSA strains in some 
hospitals after its introduction from the community [21]. 
MOLECULAR BASIS OF VIRULENCE 
OFCA-MRSA 
Sequencing of the genome of CA-MRSA strain MW2, which 
caused fatal sepsis in a 16-month-old girl from North Dakota 
[18], identified 19 putative virulence genes not found in 5 
simultaneously examined HA-MRSA strains [42]. These in-
cluded genes for several superantigens, such as enterotoxins B 
and C, as well as the amphipathic leukotoxin, the Panton-
Valentine leukocidin (PVL). PVL, first described in 1932 [48), 
is a bicomponent synergohymenotropic (synergistic mem-
brane-tropic) toxin that was present in <5% of unselected S. 
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aureus isolates but is present in the majority of CA-MRSA 
isolates studied [49, 50]. CA-MRSA isolates from Australia, on 
the other hand, infrequently carry the genes encoding PVL [36]. 
PVL is encoded by contiguously located cotranscribed 
genes, lukS-PVand lukF-PV, inserted near the att site [50]. 
These genes are transmitted by a temperate phage designated 
0PVL [51, 52]. Their gene products, 33 kDa and 34 kDa in 
size, respectively, assemble as hetero-oligomers and synergis-
tically exert cytolytic pore-forming activity specifically di-
rected at the cell membranes of polymorphonucelar neutro-
phils and monocytes and/or macrophages [49, 50J. Injection 
of PVL into the skin of rabbits causes dermal necrosis [53), 
suggesting that it may playa role in the severity of skin and 
skin-structure infections in humans. In addition, an associ-
ation between PVL-containing strains of MRSA and virulent 
necrotizing pneumonia has been reported [54]. 
RESISTANCE TO ANTIBIOTICS OTHER THAN 
/3-LACTAMS 
In contrast to the multidrug resistance usually seen in HA-
MRSA strains, antibiotic resistance in CA-MRSA strains is often 
limited to iJ-lactams. The small size of SCCmec type IV may 
preclude its carriage of additional genetic material, in contrast 
to the characteristic presence of additional genetic material in 
SCCmec type II and SCCmec type III [25, 26]. This does not, 
however, preclude chromosomally encoded resistance or the 
presence of resistance plasmids in strains carrying any of the 
mec types. For instance, some CA-MRSA strains isolated in 
western Australia contain a 41A-kb plasmid encoding resistance 
to tetracycline and trimethoprim, as well as resistance to mu-
pirocin and cadmium [55, 56). Fluoroquinolone resistance is 
frequent in CA-MRSA carrying SCCmec type IV isolated from 
homeless youth in San Francisco [57). Nonetheless, in contrast 
to HA-MRSA strains, most CA-MRSA isolates remain suscep-
tible to tetracyclines, clindamycin, and trimethoprim-sulfa-
methoxazole (TMP-SMZ) [11). 
AVAILABLE ANTIBIOTICS FOR THE 
TREATMENT OF MRSA INFECTION 
Vancomycin. Compared with iJ-lactam therapy, vancomycin 
therapy has been associated with slower clinical response and 
longer duration of MSSA bacteremia, and it has been asso-
ciated with more frequent complications in patients with en-
docarditis [58, 59). Failure of vancomycin therapy may be 
observed in the treatment of patients with bacteremia due to 
strains of MRSA that have MICs of vancomycin well within 
the range considered susceptible [60]. Heterogeneous van-
comycin resistance, which is not readily detected by routine 
clinical laboratory methodology, is also associated with failure 
of vancomycin therapy [61, 62]. The appearance of vanco-
mycin-intermediate S. aureus and, more recently, vancomy-
cin-resistant S. aureus is of further concern [63]. 
Quinupristinldalfopristin. This combination is active in 
vitro against MSSA and MRSA [64). It is bactericidal against 
S. aureus, although in the presence of constitutive expression 
of macrolide-lincosamide-streptogramin resistance, it is only 
bacteriostatic [65J. In a randomized trial, patients with noso-
comial MRSA pneumonia who received quinupristin/dalfo-
pristin had a clinical response rate of 19.4%, compared with 
40% in vancomycin recipients [66). 
Linezolid. Linezolid and vancomycin yielded comparable 
results in hospitalized patients with MRSA infections at a variety 
of anatomic sites in a randomized, open-label trial [67), as well 
as in the treatment of skin and skin-structure infections caused 
by gram-positive organisms [68). A retrospective subset analysis 
of 2 prospective randomized clinical trials found evidence sug-
gesting that Iinezolid was superior to vancomycin in the treat-
ment of hospital-acquired pneumonia due to MRSA [69, 70). 
Daptomycin. Daptomycin is a novellipopeptide antibiotic 
with bactericidal activity against S. aureus that binds, in a cal-
cium-dependent manner, to the bacterial cell membrane, dis-
rupting membrane potential [71]. Daptomycin has received 
approval from the US Food and Drug Administration for the 
treatment of complicated skin and skin-structure infections due 
to susceptible gram-positive pathogens [72]. Daptomycin ther-
apy failed in a trial involving patients with community-acquired 
pneumonia; daptomycin not only has limited penetration into 
pulmonary epithelial lining fluid, but its activity is inhibited 
by pulmonary surfactant [72, 73). 
Tetracyclines. In vitro susceptibility results involving tet-
racycline derivatives must be interpreted with caution, because 
S. aureus isolates that are tetracycline-resistant but that have 
relatively low MICs of doxycycline and/or minocycline may, in 
fact, harbor inducible efflux genes [74, 75). Minocycline has 
been shown to have bactericidal activity similar to that of van-
comycin against a single strain of MRSA in an animal model 
of endocarditis [76). Of 14 patients with MRSA infection who 
were treated with doxycycline or minocycline, either alone or 
in combination with rifampin, 3 (21 %) experienced treatment 
failure [77]. 
TMP-SMZ. TMP-SMZ was less active than vancomycin in 
a rabbit model of MRSA endocarditis and less rapidly bacte-
ricidal than nafcillin in a rabbit model of MSSA meningitis 
[78,79). A randomized trial of treatment of S. aureus infections, 
47% of which were due to MRSA, concluded that treatment 
with TMP-SMZ was inferior to treatment with vancomycin 
[80]. An extensive literature review, however, concluded that 
TMP-SMZ "may be effective for the treatment of infections 
due to low bacterial burdens of susceptible strains of S. aureus" 
[81, pg. 340). 
Fluoroquinolones. Although most CA-MRSA strains are 
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reported to be fluoroquinolone susceptible, this is not true in 
some locales [36, 57J. Fluoroquinolone resistance emerged very 
rapidly in HA-MRSA in the years after widespread utilization 
of agents of this class; at one institution, fluoroquinolone re-
sistance increased from 7% before 1988 to 83% in 1990 [82J. 
In vitro passage of both fluoroquinolone-susceptible MSSA and 
MRSA in the presence of either ciprofloxacin or levofloxacin 
is associated with the frequent selection of clones resistant to 
these antibiotics [83 J. Furthermore, fluoroquinolones select 
MRSA from among heterogeneously methicillin-resistant pop-
ulations in vitro [84], and fluoroquinolone use is associated 
with an increased risk of nosocomial acquisition of MRSA (but 
not of MSSA) [85J. The fluoroquinolones with C8 substitu-
tions, such as gatifloxacin and moxifloxacin, appear to be more 
potent against S. aureus than are older drugs of this class, and 
they may be less likely to select resistant mutants, an effect that 
may be strengthened by the addition of rifampin [86-88J. 
Clindamycin. Clindamycin has been used successfully in 
the treatment of invasive CA-MRSA infections in children [89, 
90J. Inducible resistance to c1indamycin, however, is not de-
tected by routine susceptibility testing, but requires the use of 
other methods (e.g., a double-disk diffusion test) [90-93J . Flat-
tening of the zone in the area between the disks to resemble 
the letter "D" indicates the presence of inducible resistance 
(figure 2 and table 2). 
Rifampin. Rifampin selects resistant mutants from among 
both MSSA and MRSA strains at a frequency of 10-6 to 10-8, 
but this may be prevented by using rifampin in combination 
with a second active drug [94J. 
Topical agents. MRSA strains that are resistant to mupi-
rocin, mutants of which can be selected in vitro at frequencies 
of 10- 7 to 10-8, are reported with increasing frequency [95J. 
MRSA isolates with elevated MICs oftriclosan have been iden-
tified [96, 97]. 
OVERVIEW OF CHOICE OF SYSTEMIC 
ANTIBIOTIC THERAPY 
For some infections that require parenteral therapy and are due 
to MRSA strains that are multidrug resistant, the treatment 
choices may be restricted to vancomycin, daptomycin, linezolid, 
and quinupristinldalfopristin therapy. The potential superiority 
of linezolid therapy over vancomycin therapy in treating nos-
ocomial pneumonia due to MRSA has been noted [69, 70J. 
Daptomycin is ineffective in the treatment of pneumonia (Cub-
ist Pharmaceuticals, data on file). The bacteriostatic activity of 
linezolid may prove to limit its effectiveness in circumstances 
in which bactericidal activity is required [67J. 
Choices for treatment of infections due to CA-MRSA may 
include, in a<;kijtion to the drugs mentioned above, TMP-SMZ, 
tetracyclines, c1indamycin, and fluoroquinolones. The wide-
spread use of fluoroquinolones for treating these infections 
may, if history repeats itself, lead to the rapid emergence of 
resistance to this class of antibiotics. Tetracycline therapy, con-
traindicated in children and in those who are pregnant, may 
prove to be effective, but further clinical data are required. 
TMP-SMZ appears to be effective in treating infections of lim-
ited extent and severity. Linezolid is an effective agent for which 
Figure 2. Image shows the results of a double-disk diffusion test for inducible. erm-mediated resistance to clindamycin. The demonstration of 
flattening of the clindamycin zone between the disks is indicative of inducible resistance to clindamycin [34J. 
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use has been limited by its cost. Antibiotic therapy is not always 
required: a retrospective analysis has found resolution of CA-
MRSA infection in children with subcutaneous abscesses <5 
cm in diameter who underwent incision and drainage in the 
absence of administration of an antibiotic to which the path-
ogen was susceptible [98 J. 
INVESTIGATIONAL AGENTS WITH ACTIVITY 
AGAINST MRSA 
Semisynthetic glycopeptides. Oritavancin is a semisynthetic 
glycopeptide derivative that is active against some vancomycin-
resistant, gram-positive bacteria [99, 100]. A randomized trial 
of oritavancin in the treatment of skin and skin-structure in-
fections demonstrated results comparable to those observed 
with a vancomycin-based regimen [10 1]. Its mean terminal 
plasma half-life (± SD) of 151 ± 39 h allowed it to be given 
in a total of 3 daily doses [10 1, 102]. 
Dalbavancin has a terminal plasma half-life of 9-12 days 
[ 103]. A total of 2 doses given 1 week apart in the treatment 
of skin and skin-structure infections resulted in a 94% cure 
rate, compared with a 76.2% cure rate in those patients ran-
domized to receive standard-of-care [103]. A third drug of this 
class, telavancin, with a terminal plasma half-life of7 h in young 
volunteers and 11 h in elderly subjects, was effective in a neu-
tropenic mouse thigh model and is also in clinical trials [104-
107]. 
Glycylcyclines. The minocycline derivative tigecycline has 
bacteriostatic activity against both MSSA and MSRA, including 
tetracycline-resistant strains [99, 108, 109J. In a randomized 
dose-comparison study, clinical cure rates were 67% and 74% 
in patients with skin and skin-structure infections who received 
25 mg and 50 mg daily, respectively [110]. 
Novel {3-lactams. A series of {3-lactamase-stable cephalo-
sporins with high affinity for PBP2a are in clinical development 
[Ill]. The PBP2a affinity of BMS-247243 is 100-fold greater 
than that of methicillin or cefotaxime, and the drug is bacte-
ricidal against MRSA at twice the rate of vancomycin [112]. 
Other drugs of this class in development include the zwitter-
ionic cephem RWJ-54428 [113], CB-I81963 [114], BAL5788 
[115], a prod rug of BAL9141 [116, 117], and S-3578 [II8J. 
ME1036 (formerly CP5609) is a C2-modified carbapenem with 
high affinity for PBP2a and with an MIC.o of2.0 ,ug/mL against 
MRSA [119]. SM-I97436, SM-23272I, and SM-232724 are 
novel methylcarbapenems that are also active in vitro against 
MRSA [120]. 
Fluoroquinolones. DW286, a naphthyridone, is among 
several fluoroquinolones in development that have in vitro ac-
tivity against MRSA [121]. Active against MRSA strains that 
are resistant to other fluoroquinolones, it selects fluoroquin-
olone-resistant mutants at a lower frequency than do older 
agents (as may another fluoroquinolone, ABT-492) [122, 123]. 
Oligosaccharides. Evernimicin is a complex sugar deriva-
tive with a novel mode of action [124, 125]. A related com-
pound, avilamycin, has been used in animal feed, raising the 
specter of rapid emergence of resistance to this class of drugs 
[126]. 
Miscellaneous antimicrobials. The rifamycin rifalazil re-
tains activity against some isolates that are resistant to rifampin 
[127]. Epiroprim is a dihydrofolate reductase inhibitor with 
activity against some trimethoprim-resistant strains of S. au-
reus; its combination with dapsone results in in vitro activity 
against S. aureus that is greater than that of TMP-SMZ [128J. 
Iclaprim is another dihydrofolate reductase inhibitor with ac-
tivity against MRSA [129]. 
Other examples of modifications of existing molecules with 
antistaphylococcal activity include the oxazolidinones ranbe-
zolid [130, 131] and eperezolid [129, 132], as well as N-acylated 
ornithine analogues of daptomycin [133]. Among drugs with 
novel targets are the peptide deformylase-inhibitors NVP-PDF 
713 [134, 135] and BB-83698 [136]. 
A number of naturally occurring cationic proteins have in 
vitro activity against S. aureus [137], and some have been dem-
onstrated to have activity in animal models of infection [138]. 
Lysostaphin is active in vitro against S. aureus [139] and was 
effective in a rabbit model of MRSA endocarditis [140]. Its use 
in a patient with S. aureus infection and neutropenia was first 
reported in 1974 [141]. Specific bacteriophage has been dem-
onstrated to be effective in protecting mice against lethal S. 
aureus infection [142, 143]. 
Targeting virulence factors. RNAIII-inhibiting peptide in-
hibits S. aureus pathogenesis by disrupting quorum-sensing 
mechanisms [144]. The accessory gene regulator (agr) is an 
important regulator of virulence that is, at least in part, related 
to quorum sensing [145]; a truncated thiolactone peptide has 
been found to be a potent inhibitor for all 4 agr-specificity 
groups of S. aureus [146]. 
S. aureus immune globulin intravenous (human) (Altastaph; 
NABI Biopharmaceuticals) is a hyperimmune, polyclonal, in-
travenous immunoglobulin product derived from the plasma 
of human donors who have previously been vaccinated with 
S. aureus polysaccharide conjugate vaccine (StaphVAX; NABI 
Biopharmaceuticals), a bivalent conjugate capsular polysaccha-
ride covalently bound to recombinant exoprotein A, which has 
been demonstrated to provide temporary protection against the 
occurrence of S. aureus bacteremia in patients receiving he-
modialysis [147, 148]. Patients with S. aureus bacteremia and 
persisting fever are currently being enrolled in a phase 1111 trial 
[149]. Also in progress is a phase II prevention trial involving 
infants with low birth weights [150]. 
Tefibazumab (Aurexis; Inhibitex) is a humanized monoclonal 
antibody directed at the microbial surface components rec-
ognizing adhesive matrix molecule (MSCRAMM) clumping 
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Table 2. Macrolide-lincosamide-streptogramin resistance in methicillin-resistant Staphy-
lococcus aureus. 
Gene Drug resistance 
Mechanism of resistance determinant Erythromycin Clindamycin 
Efflux msrA Resistant Susceptible 
Ribosomal methylation erm Resistant Susceptible or resistant (inducible);' 
resistant (constitutive) 
NOTE. Data are adapted from 134). 
a Resistant strains have inducible resistance. Determination of resistance requires specific testing (e.g., use 
of a double-disk diffusion test). 
factor A [151] that is currently being evaluated in a phase II 
trial in patients with S. aureus bacteremia [152J. INH-A21 (Ve-
ronate; Inhibitex) is a donor-selected human polyclonal im-
munoglobulin preparation that is also enriched in antibody to 
staphylococcal MSCRAMM proteins and that is undergoing 
clinical trial evaluation for the prevention ofinfection in infants 
with very low birth weights [153]. Another cell surface com-
ponent, teichoic acid, is the target of BYSX-AllO, an IgGI 
chimeric monoclonal antibody that is in clinical trials for the 
prevention of staphylococcal infections in infants with low birth 
weights [154]. 
Aurograb (NeuTec Pharma) is a single-chain antibody frag-
ment lacking the immunoglobulin Fc domain targeted at 
EMRSA-15, a 61-kDa ABC transporter expressed by epidemic 
strains of MRSA that is in clinical therapeutic trials in the 
United Kingdom [ISS, 156]. 
Pooled intravenous immune globulin preparations neutralize 
a number of staphylococcal superantigen toxins and, as a con-
sequence, are commonly used in the therapy of toxic shock 
syndrome [157]. The identification of a conserved epitope on 
staphylococcal enterotoxins that appears to be critical to their 
activity raises the possibility of another approach to superan-
tigen neutralization [158]. PVL can also be neutralized in vitro 
by commercial intravenous immunoglobulin preparations 
[ 159]. 
The story of antibiotic resistance and virulence in S. aureus 
is, as has been stated by others, one of "depressing evolu-
tionary progression" [37, pg. 92]. The emergence of CA-
MRSA, the rapid introduction of SCCmec type IV into mul-
tiple genetic backgrounds, and the epidemiological success of 
the resultant strains indicate that this problem will continue 
its inexorable march [37, 160, 161J. Mathematical modeling 
demonstrates difficulty in the epidemiologic control of MRSA 
in the face of its increased prevalence in the community and 
the increasingly daunting tasks for hospital infection-control 
programs [162 J. An effective vaccine will be the only effective 
long-term solution. 
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APPENDIX 
Cassette chromosome recombinase (eer) A gene neces-
sary for the mobility of SCC that enables its site-specific in-
tegration into and precise excision from the S. aureus 
chromosome. 
Genomic island Genomic islands (often abbreviated as 
GIS or GEls) are horizontally acquired chromosomal regions 
of DNA carrying several genes encoding traits associated with 
increased adaptability or fitness under specific conditions. They 
are termed pathogenicity, fitness, symbiosis, metabolic, or re-
sistance islands, depending on the functions encoded [163]. 
Housekeeping gene A gene involved in basic functions 
required for cell viability and constitutively expressed in most 
cells. Housekeeping genes evolve much more slowly than do 
tissue specific genes that encode proteins necessary only in 
selected types of cells. 
Insertion sequence A DNA sequence involved in the mo-
bilization of genetic information to and from vectors such as 
plasmids. 
mee gene complex Gene complex composed of mecA and 
its regulator genes, mecJ and mecR. 
mecA The gene encoding PBP2a, responsible for resistance 
to methicillin and other {3-lactam antibiotics. 
mecI The meeA repressor gene. 
mecRl A signal transducer gene that encodes a trans-
membrane receptor that responds to covalent binding of a {3-
lactam antibiotic and its extracellular sensor domain. Binding 
initiates events that lead to inactivation of the mecI gene re-
pressor product by a protease, allowing expression of mecA. 
Staphylococcal chromosome cassette (SCC) see (or 
SCCmec) is a mobile, 52-kb DNA cassette containing the gene 
that encodes resistance to methicillin (mecA), as well as those 
483 
genes (ccrA and cerB in most cases) encode the integration 
and excision necessary for its recombination in the staphylo-
coccal chromosome, in addition to insertion sequences. 
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Throat Swabs Are Necessary 
to Reliably Detect Carriers 
of Staphylococcus aureus 
Dominik Mertz.' Reno frei,' Barhara Jaussi,' Andreas Tietz.' 
Christine Stebler,' Ursula fliickiger! <lnd Andreas F. Widmer' 
'1)':, :~!{)(i tJf InfeetfOtY:; DiseasG~ fwd l~ij:.;;1jt;J! EfwJBrf',oi09V and ;'~;'icrtJbCikJO'{ 
L;:L~;l(i1:my lJrlivef::nv H~IS:Plt:i~ Bas'!!!, Jnd :Trm~~fw;im: C>~f1iHj, Ba$t:~, 
Th(' anterior nlln's arc the most important screening :lite of 
colonil,.ltiol1 with StllpllylowCCll$ l1ureus. We screened 2966 
individuals fOT S. mm:lls carriage with swabs of both nares 
and throat. A total of 37.]O/() of persons were nasal carriers, 
.Hld ) 2.81l/o were .solely throat earners. Screcning of throat 
swabs significantly incl'eases the sensitivity of detection 
among carriers by 25.7%. 
Ill';' anterior nares Me; considCf<'d to bt:' the primary coloni-
i ,rion sile ,'f Slflrfll'it)(oCOI$ ,lIIrClh 11--31. Approximatdv 30"'ll 
(l{ dl'~ lwalth~' population carri,·s S. IImOI, in thdr Mlferiot 
1i.1J\'S : ,I. S 1. Carriag'? 01 s. ,mre'ilS in th(: n(j~c ,rppe;w. to pLl)' 
,j k,'v to].: in Ihe epidemiology and p,lthogc'!1(:sis Ilf lllfedioH 
,wd j~ associilted with dfl irKrcascd risk of infectious comp!i· 
e;,lli(ll1:> .lner surgery in patients with t'nd·slilge renal f,li1me an.i 
in I h"ot' with intravH.\nt!ar dn·i(es f l, 61- A!,proximatd~' i<O{~I, 
,,( inv,.\sive nl.1sncornial inl-C(lions are of endogenous origin in 
nasal (aniers 17, (II. 
The' ernct'g,CfKC of nwthi(iJlin-H'$i,stant S. lIl/retlS (J\f!l.'lA) in 
hO:;l'ilal~ and in the community ha~ triggered many s(rt'cning 
i'((lgrarns to identiJ:" carriers of S. II!II'CII:;--····in pMliwlar, l\-l1<.SA. 
Lull' identification of cHriers is ,1 (Tucial Mt'p in MRSr\ pre· 
\ "mion ['l"ogmrm; this is esp('oaHr true for '\eardl and dt'· 
,Iro\," ,trJtegies. which <lre I"l'wfllrnended in The Netherlands 
U'. Scn:Nling uf all ptT$OIlS who are admittc:d w the h();pit:ll 
h (urrcJltly bt'ini.~ (ll·b.-Hed in Ill" l:nited Stilt"S. 
"."ht S·. (/IlrC/IS scr,'cning program, thaI. indude :'v! RSA rt" 
(jllirc' oi>(:lirnm:nt '.If ,j swab spedmen from the' anterior n,lfes 
Ht~u.'!v(·'d Hi h?t~ff;(l(y ?OD/, ;)\'!,;t;>~1~(:1>-':: ~!lj AfJilI :~UTr t;rt~t'tro:H(:<11iy rf'.~tJi!.:~h"l-~ (:. ':1.:-ty< 7;)(}1 
'h:r;r~nr:,~ (it ~~orr(!S{}O;l-dHm:1: Ur /\rti(~~~;S F \>Vldmw, Div !)f 1!'if~1>:;t'C'U.f. rJ:sn<J~3flf, ,:?,.: }'kf~rj!~ifl 
f.p;den<.d~)',:'" ;,!t';'d~!~.ir~l hi"'NHfd:' i.hv::-!, I"'HII;f:.;ql;·ibe': ~l, !>i'~~:l31, t~(!:a~: f\'"\i~lli~'i,IJ'd 
CfiJllcal InfectiOUs OiS!}HSHS 2il01;45:41!;·-1 
':1:~13 .. 1::r,:f5 '"'?PO(' ItlE.~q~~-Wp tS!:J (;;',1 
';'.; :i;HC;~l?JC16 
only; it 5w()b specimen from tht' throat is not yel c(lrlsider(,{j 
to Iw standard,. TJw additional yield of culturing the throat is 
wnsidc'red to bt' negligibh:. bix,mM.' it adds di.~comfort fiJr the 
patient aml (mt to the health care wstem without significantly 
in..:rea,ed ~l'l1sitivity. This belief is based on the obsen,.uion that 
throat carriers of S. {//lre1l.~ are likdy to carry S. oureus in the 
Ilare~ as well. How<!ver, colonization of the throat but no! of 
the fwn::; rnay- be more (ommon than is currently 
,Kkn,)wledged, 
Pub!.icaliolls from the 194/)s reported throat colonization 
rates of 4<1'( ... ··63% [:~l. A feC(mt study confirmed the observ.ltion 
that the throat may be sdectively colonized and escape current 
routine scrt'cning programs 1 JOJ, 
Unr~'mgnizl:d carriers rna~' spf(~ad !vlRSA and rl:llder infec-
tioll-control programs futile. Therefore. we questioned lhe 
practice of sGcening of the anterior nares ;llone ilnd ('valuated 
til(' additional benefit of screening hoth thl: !li!rcs ilnd the thm:lt 
in 4 different ~t\ldy populations. 
P'ltients a.nd methods. We collt'cted data from 4. difIt'rent 
groups of individmls. The fir,t group induded pati.;>nts ,md 
health (are worker, who were s(f(·{~n .... d afwr exposure to an 
tv1 RSA carrier during tiw )'eMS 2000-.::n05. Slnc:e 1997, thi, 
procedure h.l!, Iwen part of the ho~pit<11' s policy (or preven!inf) 
of the 5pr~'ad of MRSI\. The ,("cond group consisted of lwalth 
or .. ' Io\'(,lrkers \',!ho p<lrticip<lted in a trad(' f:1ir fnr medical and 
hospital equipment (the Intermltionale Fachllw~se fur Arzt-
tlnd Spitalbedorf colwentiol1 at an exhihition cenler in Zurich. 
Switzerland) Of) 26-·29 October 2004 and who voltml~'ercd to 
participate in a pr,:va/cllce surV{'Y (\( S. aI/fellS carriage iUllong 
th(' Swiss population. The third group included healthr bk.od 
donors who\vere screened I()f $, aureus in the year 2005. Gr(lup 
4 consists of a large sample of nasal and (I1m.11 cuitUf('S thnt 
W(:f(' pooled in lhe labor.ltorv; separate results are not <tv,lilabl!:. 
This group comists of patients and health can.' workers, a, III 
group I. 
jvlRSA carriers '"ere an,llyzed separately to avoid any poten-
li,1I bias, beGlU",' i1 is unknown wh.,tller IvlRSA has the S<lH1C 
colonization pattern as IHethicilJin-5us«'ptil)lt:' S. aureus 
i tv!.S):'\ L Screening was perfon1wd bv inft:ction··control nurses 
Of phy,ic.ian5 aftt'T appropriate \r;)ining. The study was ,lp· 
proved by the human whjec!.s (ommittC'c of the tinivcrs.ity of 
lt1.sd (Switzerbnd), 
Specimens were Ob(,lilwd with .! sterile pnl)'cst(~r fiha···tipped 
,"'I,lb that hOld he"'l) l110isterwd v,';th sterile ~JJin('; s,nnpks were 
{,I ken from the a nteril)f nares (:.; rotntions in each <1nh'rio[ 
nostrill and from the posterior vI'<1I1 o( the pbarynx \1~ing a 
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Table. 1. Rates ion of Staphylococcus 8ureus frulli the :; and the throat. 
(jro:.l[.>5 1 <3 GI()UP 1 Group 2 Group :5 Group ~1 
~J(). of p~~r:::;0ns screened 2966 1332 6:M 1500 2075 
No \{\HH'\ 5. :JureU$ t-t1rri:;lqf: ltX>j(} 3(39 3(]'4 807 109:? 
Overall r~,~t(; of p-ositivitv, fX; 49.9 44.4 47.9 53.8 52.1 
N,:jr(::~ ,";,Jit\;r e~, 
N':I <.JT p~:?r :):')t·l~) w;th Pl):~':;1! ·/f~ ItJsufrs 1 100 :301 2J7 ()G~' 
Ov"'ill' fa!,:~ of n{}~:)i ~ i v~t\l, '?,f,:; a7.1 30 2 37.4 :375 
U\:(~~'f1!; ! a ~(-~ 1)1 D(}t~jtl'iltV {j(':'F:;ri9 c,:)r:ler;~. 1.,\ ~1 J ( .. 3 8, n u 6tHl 
Nal(:)f:. and thrm,t Cultures 
pO~'jitiVt~ re!;utts of both 
Nt) ()f P()fSCH1S 650 188 119 a·~;~ 
()v(~r;dl tdtf? ()f ~:'()!:lit:vitv 21f''flon~z carri(:H'S, i::h 4:) 9 fjO.9 39,·} 42f) 
p()~;;tiVj~ wsuft.;; of nares CU}iUf(1$ fmC! 
nt?'~F:'ltive tesucts 01 thrmlt CUfiUtflS 
No. of persons 4::,0 I+J 1 18 219 
()ve~(a!l ralE~ of POSitN'ty <31'fl():')g Chrne!"3 <'}:, ~30,4; 30 G 3B P .I 27 1 
NeQa~i\/(t fE>Sl!I($ of nE:lf(~S CUi~'~lfes and 
P(;Sitl\tH re~;tJlts of thrOEtl cultures 
~il). or P('(~3()nS :180 68 67 245 
(}Vfrr;;il' raw of P()SftiVl1V, t.:; 12 8.2 10.G lC3 
Ov,,,rt]/i raH) of pOSiHVity arnon9 Carnf1[S, ~<l 2~)'7 18.4 22.0 30.4 
NOTE, C,r{,llif' 1 p,,':r~:,Gf!~~ v:h:,; ~ .. !·'dpP/.,i(·:·nf .;;Iute:J5 ~',Clfn:r=llj9 i.l,j~,nn h"Jspit:;I' S~<)V, gH;l.lf':':': ho3:a~H' r:';~r.:,: \N(;r~E'(~r 9!'m.;p 
bkl·,::l (k':',~", ~:" ~y\';~;:) ,1, PtH;f':"~~'~ :.1111,1 b-';dlth C,:'ft,! '/iC,·rh,;(:,:, ~\';'~' ... vhor~': ~,,\\,ab~~ tf<)f"', fhf:~ r!,~;rG!''; dr~\,j rhrf).(}! ;i,,'(.;.r~ pooit:';:G dr'l::} for 
~:'t:;::~·:' ",1' i': v t~~,,\dL:' .. V{~fi:~ t;.r;~},:('l(> ;Jt··,!(~ 
"ecund swab. :,wab~ were sent to the laboratofr in a lTan.<.pnrt 
tube ()I,·140 Tr;lJl:'y~(crn; COP,l!l) and were proces~ed within 24 
h. Fnr culture., OJ ,dedi'lc' rnrichnl<'lll broth (br .lin lwan in·, 
fu:;i(lO broth with h')'" >~aCl) wa, ino(1I1akd. After ilKubati(J11 
at Y;"C overnight, the bwth was ~uIKltlwft.'d onto bot.h dlfO-
rnogenic <ii:<ar {(ll' S. 1111r,'fiS (Chrornagill' St;tph.,lUreus: HI' 1 ill> 
tlratori,:\\ :md Columbi,l agar with 5'~() ,h,:ep hlood (HechH1 
lhd;inson 1. Plat('s wer .... r,'ild Jlter 24 and 4il 11, and ('oionie:, 
Ih.lt Wde ql~pec!ed nf heing S. IlIIrt'IiS wen: itHth<.'1' ,mah7t?,,1. 
.'J. mil'l'U, WilS i(kntifi,:d on the ba"is of V.1riou, lr,.li{S, such ,1" 
(IVi,',ll growth (Ill the dW)n1og('nil medium andinr blood agar 
,md ,.i<.'trxlinfl ,,( ,.·lutlJpinr: Lhlor, I'n,rC'in A. ,wel C:lp';(lbr <111 
tigen:- (P.I:-'!OfCX :,tal'h Plu:.; Bio· Rad l. S. Wlrel'; isol,HCS hTT-c 
lCSl("d for (lX;h jIlin fesi!<l.Hh'l.' hv lhing ,m oxacillin diSK, ,Ul 
m.a,:i]Jin s(n:cElin~ ,Jg.H plate, or" m,lft r,,(cnily.;\ (('f,}xilin disk, 
in '.K(ordMKC with guiddines i.ssu('d by tlv: (linical and tab 
nr,tlory St;wdards Jnslitllf(' rfOnlH.:dy NeeLS). JI l't'l>ults were 
equt\'()Cal or if MIl.SA W;h SliSPI.'(H~d, additional tcs!~ WCl'<' per·-
f,mnt'd, as (oHows: the preWI1C,' of ;H.lreaSt~ was del,:rmin('d 
ming Rapi,b.· ."I;ipll i hi(I\j('riwx)' the i'vlibA .. Saef'fl (llenka 
,,<;,jk,~n) 1,las w'l.·d tn d,?!('(! pcniciHio···binliing pl\}!ein 2;\ .• me! 
pc.n II/as ll';ed to d('1C~:! the mecA ;md 1i~mA g(~nt's; al,;,), .1 
':()Inprc-hensivc <HHihiogr;nn "Hi> performcd in aCCOrdalKC with 
tht' (Jini,";!! and I..lhHalory Standards InstItute guiddint:s. 
U:csuits. i\ «lui of :>()4 J persolls Wt'!\C .inc·luded in Ol.ll' study. 
'litre'\, gnlllp' (gr<)Ur'~; [".' I. whidl illcluded a tolal nt 2966 
individual~, wert' screened till'S. aI/rem «lrriage, \vith ~eparal'" 
result" i()J' Bose and throllt carriage, A fourth group (group 4) 
musisted of 2075 individuals tilr whom data from n;m:s and 
!hroat swahs were pooled in Ih(; laboratory, Tn\" av('rilgt~ ag<: 
was 50 :.t: 21 Y"'<lrs, and 50.4% of the suhjec!s \WI'{' female. In 
groups I--J, a total of 1480 individual, H'>.9'Ni) tested positive 
!~)f S. II/lftilS (t,lhk I ). A total tlf J7.1 (~{\ of the study populatiNl 
(in groups 1 .. · 3} h,ld nasa! cMriage of S. wrrellS, with OJ' without 
positive l11ro.lt mltul'e result ... A total of JRO p<.'r~om, (12,0';';' 
IJf til(' study ill1pulation and 23.7'!{, of tit,: S. aI/rem (arn;:f5) 
Wt~1"7 colnnih'd in the !l1m,1! alone. 'rhus, s.cre"nmg of the throal 
<;ignilk,Ultly IJ1dT;!;;<.'..l th.;- sensitivity by 25.7 i l'H. '1 hl' ,mt('ri()!' 
narcs W';-fC the ,ile most frt'qtk'ntly (olonizcd with S. (wrefls. 
with rlw exc'l'ption of the group ofbiood dOl'H)J':;; am0I1!1 blood 
d'Jl1<lrs. the throat swah cultures viddcd S. Mllrt'us mort' fre· 
quently tn,tn cultures of swab 'p(;cimcns from lhe nares. Th;-
rate of S. mm:tls (arri"g~ in group 4 (i.e., the pook'd n!suits 
gwup) wa5 52.I')(i., which i~ ~imiL1r to that observed with the 
combined results I~ .. r lIMC;; and throat swab cultures i.n groups 
1·5. 
A :,nll;,\,,! analrsis W;\S pcrformt'd for 37 subjects with }"·fHSA 
carriage ({).74(~·i, of aU individuals 5crct~nt'd). In 23 MRSA car· 
rh:~r~, sep;lrate results \l7t'rC Ilvail;lblt.' for cu!tUfX>S of throat and 
nasal ~wab .. pcdrm:ns. The additiomll yield o( throat ct1lturc~ 
wa.~ wrn!,al'abk with the results described for 1".1S5;\: 5 of 23 
(22.'q, (If all i'vlRSA caniers versus 25.7<;'() of all MSSA carri('[sl. 
1 
"1 j 
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t hl~ 13 rge.\! S1 utly to 
h,:1VL' c'V.'lhi . .itt'd i he inlponan('c of t'l ro~H in S. iUli"t'i15 elf·· 
r IJ1~(' The .lddifi(lfWI thrlM! ;,INab ,:utlttr(", fnfr(';)<.('d til,' yield 
irl)1l1 .':"\' (C\l]tlJ1'C, (If !1'H'(';' ;.wab, onlyl tn ,1111lo:;t :;!J'!\) (cui· 
t un.'s ,)/" flares and [I1[(1.1t :;wab~ combilH'cl'l, an ilhTCa'ie of :;,,1]' 
,jrivity hy 2;'.;"h" Rc:;ult'i t()f group 4 tthc pooled specimen 
gt'nul' )--·-separatc cultures 1)( ("wab spetimclls from nares ilnd 
1 he throat W('I'(' no! pcrh.lrmcd---··\,OITo!mratnj the n:~;;ults h11' 
gr\lups l .... ,),with a l'n;·vai.:n(c ,;( S. I1HtCUS Guri<1!!t' of 49.'1q·iJ 
and 52.1 (~,;" rcspl'clivdy. Ther.:fore, pooling < ulturt, ft:su!ts for 
~w'lb, ii'om nar,'s :lI1d 111(' Il1m:11 mil)' he an appropriate method 
( ... npttmi7C rh,,' yidd (If S. (.lIlft'If.~ .. positive wbile "'ilying the 
,."xp('n~es of .ldditiorul cultures. 
'Tilda)', S. 11111'1'11.' sacl'lling i.., mainly perliJfl!led to identify 
~1 R;';i\ carri.:!'s. Unidentiiicd thro,}! farrier~ may sprt'.llJ ;vIESA. 
t'xpl.lining, in pMt, whv nlMW decol.oniz.lttnn ,>,hemes ;m.? 
pronc to Ciilnre. Thront (;]lTi:\gc cI'cn triggered a farge lJUtbrGlk 
of \IR5:\ infection, whi,:h wa~ [n!u.'d b.l\.k h) a ilt'afth ('l!'t~ 
"'<lrKer who WdS ,oldy cololli/.ed in the thro.1I. Hnutinc nasal 
\Cfl','ning f.likt! tn identil)· this (ani.c)' [It i. Admi,~ion ',·n.'cn' 
ing (If ,declt'd patients or of all palieI1h th~lt aims to cl\l1tl,)1 
~d H,,/\ inknion is perfnrnwd in many hnspiLlls, but 'Int'cning 
t<)Cuses l,n the' narc" alnng in most institutinnA !9:. 11ow('v(;'[, 
thrnat '>Viall 'I'C('im(TI' hane hCl'n obtailwd mntindv in The 
:--':l·ther!and, for dc,';ldes ,IS part (If tilt: sllcccs,;fllJ scardl'and, 
,festr,)}, polin'. which j, 'Hltlinc,j in their natinfl.1! guidelines 
(httr'://ww,\'.wip. n1). 
t)ur (bt~l (\l!lfirm the rc.~sult.'i of prCVi(Jth studics that the 
anterior nilfC~ are till' single most colonized site with S. arm'lIs. 
The fat,' of carridge W;I$ higher in the throat than in thc' f),ln.'S 
only ,unong h!(IOd donor', (gn,up j). The tinding may be reLlt('d 
h) tf\(; (a ' .. : [ that onlv I lrainni. highly m!)tiv;H(~d investigator 
uhtainvd .111 of t hl'\(' swah S!1l'Cillll'l1S. l.Iml'aiw:d investigators 
IT;;I)' lind il ddfi(ult tnS(rCell the posterior wall (If [he throat 
while avoiding p;ltknt di;.,·ornf(lrl. ,\It(Tl1atlvdy. duoall:arri;lge 
[naY imk"'d bc more i'Ol11mllf1 among hCillthy individual.s til ,HI 
:nllong individual..; who drc ::,p(J~t'd to the h"illrh (are "f.-tern, 
hut 'Udl a hypo!he~i:; rcql!i!('~ (ollfinmlfi(m bv nther inn:"!i,, 
)iiltn!'s in di/l,:r('nt. nnn· .. health carc populatinfh, 
lJ\'lT:\Il, the ~H<.:v'llc!l(c of clrriagc was -50'1'", whid) is higher 
th,m th" l.lle n'p<l!'kd in most other "Hldit~s (25% .. ·.E,'!'i!., I:' J. 
5t'\,\:r,1I lilCtors 111<1\1 c:;;phrin this discn'paney. First, in other 
'illdic,. throat clrriage W.l' 110t (,lkctJ int.) .1C«'ltnt. In t'.!<.:t, the 
rale' of n,lsa! ",lrrial't' (with datn fwm throat culturcs cxciud(:d I 
IN,!' ('omparabk a( 'I rate' of 37.1 %. S,xond, enridHllCnt broth 
Ill;)V hav(· additinnaHy tl1(!'c<lsed the s,.'nsitivity of the culture 
11,~ i. Third, ,'nl)' ,\,cd.tll'.' t rJined lw,ilr.h ,:,H,: work("r" ohtained 
the' ;,wab spl'Cinwns, ,,' 'dmpie<, wt:r,~ (lbt:!ined li'PIll po,h.·rior 
wan ,,( the thrO,lt .md {1t1l (he mnlllh. 
The <lddilioll of 
the :.intl~ri(lr 11,:1.i\:5 
~cH'{'ning by 1""/",,. Overall, };. J ()';, ,)f :>ubjccts had na,a! car .. 
riai;t: of S. ,1111'1:11>, hur 12.S% of the individuaL, h:td tl1m,lt 
carri,lge ilJolle, MId these subjects would have e~Clpl:d tradi 
tional sl'r('.;ning methods. Therd~m:.', any \cf.:-cning f,,)' S. all 
1'(·us--.... ·in pnrticular, screening for MRSA-should include borh 
cultnres of sw.lhs samples from the anterior narcs and the 
throat. Pooling the ~:llnpk~ can m<liniilln the additional ex 
peDSCS a~soci;\ted w'ith throat screening while maintaining 
s{'n~itivitl'. 
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frl:~{ll<~nl than ..;oJnnildt.ic'1l1 in tht: antt:fH.r n(H'(~5. J Ctin l\lidO($!:'h,,} 
2006: <HJ:UI·V. 
I L f.:i"Ylm;m~ J. \,,111 Lc,'u"n'n \\" CO{,~'Hl~ \y, ,'I at: !',,()d·iniri:uc·d (H.lt .. 
t'tvak f~f rn~ .. thidHin· n:~i~;t~l!J1 Sti!{Jhrlo(\~(TtJ:S Jt!'rf"U:-; anaiy/t~J b f! pht'n,.}'< 
.tr"J l!"nntyping. I <Jin 'licr\,bi"j 19':15; .n:) 121··i'L 
1 :~, ~Jfdar :''1', l\',U';Hl$ r, (;ordnl\ B, ~\td\'1 PG. COlnp:trj~()ll ut' \,,'t!!lufe 
.... d\','llrnt~ J't'Jt,tho",h ((II' tkkdipu of nasal .... arriage (if rncthiciIH1<' n::"tli-
tant StdphY/~)('~l((US {HltCII:,: ,t pru:-,p~·ni·.,,~ ,tud:' ",:.onlpanng J~; Fwrhor!:-;., 
I t:~hn ~d!Cff.bttA 200,\~41,}lh:\,.·.('~, 
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Cutaneous Leishnlaniasis during 
Preg.nancv: Exuberant Lesions and 
.... I 
Potential Fetal Complications 
Olmiel J. Morg,m.' luiz H. Gllimaraes.' Paulo n.l. Machado; 
Argcmiro O'Oliveira Jr.} ROCfue P. Almeida.' Ednaldo L lallo.' 
Daniela R. Faria,' Wagner L Tafuri.' Waldercl O. Outra,' and 
Edgar M. Carvalho' 
:,I!'Vf:",cn of in:Bffli!t!(:Jfa! MCt11Uno anj !nfectimJf; D!sea::;e;), VVei!! ivh::dicu! 
Col!f:~!Jt~ of C(:tm~;l Un!''/f'(~itv, Ne .. v York, anfi de Ip'!HOohqlc dt) 
Hr:~;pitni UtJJ'iCI $i:~lri(l P!ot Ed~F1fii :)antG':;, (Jl1;jjors;dad(~ Fnrierar da BahIa 
r~:,:1!'/ackiL ;:'!l',:d ·'r.:pp~lr;i1Ir!€pto I<:~? r.. .. 1ud::;i!(j~.;ia< t}nrvH::<!,;~dl~ rr;~dl?!,)i d~; f\.4int!:, 
L;e l ::11s, E~~~:(; j":OHll)ntH, (Ha..:-II 
Cutant'ous leishmaniasis atlects millions of people world-
wille. After observations of atypinll lesions in pregmmt 
women at the health c('nters oj' Corte de Pcdra, Brazil, 9 
years of records were reviewed, ltnd 26 pregnant pntients 
were identified. A retrospe('tive elise-control Mudy revellied 
that lesions in pregnant women ,vert' much larger than those 
in noupn'gnant patients in an age- and sex-matched group 
"mean area, 6.08 em' vs. 1.46 ow;; P "'" .0(8), Imd many le-
siolls h~j(l an exophytic nature. Despite foregoing treatment 
until after (.ldiveI'Y, response to pentavllient antimony ther-
apy \\'al> favorable (rUle of cure with I wurse of trcutment, 
85%). High fOlks of pn~tenn bil,ths (to.5'!';.) ilnd sti!lbi.rths 
(10.5%) Wt're reported, Cutaneous lcishmalli'lsis during preg" 
nilncy produces distinct lesions and "HI}' have adverse fetal 
dfefts. 
\\'orklwid,'. ki:-.hm.!ni'l\is ;lfit""!s > J 2 million p<?ople in 88 COlln .. 
Irks, with ,1 )'t';lrlV Hlcidencc fl1';: millJOl1 ,'as.:s (ll, The majority 
(If (,he;; arc dl\,IHt'OU:' iei;;brna!lia.~is (CU, which i~ mo~1 com, 
Inon in ,ldc.k\(.t'rlts ,mil j','Uflg adult.;. jJ-,)!1l rur.ll area, "f ex .. 
t [,'fIlC l'overT\' I:' ] ... ,) popui:ltloll with a hit:!! fertility Lite. Pr<?~· 
!l,l[l(\' j, ,lz;s()ci;ltcd with ImplY,Vell1Cl1t (,f 11)('SI inlhrrllnatot"y 
di\(',!.\,'., 1 .. \ 1 dill! ,HI in.: l\:a,.;(~d ous(t'ptibilit\, to lT1JflY inktli,)1J$ 
,l}!,(:llb. il1duding '\'/,IiIlr1d I '} I and f.j,:cria I1WIIO(}'IOX,cItt's 
;\ lOfcuvcr, dUrin), pn:gl1<H1cy, mar1\' infections .1f~ <l5sod .. 
L: Ja"u,!,", ,}:~cup':':~;: L.";' /\rnf ::UGT cl~'ic:;nflw;l!l'i J;urqYfH;i! ~.: .h~'-: .infl} 
n!~:l( r'l:~ c,> i;'J' "\'~~~Pf:l~tI«(I:':'; D' (1;)," tl! .1 Mu~~j.'w, Dru~~!(!! (it lffh""\1f1f/1;~: j\.'11;t1!(,1r(~ .:.l~;d 
!q'"z!, '.'. \,h.d:'-J~d:F,. 'l'f'C H r\'~"ik';l C.I~jC;l"·;:1 ("ffne;! t;nh',::;; h u;)r; r(rk l .. ,\,~~, t~4,'f NF'I\.-
'L'd ~'i'( irK;:I! 1dw<:(I.JH;i;~n·i:· !':rrf 
Clinit:llllnfeclious Oisaases 2001;45:418 .. ·82 
r:; • em 2007:45 (J 5 August) • BlUEI !,FPOKl 
,lied '\'lith advt:r,<,,' f.:tal oukonws [6:. In thi:' C;1!'e of ki~hman· 
infection with the vi&cc:rotropk f,)nn h;b been de,criht'd 
during pregnancy, rewltinp; in vertk:;! tran,;mis~jon ,]nd (cIa! 
Jus, wht'n t realmen! [liltl),,' occur, [71, After occdsioHnl ,,[hlT 
v,{t.iOfl\ of atqJk,ll CL during prt'gn<1!1cy, we n:-lm,;pectivdy 
revic\wd all Cl5CS of CL and mtl«()(lljlmeou~ !ei~~Hnania;,i~ 
r;"IL) ,een at a rdcr<?l1o? remer, identifying gravid pati>i'nts \a 
standard s(rt~,'ning question). We feport dinic.,! asrwcb. of Ih",;;e 
(:.151.'8, including lesion size and impact Of) pregnancy nuh:ull1t. 
In addaioll, it f('trospl.'cLive case-control5tudy compilting lesion 
sin' and response to (hcr,IP), \\,~lS perii)nllt:d_ 
Methm/s. The swdy ,vas p(~J'f()rmcd ;1! ttlt: Corte (I( Pedr>! 
Hefcrcnct' Ccoter f(}f Ti::f:urncmiHY Lej,hm.miasis in B;lhia, Hra· 
I.il, WlllCh has been in operation for >20 )'t';HS [2 i. Ye . lriy, >1,00 
patients .m.' tf(,;.ltcd {()l' CL and l'v!.L at thh (enkr, 
W(: manuaHy' rt'view<?d charts {(Ir ,Ill patient; with (;1 or .\!J 
who wen' 5et~n at the rderral ('cnter during the period 199;'··· 
2005. sel('Cling patients \>\'h" were pregnant and h~d !>ign;; of 
leishmaniasis. elSe, were ddined bY' inclusion nikri.! of J .lc( 
init£' diagnosis of CL OJ' ;\11, as the combination of a compalibk 
ksinn and (Il biopsy r<:'suits ,howing ama~tagl)l('s Of ClHllpat 
ihle hi~topathologt( finding.';, (2) ['ositin: (ulture n'$uh~ from 
.1 lesion aSptraH' <;pccimcn, (If L,) positive l.<'i~hmanjn k;;, rc 
~\llt>;. Exclusion rritrri.l were incornplete do(umenLltJOH oj 
pregnan.:y or of IH)$lpanuITI follow-up. COlllrnJ SUbji:ct;\ W('fi' 
agc"mJtdwd (within:' years of age) and st'x-r\l,Udkd; lhe :; 
consecutive patJenb with definite leishrnania~is who were ('va!· 
t;:lted after each (;1$<' patient were dlOsen a,; (,(Hllm! ~lIhkdS. 
Prob,lbk CI. or f>H, wali defined as a cornpatiblc iC1'i'lIl with 
. iack of defmitive test results. 
AI the initial vi,it. patiern weight, bior\ size ;md Incalion, 
alld lh" numb.:r of lesions were recorded, and past medical 
history wa., (~VahMtt'd in a ~fandard manner by I !lm~e. Ali 
women tIl' dlildbearing age were evaluated for pregn:l!KY, Lell>h· 
rn.lnin H~sting W:1S pertimm:d ,It (he initial visit. The inilial 
le,lon ,i7:(, wa~ the "i7.e oi tl'll' k,i(111 fl~corded ,1t the initial \'i~iL 
T!w m.lximum I""illn ,;i/e \V;1;; the Sill' of the 
mented ksiofL All patients found ttl be prc!!nant wen? fnlh.)\\!t'l! 
up clinicallv wit bout m';Jlrrh'nt ((J!' ddjlliti\'{~ ki~hl1!ani;1;;i5 f i.t'., 
pcm:lV;lknt antirm)!lr c,mlp<)u1'l(b) until aft<~r delivery. 
This study wa~; approved by tht~ Committe(: p( l:.thics o(Tl·",· 
Ftdc-r;tl University of Bahia (Salvador, Brazill and the instillt 
lion.li r,~vkw hO;l[d of \t\i<~ill Medical College of Comell Un;· 
Vl'f~il}' (Ne'W York, NY l. Laboratory studi(:s w,;·re perfnrnwd in 
the univer"itv laboratory u$ing stand:lf(j (omnwrd.l! tc'cb, 
niqt](;", lfi.,lnpathnlogk t'xamin,ltion \\'.)5 ped(mn(·d in [he p,J~ 
Mnined h 2 rc,l!.kr~ 
!ll.ll..F :md \VJ . .T.l. \dw ' h ,lick' for d('f'lTHll dod 
cl'idt'rm,ll dlilJlgc:S, the natur{~ of the inJlarmnalory inJi!tra!e, 
,m. I the pl''::S(~IK(' of innasligolC' (,mIL;, The i,nj;nes \I'\:1't' dJ;u-
,lcteri{;,,'d ill the I.cislllllillritl C,)l1ection (If lht' O~\\',ddn CrUl 
t'i,riIU(C \.l'(iu ,h,' J,llwiro. Brazil) by rrllrltilodb (,IW,m(' ete,'-
,IS dc,crihed d:;.('wllen: I 
r 1at.1 were clltnl'd inl<) Ex(d (Nlicwsofl Le,jol1 ,u(',], wer(' 
",lkubl1cd ;J~ ell'l';;''.)' 1'11(' \'limn- \Vhitney {J t,'s( I \Vikoson 
rank ~l!ln h:slj .HId l\:;u-;on LUlk !t:,( \\'CIC performed using 
')[,Ita, I'CP,i<l11 ;'.0 (Sta!.l), p< ,n:; W,\5 cnIl~iderl'd to ht' ,Litis-
I indly significant. 
RC'<llIt.<. \'\Ie itknli1i<'d 2.7 pregnant Fdtie!1ts .unnng ',,4200 
p,'opk with sw.,picion ,Jf leishmaniasis, (If til" 27 pr('gn<1ni 
p,l! [e'nt", tlH'r,' we're g pa(il~nIS with probable ki,hmaniasi;, ~Hld 
I ~ with .:!dinite l('i;;hnlal1i.1~h, One paticnt 'N;), ('xdude,j he-
C;lllse III 1.1<'k flf pO<;lparlUrn f'nlluw-up inf')ml.ttion, 
l'hc (l'i.H';l('{eri"li(;; (.i ,"c.) patients with lehhm,)nidSi, dunng 
I'n.~gll,1tlc)' art' f'n'~t'nkd in table I. I .. c,jnn\ i1I'PC,H't'd ;1\ a meiln 
or 3lYl'kai lesions were i(itlnd in 11 
(4':·~'(,) of 26 patient chartS l fIt~llft.' 1). N (j manifcs!,H iOlls of Cl. 
dt:vdoped prior tn pn.:gm.l.!'l(y in any of the p,lticni$, EX(Jphvtic 
k<,jons \\\.:r(' nOll.~ignifJcand\' con-dated with !rirrw\tt:r of pH'g' 
nancy (f> ''''' .:DIl, by PeHrson nmk [,'51: n" :::::: OJN6). 
('<:'£i0I15 showed docurnenh'd postpartum illlprovc'Hlcnt in .3 
patients prior to treatment; nonc,tbeks5, these paticnts ,mbse, 
tjuently fTCcivcd standard trcHtmcnt (llgnn:: ,2), TW(l patients 
(7.7'!'()} initiar,,~cl penuwd(,nt antimony tr~;;tmem during the 
fir~t trinlt'1'1er but stopped treiltrm'nt \,lIhen pregnancy ',\'<15 dis· 
mvcred (after 7 dilYS of treatment in 1 patient .H1d aiter 13 
days of lre,Hlllen! in Ihe other patit'nt), Both patients (ontiflllCd 
to ha\'c adiy(' !"sInns throughout their prq~niln('v, "ll(l r1('ithcr 
wOt1un haJ <HI adn:fs(' fetal i.\ulwrrw, 
~Jjl1d(',,'n p;llients provided information regarding pregnancy 
cOlnplic1liollS: :-: (lO,:')')!;)) of 19 patients deli,'cfrd pr'~lerl1l. 2 
( 1O.S%) experiOl(.:d a stillbirth, and 15 (7<)'71') reported norm,\l 
deliveri,':> (table J L CutaneOllS k~i(lns in p.ltients who <'x!',; < 
Table 1. Clinical and laboratory findings for 26 pregnant patients with probable 
and definite leishmaniasis, compared with findings for 36 nonpregnant control 
subjects with definite cutaneous leishmaniasis. 
crirw~al hnding 
[)iS5€~rr'lif"dted td~))on:i<~ 
Pri;'f1~::nTi twth 
~;tllf;wth 
f1epc,rtE;(j 'lonna; [:);(,1'. 
Lai'><.)fa!f)! y f ll 'h51QQ 
f·\y~it:vo c;lil:Jrt~ i't?su:t 
C(jnlpetlb!~~ b1cPsy r€fs~.dt 
Pr"9P ilnl Nonpm£)l'Iilnt 
pa~,~~n1S controi subtect:::t 
:3/2€5 (11.5) 
2/26 ',1.7; 
;>/2G (77) 
2/26 \77) 
2/26 ~7 7( 
1(26 i3 4\ 
2,/26 i7.}J" 
2/19 nO:>1 
2/19 (lOSI 
1 5/19 (m 0) 
7/11 (6301 
11/11 (,Om 
:;:/11 i.1.'j) 
o 
D 
o 
o 
}tJ6 (\9 ~,) 
[) 
o 
o 
3/71,428) 
4/4 noo) 
'f",' ··,:·,-~,·.:;",n·} ~ : (:' :-;·t;~ :';i q!ij~~.J'·~!1'''';~1 !!'H:::';.");Yy! 
.>~ ;-/ ;1hI\;;Ji"lrH'lc, ~L~'-;iHjy 
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Figure 1. Appcmrance of cutaneous Inishmanil1$i$ GlJrinq pregnancy. A Tvpicai, w(~!i,dern<lrr~ated ulcer with raised bordllfS on a palient'" leg B. 
Ivlild1v f1]i~!>[ L VWII;COUS lesion ()'l a patient's back. ~,tbsSivt~. V')(j61iJti'l8 \esln(ls on it patient's buttock re) and thigh (0}. l1ulers represent Cr;ntil1leter ~\. 
n ellu:d ;1 f'f'('term birth (if' stillbirth did not differ from tho5e 
in patients Whd fxpcri(' IK('d normal ddh'\'ries l\lith rt~S!)el:( to 
dillieal (hi.lra(ll:'ri~ti,.'i or (rimester of omet of infe(tion . 
J3iopw 5pl'cill1t:I1S fmln pregnant individuals had an inflam' 
In.lIor), exudate thaI \\iilS more intense than lhat tvpically found 
in Ct, with a predominance of ncutrophils, \\:h idl is not typo 
icallY' obserl'ed. Cu ltUf(" t(·"ulls w{~rc positive for /,eislwul/Iia 
:;pt·~j('s in 7 nf I! pmlcnts eXiHuincd. Fiv<~ spt'cinwns \\'{'re no 
longer viahle . '1\"'-0 spe(imcn.~ \\Tre typed a, Lels/wwllia bra·· 
;:il il'!l!.i.; by multilo(us enzyme electrophoresis. 
Eighteen pati,~ nts with definite kisilrnaniasis ,vCfe compared 
\ .... ith 36 all"'" and sex··rniltched control ~uhied;;. ;-':0 diffrfeuce 
lVilS j(lI.Jl'ld betwecn pregnant patients and nonpregnant control 
,ubic,;ts wi.tll rq;;lJ'd to thl' med ian Si7(' Of tlK' krshmanin dc · 
Lly·ed·lypi? hypersensitivity !est r('su l! Und\lliltion, 1.77 CH)"' fin-
t(Ttju ,lrlile ranf'l' 1I(1!{ ). 1.11 <~.:;:) ,:Ill ' j \'s. 1.77 (01 ' IIQR, 
n . .'lo···~'.'11i (Hl'!). rnt'dian du ratiol1 of If,ions prior to tilt' tirsl 
vi,it (1.25 months !JQR, UJ·2.0 In<)]1111."1 \is,I.G month rIQR, 
1.(1· :: ,0 Illollth."j L m(~di il n Iltunbt'r oi lesions (1.0 l<~si()ns IIQ R. 
1.() .. )'O k5ions) \'., . 1.0 k'~i()11 IIQR, J.{}····2.0 irsions)), and me 
diM) Ilumb(~r of tn'<llrnent (() ursc~ (].o course [IQR, 1.0··2.0 
cour,cs] VS. l,() course IIQR. 1.0· .. ·2.0 COUfS('S!). Both tllt'dian 
illiti,ll i<' sinJl arc;! (6.01> cm' [fQR, 1,I(S ··· j 2.Dl ern ' l \". 1.46 (nT' 
,lx\j , em 2007:45 ( I :; AUl:\tl,O • BRIEF RfYORT 
UQR, 0.1'9-3.78 Llnl!: P := .008. by M.aun·\Vhitncv U test ) ,)f)d 
median maxim;lllesi.on ,11"C<1 (14,46 nn ' [IQR. 5.50-54.95 em' l 
V~;. L46 em' !JQR. 0.79- 3.78 emil; P< .O(Jl, by J\ti<mn ·\VhitrtE,!· 
U lest ). wefe significantly furger among pregnant \'talUm than 
among (oulJol suhjects. 
Discussion. This study dem()ll5trate~ the influence of preg · 
1t.11K)' on the clinical manifestations of (:1. in a region with L. 
bmzilieHsis tran:;mission. Patients who presented ""~Ih CL whil<: 
pr("gnant had Illllch larger lesious than did nonpregnant womt~n 
(median initial lesion are,l, 6.08 em l V5·. 1.46 ern"). desp ite show · 
ing no diftercrlCl' in disease duration. Lesion ~ize was abo larger 
Mll<Hlg (lur patients than among patients set'Jl in a historiC,l! 
cohort from rhe sa.me region who did not receive rreatm.:'nl 
(nledinll lesion area, <I ('m' ; IQR, 3- 5 cm 1) [9 ]. In contrast HI 
the typical presentation of a wd.1"dernarGlfed uker with rai,ed 
hord('r~, ksiollS were frequ.:ntly of .1 cauliflower a[)pearanct'. 
which rahed' concern for other diseases, such as dlfOl11mnr·· 
cosis, y,IWS, or neoplasms. Although not previously reported, 
HlOt"c"cxlIherant CL involving other species, including l.eis!: ·· 
mania major. ha~ been obscrv('d during preg.nancy in Northern 
Afrie) (H. l.o11zir, personal communication). 
In a C57BLi6 nwuse l.. major model. larger C1, lesions 0 1.> 
.::urrcd during pregnancy. which correlated with decrt~ased Thl 
.'.-. 
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Figure 2. Sponlanf)(Jlis irnpwvl"nent o! cutaneOlJS le!.:;hrnani;;sis postpartHm. Raised. atypical lesions seen during pregnancy iA and [}), 1- 2 months 
p\):;t~rv;lJm prim to trl).'ltnlent iB ilnd E.l. ilnd after 1 (;(J(JfSil of pent3val!>,nt antimony trea tment (e and n. 
cytokinc production I to]. 'The human cell-mediated immune 
re:;porhe i~ altered during pregnancy [11], with an O\'ercom· 
peflsatio ll immediately ,tfh:r del ivery. BeGll1sc the ma.in his to-
pathologic.al diff<'ITnce in lesions in pregnant women with Iyp· 
ical ksiorls \\'<\.<, inneased. neutrophilic inti.ltration and fibrinoid 
11('(f'(l<,is, differcnt ial Jlt'utrophil signaling. (ll' actiwlliol1 llIay 
pl.ly .; ~p,'cifi c role in ,kvci{){,lllenl of al~viud lesioll$. 
<:;t;lIldar,! trcaiment of CL caused b~' /.. i>r,uiiictfsi, is 20 dJ}'s 
of' intr,lvcnolls pentavalent MHinllHlY componnd. which is po·-
lcmiaJJv abortogenic. l:kc<lllse of this (OI1(:Cl'n, tmly 2 patient!. 
r,xci\'cd antirnoI'J)' during prcgllillKy (the 2 patit'nu, <lOpped 
lH'.Jtrl1Cn t alkl' they realized llh')l were pregnant). or note, these 
patients experit' l1ccd full - tum deliveries of health,' infants. al· 
though their Ic~ions wert' no! cured until after delivery_ Ikc,msc 
spontancous cu re has been r<~p(}r('(:1 to occur after ddi",,,ry I'll, 
th,' III ('!'i ( of different treatments cannot be cvaluatt'd. !'\o pa-
tient;. in this ~ t udy "'{-r,,' cured \"hilc pregnant. No patients 
deve loped fl1uco~al disease. :llthough the Snl;J.Il 5ample ,izc liJn·· 
it,; g('nt.'rahlations. 
:\n ut1<'XI'fct",d ,inding was the hil.~h 1';1\1;' of pn.'lt'nn hirths 
Mil.! stillbirths. VMiilus matt'rnal infections, including malari.\ 
i 41. li~teno " i, 15 J. and visct.'ra l leishmaniasis 171. are :Js50(·i.lkd 
with fetal (ompliciltion<;, [n <l murine model of (o;!" cutaneOllS 
int(~(!ions incr<';l",~d the rate of impLmlario l1 failurc and fetal 
rcab~(lq'tiIHl : 12J, In northeastern Brazil a~ fI whole. infant 
ITll)rla!ity is high (-38 of 1000 jn(ant~ die per year) r 131. Th(' 
rate." obs('r l·c.J in this ,Iudr are ._'I - fold hjgh'~ f than t he normal 
rates fill' lhe rCI"inn; h,""(: \'cr, the small size of this 5tudy .limits 
conclusions l'cg.m.iing ad\'t'rsc fdal <.H.HCOrtW. 
'fhis sllldy i\ ]imit<,(\, hc(;tus(' we did nnt mea,urc the 1'10:;1 
immune response, including HIV ~er()positivity, wh.ich could 
modify disease presentation. In addition, our study W,t') ret-
rospccti\'(: :Ind,-thcref'iJre, had no formalized protom[ f()r treat-
ment or datit (ollc(till·n. 
CL during pregnancy is characterized by larger k'" ions with 
a highlr at),pical, <'x.ophytic appe.lrancc, No therapy is known 
to cure dise,lse during prc·gnancy. although postpartum cnre 
IU5 been found to bt: complete. <::1. during pregnancy has ,1 
nO!;lbly diffef't'nt clinical prescntation and may inCrCil$C the nsk 
of fetal (omplkatio!ls. It is important for physicians who are 
CHing fm patients in regions where disea,<: ;$ endemi( to f'tT-
ognize this presentation_ 
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Methicillin-Resistant Staphylococcus aureus (MRSA) 
Nares Colonization at Hospital Admission and Its 
Effect on Subsequent MRSA Infection 
Kepler A. Davis,' Justin J. Stewart,2 Helen K. Crouch/ Christopher E. Florez,3 and Duane R. Hospenthal' 
'Infectious Disease Service. 'Department of Medicine. and 'Infection Control Service. Brooke Army Medical Center. 
Ft. Sam Houston. Texas 
Background. Asymptomatic colonization with methicillin-resistant Staphylococcus aureus (MRSA) has been 
described as a risk factor for subsequent MRSA infection. MRSA is an important nosocomial pathogen but has 
currently been reported in patients without typical risk factors for nosocomial acquisition. This study was designed 
to evaluate the impact of asymptomatic nares MRSA colonization on the development of subsequent MRSA 
infection. The incidence of MRSA infection was examined in patients with and patients without MRSA or meth-
icillin-susceptible S. aureus (MSSA) colonization at admission to the hospital and in those who developed colo-
nization during hospitalization. 
Methods. Patients admitted to 5 representative hospital units were prospectively evaluated. Nares samples 
were obtained for culture at admission and during hospitalization. Laboratory culture results were monitored to 
identify all MRSA infections that occurred during the study period and 1 year thereafter. 
Results. Of the 758 patients who had cultures of nares samples performed at admission, 3.4% were colonized 
with MRSA, and 21 % were colonized with MSSA. A total of 19% of patients with MRSA colonization at admission 
and 25% who acquired MRSA colonization during hospitalization developed infection with MRSA, compared with 
1.5% and 2.0% of patients colonized with MSSA (P< .01) and uncolonized (P< .01), respectively, at admission. 
MRSA colonization at admission increased the risk of subsequent MRSA infection, compared with MSSA colo-
nization (relative risk [RRj, 13; 95% confidence interval [Clj, 2.7-64) or no staphylococcal colonization (RR, 9.5; 
95% CI, 3.6-25) at admission. Acquisition of MRSA colonization also increased the risk for subsequent MRSA 
infection, compared with no acquisition (RR, 12; 95% CI, 4.0-38). 
Conclusion. MRSA colonization of nares, either present at admission to the hospital or acquired during 
hospitalization, increases the risk for MRSA infection. Identifying MRSA colonization at admission could target 
a high-risk population that may benefit from interventions to decrease the risk for subsequent MRSA infection. 
Methicillin-resistant Staphylococcus aureus (MRSA) has 
become a progressively more important human path-
ogen since its initial description in 1961 [1] and the 
first documented outbreak of infection in 1968 [2j. The 
most recent data from the National Nosocomial Infec-
tions Surveillance System of the Centers for Disease Con-
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trol and Prevention showed in August 2003 that MRSA 
on average accounts for 57% of S. aureus isolates causing 
nosocomial infection in intensive care units (ICUs) [3j. 
This is higher than the reported prevalence of 35%-
50% for 1995-1999 [4j. Risk factors for MRSA colo-
nization have been well described [5j. Rates of colo-
nization or infection with MRSA vary by geographic 
location, type of health care facility, and the specific 
population being studied. In acute-care settings, the 
prevalence of MRSA colonization varies depending on 
patient location within the facility. The reported prev-
alence of MRSA infection or colonization in the ICU 
has been 4%-8% [6, 7j. The prevalence of MRSA col-
onization in the general inpatient setting has been re-
ported to be 0.18%-7.2% [8-10], with a prevalence of 
nosocomial acquisition of up to 1.7% [11, 12j. Com-
munity-acquired colonization has recently been de-
scribed as an important reservoir of MRSA, with a reported 
prevalence of 1.3%-2% [13, 14]. 
Whether MRSA is more virulent than methicillin-susceptible 
S. aureus (MSSA) is a controversial issue. There have been those 
whose findings support increased virulence of MRSA, com-
pared with MSSA [15-17], those who demonstrate no differ-
ence in virulence [18-20], and still others whose conclusions 
are equivocal [21]. Those who argue that MRSA is more vir-
ulent than MSSA have demonstrated higher mortality associ-
ated with MRSA bacteremia in analyses that controlled for other 
factors [15-17J. Other investigators have demonstrated that 
inappropriate antimicrobial therapy, comorbid conditions, and 
advanced patient age-rather than methicillin resistance-ac-
count for increased mortality associated with MRSA bacteremia 
[ 18-20]. However, there are studies in which MRSA infection 
or colonization were demonstrated as leading to increased risk 
of subsequent MRSA infection during the same hospitalization 
[22,23] and up to 18 months after hospital discharge [24]. The 
reported rate of subsequent MRSA infection after identification 
of MRSA colonization is -30% [24-26]. This increased risk of 
infection with MRSA has led some to recommend screening all 
patients [12,24] or those at highest risk [27, 28] for colonization 
at admission to the hospital. This study was designed to measure 
the prevalence of MRSA colonization at admission to our insti-
tution (Brooke Army Medical Center; Ft. Sam Houston, TX) 
and to determine its impact on subsequent MRSA infection. 
METHODS 
Data were obtained from a prospective observational study of 
subjects who were admitted to 5 systematically chosen repre-
sentative inpatient hospital units. The study was approved by 
the Brooke Army Medical Center institutional review board. 
All patients admitted between I June 2002 and 31 August 2002 
were eligible for inclusion. The observed hospital units included 
a general medical/surgical ward, a medical ICU, a surgical ICU, 
a trauma ICU, and a monitored step-down unit, the patients 
of which, taken together, represent our typical inpatient pop-
ulation. The study hospital is a tertiary care military medical 
training center located in San Antonio, Texas, that had 203 
available inpatient beds during the study period. This facility 
serves a patient population of active-duty and retired military 
personnel and their dependents. Individuals in this population 
receive the majority of their medical care from the military 
health care system in San Antonio. Additionally, the facility is 
a level 1 trauma center that treats a limited number of civilian 
trauma patients who would otherwise not be eligible for care 
within the system. 
Nares cultures were performed within 48 h after admission 
to an observed hospital unit. Cultures were also performed 
when patients were transferred to other study units, weekly 
during prolonged hospital stays, and at hospital discharge. One 
sterile culture swab (BBL Culture Swab; Becton Dickinson) was 
used to sample both nares. The swab sample was streaked onto 
5% sheep blood agar (BBL Stacker plates; Becton Dickinson) 
and colistin-nalidixic acid (CNA) agar (Columbia CNA agar 
with 5% sheep blood Stacker plates; Becton Dickinson) and 
incubated for 18-24 h at 37°C in 5% CO2, If no growth was 
detected, plates were incubated for another 24 h. Colonies with 
i3-hemolytic activity and properties consistent with those of 
staphylococci were screened for catalase activity (3% H20 2), 
and if they tested positive, they were then screened with a rapid 
slide agglutination test for coagulase and protein A (Staphaurex; 
Remel). Coagulase-positive organisms were confirmed with a 
tube coagulase test (BBL coagulase plasmas; Becton Dickinson) 
and were inoculated onto oxacillin screen agar (BBL stacker 
plates). Susceptibility testing of MRSA isolates was conducted 
by Vitek system GPS-105 cards (bioMerieux). 
Information recorded for study patients included age, sex, 
length of hospital stay, and number of nares cultures completed. 
If S. aureus was detected in the admission culture, the patient 
was identified as having been initially colonized with either 
MRSA or MSSA. If the admission culture was negative for S. 
aureus but results of a subsequent nares culture during the 
course of hospitalization were positive, the patient was iden-
tified as having acquired MRSA or MSSA colonization. Patients 
without S. aureus identified in any nares culture during hos-
pitalization were identified as having not been colonized with 
S. aureus. 
All patients included in the study were followed to determine 
whether they developed clinical infection with MRSA. Patients 
were followed during the 3-month study period and for 1 year 
thereafter, through 31 August 2003. MRSA infection was de-
fined as recovery of the organism from either normally sterile 
sites (blood samples or urine specimens without a Foley cath-
eter in place) or nonsterile sites concomitant with a diagnosis 
of infection by the primary physician caring for the patient. 
Nonsterile sites included indwelling vascular catheters, skin and 
soft tissue, and sputum. All patients included in the study also 
had their names compared with those from the list of patients 
previously known to have infection or colonization with MRSA 
in our hospital. 
The precision of relative risks for MRSA infection was de-
termined by the method for calculating 95% Cis described by 
Altman [29]. Statistical significance (i.e., the P value) was cal-
culated for the difference in rates of MRSA infection by Fisher's 
exact test [30]. The hypothesis that MRSA infection was de-
pendent on age was evaluated with the independent-sample 
Student's t test. The hypothesis that MRSA infection was de-
pendent on length of stay was evaluated with the Mann-Whitney 
rank sum test. Difference in descriptive statistics among eval-
uated patients and excluded patients was completed with the 
Mann-Whitney rank sum test. 
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Tabie 1. Demographic and clinical characteristics of 758 admitted patients for whom 
cultures of nares were performed to assess methicillin-resistant Staphylococcus aureus 
(MRSA) colonization status. 
Sex. no. of patients with 
MRSNtotal no. in unit (%) 
Study unit Male Female 
Medical/surgical 157/347 (45) 190/347 (55) 
Intensive care 
Medical 53/96 (55) 43/96 (45) 
Surgical 50/67 (75) 17/67 (25) 
Trauma 54/74 (73) 20/74 (27) 
Step-down 88/174 (51) 86/174 (49) 
Total 402/758 (53) 356/758 (47) 
RESULTS 
During the study period, 758 of 990 patients admitted to the 
observed units had nares cultures performed within 48 h after 
admission to the hospital. The mean age was higher for patients 
admitted to the medical ICU, the trauma ICU, and the mon-
itored step-down unit (table 1; P< .01). Among patients ad-
mitted to the surgical and trauma ICUs, the mean and median 
length of stay was longer (P < .01) and there were proportionally 
more men (P< .03). Cultures were performed an average of 
1.7 times (range, 1-6 times) for each patient during hospital-
ization. There were no significant differences with respect to 
sex (P = .223) or length of stay (P = .163) for patients who 
did not have a culture completed within 48 h of admission, 
and thus these are not included in the evaluation. Patients who 
were not included in the evaluation were less frequently ad-
mitted to a medical-surgical ward (22% vs. 45%; P< .01) and 
were more frequently admitted to the telemetry unit (47% vs. 
23%) than were patients who were included. They were older 
(mean age, 60 years; P< .01) than those who were included in 
the study. 
Of the 758 study patients, 163 were initially colonized with S. 
aureus. Twenty-six patients (3.4%; 95% CI, 2.1-4.7) were colo-
nized with MRSA, and 137 (21 %; 95% CI, 18-24) were colonized 
with MSSA (table 2). The incidence of subsequent MRSA in-
fection for those initially colonized with MRSA was close to 10 
times the incidence for patients colonized with MSSA or not 
colonized with S. aureus at admission (P< .01 for both) (table 
3). The relative risk (RR) for developing MRSA infection was 
much higher for those colonized with MRSA at admission, com-
pared with those colonized with MSSA (RR, 13; 95% CI, 2.7-
64) or those not colonized with S. aureus (RR, 9.5; 95% CI, 3.6-
25) at admission. Patients who subsequently developed MRSA 
infection were older (mean age, 69 years; range, 29-91 years; 
P = .015) and were admitted for a longer period (mean length 
of stay, 16 days; range, 1-67 days; P< .01). They also tended to 
be admitted to a monitored unit (P = .lO). Table 4 describes the 
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Age. mean Length of stay. days 
years (range) Mean Median (range) 
49 (17-87) 3.9 2 (1-40) 
65 (18-101) 6.6 3 (1-96) 
46 (8-84) 14 8 (1-85) 
59 (18-101) 10 7 (1-63) 
67 (20-93) 5.2 3 (1-67) 
56 (8-101) 6.1 3 (1-96) 
infections that occurred in these patients, including the time of 
onset and whether they occurred during the same or a future 
hospitalization. 
In addition to presenting with colonization at admission, 
there were patients who acquired colonization during the study 
period. There were 394 patients who had "" 1 nares culture 
completed during hospitalization, of whom 25 had a change 
in their nares colonization status. Twelve (3.0%) of these pa-
tients acquired MRSA, 3 of whom were initially colonized with 
MSSA. Five patients (2.0%) were in the medical-surgical ward, 
none were in the medical ICU, 1 (2.4%) was in the surgical 
ICU, 4 (8.9%) were in the trauma ICU, and 2 (4.3%) were in 
the monitored step-down unit. Of these patients, 250/0 later 
developed MRSA infection. The relative risk for developing 
MRSA infection for patients who acquired MRSA colonization 
was also higher, compared with those who were not colonized 
with S. aureus (RR, 12; 95% CI, 4.0-38; P< .01). 
There was 1 patient who developed infection with MRSA who 
was known to have previous infection with MRSA. This patient 
Table 2. Staphylococcus aureus colonization 
in patients for whom nares were cultured at 
admission. 
Study unit 
Medical/surgical 
Intensive care 
Medical 
Surgical 
Trauma 
Step-down 
Overall 
S. aureus colonization status. 
no. of patients/total no. 
screened in unit (%) 
MRSA MSSA 
7/347 (2.0) 57/300 (19) 
7/96 (7.3) 18/90 (20) 
2/67 (3.0) 16/57 (28) 
3/74 (4.1) 13/68 (19) 
7/174 (4.0) 33/152 (22) 
26/758 (3.4)" 137/667 (21)b 
NOTE. MSSA. methicillin-susceptible S. aureus. 
• 95% CI. 2.1-4.7 
b 95% CI. 18-24. 
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Table 3. Subsequent methicillin-resistant Staphylococcus aureus (MRSA) infection, by S. 
aureus colonization status at admission. 
MRSA colonization at MSSA colonization at 
admission, no. (%) admission, no. (%) 
of patients of patients 
Study unit Total MRSA infection Total MRSA infection 
Medical/surgical 7 1 (14) 57 0(0) 
Intensive care 
Medical 7 2 (29) 18 1 (5.6) 
Surgical 2 0(0) 16 0(0) 
Trauma 3 0(0) 13 0(0) 
Step-down 7 2 (29) 33 1 (3.0) 
Overall 26 5 (19)a 137 2 (1.5)b 
NOTE. MSSA. methicillin-susceptible S. aureus. 
a 95% CI, 3.9--34. 
b P< .01 (incidence not large enough to calculate 95% CI). 
c 95% CI, 0.9--3.1; P< .01. 
No colonization at 
admission, no. ('Yo) 
of patients 
Total MRSA infection 
283 2 (0.7) 
71 1 (1.4) 
50 3 (60) 
57 2 (3.5) 
134 4 (3.0) 
595 12 (2.0)c 
was not colonized with MRSA at admission to the medical-
surgical ward, but repeated screening later identified coloni-
zation before infection. There were 6 other patients in the study 
group who had previously been identified with MRSA infection. 
Four of these 6 patients were colonized with MRSA at admis-
sion, 1 acquired colonization during hospitalization, and 1 was 
never identified with MRSA colonization during the study pe-
riod. This patient had 2 cultures with negative results during 
the hospital stay that followed the admission culture for which 
negative results were obtained. 
Table 4. Methicillin-resistant Staphylococcus aureus (MRSA) infection, according to 
S. aureus colonization characteristics at admission. 
Time from 
S. aureus 
colonization Hospitalization 
Colonizing isolate, to MRSA in which MRSA 
by patient no. Infection type infection, days infection occurreda 
MRSA 
1 Toe amputation site abscess 6 Concurrent 
2 Bacteremia 7 Concurrent 
3 Central catheter infection 9 Concurrent 
4 Right axillary abscess 24 Future 
5 Right BKA site abscess 60 Future 
MSSA 
6 Bacteremia 82 Future 
7 LLE soft tissue abscess 268 Future 
None 
8 Bacteremia 9 Concurrent 
9 Osteomyelitis 22 Concurrent 
10 Bacteremia 23 Concurrent 
11 Abdominal wound abscess 8 Future 
12 Pneumonia 31 Future 
13 Pneumonia 42 Future 
14 RLE BKA site abscess 77 Future 
15 LLE BKA site abscess 87 Future 
16 Osteomyelitis 336 Future 
NOTE. BKA, below the knee amputation; LLE, left lower extremity; MSSA, methicillin-susceptible 
Staphvlococcus aureus; RLE, right lower extremity. 
a Data limited to 1 year after the hospital stay dunng which MRSA colonization was initially identified. 
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Table 5. Antibiotic susceptibility patterns of methicillin-resis-
tant Staphylococcus aureus (MRSA) isolates. 
Antibiotic to MRSA type, % susceptible 
which MRSA Colonizing isolates Infecting isolates 
was susceptible (n = 56) (n = 30) 
Ampicillin 0 0 
Cefazolin 4 0 
Clprofloxacin 9 13 
Clindamycin 27 7 
Erythromycin 4 3 
Rifampin 100 90 
Tetracycline 96 93 
TMP-SMZ 96 97 
Vancomycin 100 100 
NOTE. All isolates tested positive for iJ-lactamase production. TMP-SMZ, 
trimethoprim-sulfamethoxazole. 
The susceptibility patterns for MRSA isolates obtained from 
nares cultures and for those causing clinical infection were similar 
(table 5). Nares isolates from patients initially colonized with 
MRSA were more susceptible to tested antibiotics than were 
isolates from those who acquired colonization. The isolates that 
caused infection in patients who were initially colonized with 
MRSA had the exact same susceptibility patterns as the colo-
nizing isolates from these patients. Isolates that caused infection 
in patients who were not colonized with S. aureus or in those 
who acquired MRSA colonization before infection tended to 
be more resistant to the tested antibiotics, which is consistent 
with patterns of hospital-acquired MRSA. The isolates of 1 of 
the 3 patients who acquired colonization and were later infec-
tion with MRSA also had the same susceptibility patterns. The 
other 2 patients had isolates that varied by either clindamycin 
or ciprofloxacin susceptibility only. 
DISCUSSION 
The prevalence of initial MRSA colonization in this study was 
3.4%, with 3.0% of patients subsequently acquiring MRSA col-
onization. In this study, patients colonized with MRSA were at 
much higher risk of subsequent MRSA infection than were 
those colonized with MSSA or those not colonized with S. 
aureus. There was a lO-fold increase in the rate of infection 
between these groups, with a significant difference in relative 
risk. Antibiogram data for these isolates suggest that the col-
onizing isolates were the same isolates that subsequently caused 
infection in these patients. 
Recent reports have demonstrated a similar increased risk of 
subsequent MRSA infection for MRSA-colonized patients. Huang 
and Platt [24] reported on subsequent MRSA infection in 209 
adult patients newly identified with MRSA infection or col-
onization. They retrospectively identified these patients from 
infection-control records and found that 29% developed MRSA 
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infections over the next 18 months. One-half of the infections 
occurred after discharge from the hospital. Mest et al. [31) 
rep9rted on a smaller group of patients, compared with our 
study, who were in the surgical ICU. They screened all patients 
preoperatively for MRSA colonization of nares and found that 
4% were colonized with MRSA. Twenty-six percent of these 
patients developed MRSA infection, compared with 1.3% of 
those who were not colonized. They hypothesized that pre-
operative MRSA colonization of nares significantly increased 
the risk for subsequent postoperative MRSA infection. Rogh-
mann et aJ. [23] retrospectively studied the risk associated with 
MRSA colonization of ulcers and the subsequent development 
of MRSA infection in a cohort of patients with chronic sacral 
decubitus and diabetic foot ulcers. They found that 30% of 
ulcers were colonized with MRSA. Seventeen percent of patients 
with MRSA-colonized ulcers developed subsequent MRSA bac-
teremia, compared with only 1 % of the patients without colo-
nization. Roghmann et al. [23] reasoned that MRSA colonization 
of chronic ulcers increases the risk for MRSA bacteremia. 
Other studies evaluated cohorts of MRSA-colonized patients. 
Coello et al. [22] observed a group of 479 patients colonized 
with MRSA. Of these patients, 11 % developed MRSA infection 
during the course of hospitalization, but Coello et al. [22] did 
not compare this risk with that for noncolonized patients. They 
demonstrated that ICU patients had an increased risk of sub-
sequent MRSA infection, compared with medical patients, which 
was similar to our results that showed that MRSA infections 
tended to occur in patients admitted to monitored units (table 
3). Garrouste-Orgeas et a1. [25J also reported on a cohort of 
MRSA-colonized patients who were treated in the ICU. In their 
study, Garrouste-Orgeas et al. [25] observed patients during 
hospitalization but not after discharge, and they identified 
MRSA colonization in 10% of medical-surgical ICU patients, 
with 27% developing MRSA infection, compared with <1 % of 
noncolonized patients who developed MRSA infection during 
hospitalization. 
The limitations of our study include the relatively small num-
ber of MRSA infections that were identified. The conclusions 
based on this data are statistically significant; however, a larger 
data set would strengthen these conclusions. A small data set 
may introduce sampling bias, because of the small numbers of 
infections found. There were also a number of patients who 
were not included in the study because they were not screened 
within 48 h after admission or not screened at all. The dem-
ographic data of this population did not differ significantly 
from those of patients in the study group, but the former were 
more frequently admitted to the medical surgical or telemetry 
units. It is possible that the failure to include this population 
could have introduced sampling error, which could affect the 
overall conclusions, Additional review, however, demonstrated 
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that this group did not have a significant number of MRSA 
infections that would have changed the study outcomes. 
This study supports the results of previously published reports 
and further demonstrates the natural course of MRSA coloni-
zation of nares. Most of the previous studies identified MRSA 
colonization for inpatients and the associated risk for subsequent 
infection during the same hospitalization. As demonstrated by 
Huang and Platt [24], one-half of these infections occurred after 
hospital discharge. These studies typically retrospectively iden-
tified patients who had MRSA colonization at some point during 
the hospitalization-not necessarily at admission, as our study 
did--or observed a cohort of MRSA-colonized or -infected pa-
tients without comparing them with noncolonized patients. By 
sampling a group of consecutively admitted patients and ob-
serving them for> I year, we were able to define the incidence 
of subsequent infection in a prospective manner. 
We have demonstrated that MRSA colonization of nares, 
both at admission and hospital-acquired, increases the risk for 
subsequent MRSA infection. Our data suggest that further in-
vestigation of patients at risk for MRSA infection is warranted 
on the basis of the presence of MRSA colonization. It may be 
possible to focus infection-control measures on a high-risk group 
of MRSA-colonized patients to decrease the incidence of sub-
sequent MRSA infection. This study has demonstrated that an 
leu patient population would be best suited for this because it 
had the highest risk for MRSA colonization of nares and the 
highest incidence of subsequent MRSA infection. 
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Predicting the Staphylococcus aureus Nasal Carrier 
State: Derivation and Validation of a "Culture Rule" 
Jan L. Nouwen,I.2.3 Alewijn Ott,I.3 Marjolein F. O. Kluytmans-Vandenbergh,' Holime A. M. Boelens,l Albert Hofman,3 
Alex van Belkum.' and Henri A. Verbrughl 
Departments of 'Medical Microbiology and Infectious Diseases and 'Medicine, Infectious Diseases Section, and 'Department of Epidemiology 
and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands 
Background. To study determinants and risks of Staphylococc-us aureus nasal carriage, adequate differentiation 
between the different S, aureus carrier states is obligatory. We set out to develop a "culture rule" capable of 
differentiating between persistent and intermittent or noncarriers that uses a minimum of nasal swab cultures. 
Methods. In 51 healthy volunteers (derivation cohort), 12 quantitative nasal cultures were performed to 
establish S. aureus nasal carriage states. Persons with 11 or 12 cultures positive for S. aureus were classified as 
persistent carriers, and those with negative results of all cultures were classified as non carriers. All other persons 
were classified as intermittent carriers. By means of logistic regression and receiver operating characteristic (ROC) 
curves, a culture rule was derived. This culture rule was subsequently validated in 106 participants of an ongoing 
study in 3882 elderly persons, again with the use of 12 quantitative nasal cultures. 
Results. In both cohorts, the positive predictive value of 2 consecutive positive culture results for persistent 
carriage was 79%. The model best differentiating between persistent and intermittent or noncarriers used the 
number of positive culture results combined with the amount of S. aureus in these cultures. By using the outcome 
of 2 cultures, the areas under the ROC curves were 0.981 (95% confidence interval [CI], 0.949-1.0) for the 
derivation cohort and 0.936 (95% CI, 0.881-0.990) for the validation cohort. 
Conclusions. Combining qualitative and quantitative results of 2 nasal swab cultures accurately predicted the 
persistent S. aureus carriage state with a reliability of 93.6%. Thus, this culture rule can be used in studies of 
determinants and risks of S. aureus nasal carriage. 
Staphylococcus aureus nasal carriage is a major risk fac-
tor for both community-acquired and nosocomial in-
fections [1-7], and the anterior nares are the primary 
reservoir of S. aureus in humans [8-10]. Three S. aureus 
nasal carriage patterns can be discerned: persistent car-
riage, intermittent carriage, and noncarriage [11-22]. 
However, no consensus has been reached on how to 
exactly identify these different states, but most studies 
use findings from 10-12 weekly nasal swab cultures 
[23]. 
The number of colony-forming units (CFUs) of S. 
aureus isolated from the anterior nares are higher in 
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persistent than in intermittent carriers [24, 25], re-
sulting in more extensive dispersal of staphylococci in 
the environment [25] and in an increased risk of S. 
au reus infection [26-28J. Bacterial variability (i.e., the 
number of S. aureus genotypes isolated in repeated cul-
tures from one individual) is lower for persistent than 
for intermittent carriers [15, 22, 29], indicating that the 
underlying mechanisms determining persistent and in-
termittent carriage differs. Adequate differentiation be-
tween persistent and intermittent carriage is thus rel-
evant for epidemiological studies. 
At present, a large study of S. aureus nasal carriage in 
a population aged ;;:.60 years is being conducted at Eras-
mus Medical Center (Rotterdam, The Netherlands). The 
main objectives are to study determinants and risks of 
S. aureus nasal carriage. This is part of the Rotterdam 
Study, a population-based prospective study of chronic 
diseases in the elderly population. The Rotterdam Study 
started in 1990 with 7983 persons and has just finished 
its third phase, in which >4000 persons have been in-
cluded. In this large survey, an efficient and reliable way 
to assess S. au reus nasal carriage was obligatory. It would be 
impossible to perform 10-12 weekly nasal swab cultures in all 
participants. Thus, we developed a "culture rule" to discrim-
inate reliably between persistent carriage and non carriage or 
intermittent carriage, with a minimum of nasal swab cultures. 
Our main questions were as follows: (I) how many quan-
titative nasal swab cultures are needed to accurately predict 
persistent carriage in a cohort of healthy adult volunteers, and 
(2) does the derived culture rule correctly predict persistent 
carriage in the elderly cohort of the ongoing Rotterdam Study? 
PATIENTS AND METHODS 
Patient Cohorts and Microbiological Investigations 
Derivation cohort. In 1988, a cohort of healthy volunteers 
(staff members of the departments of medical microbiology 
and infectious diseases and virology at Erasmus Medical Center) 
was formed to investigate bacterial and human factors associ-
ated with S. aureus nasal carriage [23]. During the period of 
September 1995 through March 1996, a total of 51 volunteers 
agreed to participate in this study. Nasal swab cultures were 
performed weekly for 12 weeks. All nasal swab samples were 
obtained for culture by one study physician (M.F.Q.K.-V.), ac-
cording to the protocol below. 
Validation cohort. On the basis of the results of the der-
ivation cohort, 2 quantitative nasal swab cultures of samples 
obtained at I-week intervals were performed in 3882 partici-
pants of the Rotterdam Study. While this study was ongoing, 
106 participants entering the study during the period of Oc-
tober 1997 through April 1998 agreed to be included in the 
validation cohort. Persons with 2 positive or 2 negative nasal 
swab culture results were oversampled to estimate the predictive 
value of these cultures for persistent carriage and noncarriage, 
or for intermittent carriage. One trained research assistant vis-
ited the participants at home and performed 10 additional nasal 
swab cultures at I-week intervals, according to protocol. 
The study was approved by the Medical Ethics Review Com-
mittee of the Erasmus Medical Center, University Medical Center, 
Rotterdam. Informed consent was obtained from all participants. 
Definitions 
S. aureus nasal carriage state was assessed by means of the results 
of nasal swab cultures 3-12, as follows: persistent carrier, 9 or 
10 of 10 cultures were positive for S. aureus; noncarrier, no 
positive culture results; and intermittent carrier, all intermediate 
numbers of positive culture results. 
Microbiological Procedures 
Nasal swab cultures were performed according to a standard 
operating procedure, as described elsewhere [23]. Nasal swabs 
specimens were obtained with sterile cotton-wool swabs (Tran-
swab; Medical Wire and Equipment). Both the left and right an-
terior nares were swabbed by rubbing the swab 4 times around 
the inside of each nostril while applying an even pressure and 
rotating the swab without interruption. The swabs were im-
mediately placed in Stuart transport medium and kept at 4°C 
until inoculation (within 24 h). 
Swabs were then cultured quantitatively on phenol-red man-
nitol salt agar (PHMA) and in phenol red mannitol salt broth 
(PHMB). The flasks with transport media containing the nasal 
swab were vortexed for 15 s. The swab was then pressed firmly 
against the wall of the flask with a sterile pincette and cultured 
in 8 mL of PHMB. Subsequently, 500 /A-L of the remaining 
bacterial suspension was inoculated evenly onto a large PHMA 
culture plate (diameter, 14 cm). Another PHMA culture plate 
(diameter, 8.5 cm) was divided into 3 sectors, which were in-
oculated with 10 /A-L of the original bacterial suspension, 10 /A-L 
of a 1: 10 diluted bacterial suspension, and 1 /A-L of the 1: 10 
diluted bacterial suspension, respectively. The PHMB was in-
cubated at 37°C for 7 days; the PHMA culture plates were 
incubated at 37°C for 48 h and at room temperature for 5 days. 
Both were interpreted after 7 days of incubation. If, after 7 
days, no S. aureus had grown on the PHMA but the PHMB 
demonstrated a yellow color, a PHMA culture plate (diameter, 
8.5 cm) was inoculated with 10 /A-L of PHMB and incubated 
as before. Culture results were recorded as 0 (no S. aureus), 1 
(S. aureus only on the PHMB culture plate), 2 (2-9 CFU), 3 
(10-99 CFU), 4 (100-999 CFU), or 5 (;:;,:1000 CFU). 
Identification of S. aureus was based on colony morphology 
on the PHMA culture. Suspected colonies were cultured over-
night on Columbia blood agar plates (Becton-Dickinson). A 
catalase test and a latex agglutination test (Staphaurex Plus; 
Murex) were then performed. All S. aureus isolates were stored 
at -70°C in glycerol-containing liquid media. 
Statistical Analysis 
Percentages and continuous data were compared using Fisher's 
exact test and the Mann -Whitney test, respectively. Logistic 
regression was performed, and receiver operating characteristic 
(ROC) curves were constructed for different tests and com-
binations of tests (number of positive cultures, IOlog-trans-
formed CFUs [IOlog {CFU + I} 1 and the geometric mean CFUs 
of;:;,:2 cultures [e.g., {3j/2]) to study their ability to discriminate 
between persistent carriage and noncarriage or intermittent car-
riage [30]. Culture results of the derivation cohort were added 
as independent covariates to a logistic regression model with 
our "gold standard" diagnosis of persistent carriage or not (de-
rived from 10 consecutive cultures) as binary outcome variate. 
The right side-of the regression equation was [/30 + /31 X num-
ber of positive cultures + /32 X geometric mean of CFUs]. Fitting 
the model gave us /30 to /32. Then we calculated the odds of 
persistent carriage for all persons of the validation cohort by 
adding their respective culture outcomes in the formula: odds = 
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[e({30 +,61 x number of positive cultures + (32 X geometric mean 
of CFVs) J. Subsequently, the probability of persistent carriage 
was obtained by [odds/(I + odds)J. We choose the midpoint 
between 0 and 1 as the cut point. Areas under the ROC curves 
(AVC) and the corresponding SE were estimated by a non-
parametric method (2-sample Wilcoxon test) [31,32]. Differ-
ences between AVCs of the different test combinations were 
compared by the method of Hanley and McNeil [33J. 
RESULTS 
Fifty-one persons were included in the derivation cohort (19 
men [37%J and 32 women [63%]), with a mean age 29 years 
(range, 20-52 years). Twenty (39%) participants were classified 
as non carriers, 16 (31 %) were classified as intermittent carriers, 
and 15 (29%) were classified as persistent carriers (derivation 
cohort; table 1). Positive predictive values for persistent car-
riage, derived from regression models that included the results 
of cultures 1 and 2, ranged from 0.79 in a model containing 
the qualitative outcome only, to 0.88 in a model including both 
qualitative and quantitative results (figure lA). The use of the 
results of only 1 culture (either 1 or 2) produced a positive 
predictive value of only 0.69. 
The validation cohort consisted of a subset of 106 partici-
pants of the Rotterdam Study cohort (44 men [42%J and 62 
women [58%]), with a mean age 73 years (range, 62-89 years). 
For the present study, persons with 1 positive and 1 negative 
culture result were less informative. Two positive culture results 
could either indicate persistent or intermittent carriage. Pos-
sibly, the number of CFVs of S. aureus cultured could differ-
entiate between persistent and intermittent carriage. Persons 
with 2 negative culture results could help to assess the predictive 
value for true noncarriage. Therefore, after initial random in-
clusion of participants, we decided to oversample persons with 
2 positive or 2 negative screening culture results. Fifty-seven 
participants (54%) were classified as noncarriers, 17 (16%) were 
classified as intermittent carriers, and 32 (30%) were classified 
as persistent carriers (validation cohort; table 1). In 1 partic-
ipant, both screening culture results were negative, and the 
results of cultures 3-12 were all positive. The most probable 
explanation for this would be either sample handling mistakes 
or a laboratory error. Because exclusion of this person did not 
significantly alter the data, and because mistakes happen in real 
life, it was decided not to exclude this person's data from analy-
sis. The positive predictive value derived from regression mod-
els that included the results of cultures 1 and 2 was 0.79 in a 
model containing the qualitative outcome only, as well as in a 
model including also the quantitative results (figure lB). The 
use of the results of only 1 culture (either 1 or 2) produced a 
positive predictive value of 0.74. 
The numbers of CFVs of S. aureus were significantly higher 
in the validation than in the derivation cohort (figure 2). The 
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Table 1. Classification ofthe Staphylococcus aureus nasal car-
rier state based on results of the first 2 cultures. compared with 
results of cultures 3-12. for derivation and validation cohorts. 
Results of cultures 1 and 2 
Both 1 Positive Both 
Cohort negative and 1 negative positive Total 
Derivation cohort 
Noncarrier 19 1 20 
Intermittent carrier 7 5 4 16 
Persistent carrier 15 15 
Total 26 6 19 51 
Validation cohort 
Noncarrier 53 4 57 
Intermittent carrier 7 2 8 17 
Persistent carrier 1 31 32 
Total 61 6 39 106 
NOTE. Data are no, of subjects, S. aureus carrier status is based on results 
of cultures 3-12, For the validation cohort. persons for whom the results of 
both culture 1 and 2 were positive or negative were oversampled (see Patients 
and Methods), Therefore. the distribution of the different carrier states does 
not represent the population prevalence, 
median geometric mean in intermittent and persistent carriers 
were 1.4 (range, 0.3-3.3) and 3.6 (range, l.9-3.9) in the validation 
versus 1.0 (range, 0.3-2.0) and l.8 (range, 0.9-3.2) in the der-
ivation cohort (P = .001 and P< .OO!), respectively. Persistent 
carriers had significantly higher numbers of CFVs of S. aureus 
in their positive nasal swab cultures than did intermittent carriers 
(figure 2): 1.8 CFVs (range, 0.9-3.2 CFUs) versus 0.98 CFVs 
(range, 0.30-2.0 CFVs; P = .001) in the derivation cohort and 
3.6 CFVs (range, 1.9-3.9 CFVs) versus 1.4 CFVs (range, 0.30-
3.3 CFUs; P< .00l) in the validation cohort (figure 2). 
In the derivation cohort, logistic regression showed that the 
model best differentiating between persistent carriage and non-
carriage or intermittent carriage used qualitative culture results 
in combination with quantitative data. The model that used 
the results of 2 cultures performed significantly better than a 
model that used the results of only 1 culture. Adding the results 
of a third or fourth culture did not significantly improve the 
model. Results from the ROC analysis showed that all tests 
used had good performance (all AVCs were >0.9), with the 
combined model being slightly-but not significantly-better 
than the qualitative result of 2 nasal swab cultures (figure lA). 
In the validation cohort, 2 qualitative culture results (positive 
or negative) discriminated similarly between persistent carriage 
and noncarriage or intermittent carriage as the combined qual-
itative and quantitative results. All logistic regression models 
were significantly improved by adding data on a third culture. 
However, in the ROC analysis, the differences between the 
models were small. Adding data on a third (but not a fourth) 
culture only significantly improved the model when both qual-
itative and quantitative culture results were used (figure IB). 
The AVCs that used the combination of qualitative culture 
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Figure 1. A, Receiver operating characteristic (ROC) curve illustrating the predictive value of different tests for the persistent Staphylococcus 
aureus nasal carrier state in the derivation cohort. * Area under the ROC (AUG) of 2 versus 1 cultures (P < ,05), B, ROC curve illustrating the predictive 
value of different tests for the persistent S. aureus nasal carrier state in the validation cohort. *AUC of 3 versus 2 cultures in the combined test 
(P< ,05). PVt, positive predictive value; PV-, negative predictive value. 
results and the geometric mean CFUs of 2 cultures were 0.981 
(95% CI, 0.949-1) for the derivation cohort and 0.936 (95% 
CI, 0.881-0.990) for the validation cohort, respectively (figure 
1). The logistic regression equation that uses the combination 
of qualitative culture results and the geometric mean of CFUs 
from 2 cultures could be written as follows: probability of per-
sistent S. aureus nasal carriage = e({:W + {31 X number of posi-
tive cultures + (32 X geometric mean of CFUs)/ 1 + e({30 + {31 X 
number of positive cultures + (32 X geometric mean of CFUs). 
In the derivation cohort, the respective values of {30, {31, and 
{32 were -20.171, 9.341, and 1.661. In the validation cohort 
these values were -4.572, 2.563, and 0.274, respectively. 
When a cutoff of 0.50 was used, above which probability 
persons were classified as persistent carriers, it followed from 
the logistic regression equation from the derivation cohort that 
a per'son was a persistent carrier only if both cultures were 
positive with a geometric mean of ;;'0.9 (-8 CFUs per culture). 
This culture rule, when applied to the validation cohort, had 
a positive predictive value of 0.78, a negative predictive value 
of 0.96, and an AUC of the corresponding ROC curve of 0.936 
(95% CI, 0.881-0.990). 
DISCUSSION 
We examined the diagnostic value of2 weekly quantitative nasal 
swab cultures to predict the S. au reus nasal carriage state and 
developed a culture rule to enable adequate differentiation be-
tween persistent carriage and intermittent carriage among those 
individuals with 2 positive screening culture results. 
We used logistic regression and ROC analysis to derive a cul-
ture rule under ideal laboratory circumstances in a cohort of 
healthy adult volunteers. Strictly speaking, the derivation cohort 
actually was more of an exploratory data set to help select the 
variables in the model, but not the actual predictions. The culture 
rule was subsequently validated under real-life conditions in a 
subset of elderly participants of the Rotterdam Study. 
In the derivation cohort, the best test combined qualitative 
culture results (number of positive culture results) with quan-
titative data (geometric mean number of CFUs of S. aureus in 
nasal swab cultures). In the validation cohort, however, the 
simple qualitative culture result when data on 2 cultures were 
used performed as well as the more complicated culture rule. 
The culture rule performed slightly less well in the validation 
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Figure 2. Geometric mean (1°log) number of colony-forming units (CFUs) 
of Staphylococcus aureus in positive cultures in intermittent versus persis-
tent carriers from both cohorts. Boxes, median, quartile, and extreme values; 
*persistent versus intermittent carriers in derivation cohort (P = .001); t, 
persistent versus intermittent carriers in validation cohort (p < .001); ~, 
intermittent carriers, derivation versus validation cohort (P = .001); §, per-
sistent carriers. derivation versus validation cohort (P < .001). 
cohort (AVC, 0.981 in the derivation and 0.936 in the vali-
dation cohort, respectively). In the ideal laboratory situation, 
one trained physician performed all nasal swab cultures in a 
cohort of healthy individuals. In the real-life situation of large-
scale epidemiologic surveys, misclassification of the carrier state 
could have occurred for a variety of logistic reasons, such as 
differing nasal culturing techniques of study physicians, sample-
handling mistakes, and laboratory errors. In theory, many of 
these "errors" are preventable but can never be totally eradi-
cated. The fact that in the validation cohort the first 2 cultures 
were obtained at the Rotterdam Study research center by var-
ious study physicians, whereas cultures 3-12 in the validation 
cohort were performed by one trained person, certainly affected 
culture results: when cultures 3 and 4 of the validation cohort 
were used, instead of cultures 1 and 2, the AVC was increased 
from 0.936 to 0.996. 
Misclassification of the carrier state could also have occurred 
because of factors associated with individual participants of the 
Rotterdam Study. Culture results will potentially have been in-
fluenced by the use of medication (recent courses of antibiotic 
therapy), institutionalization (recent hospital admissions), and 
underlying diseases, as well as other unknown determinants. 
We confirm earlier data that showed that the number ofCFUs 
of S. aureus in the anterior nares was higher in persistent carriers 
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than in intermittent carriers [24, 25]. We also found a striking 
difference in the amount of S. aureus in the nose of persistent 
carriers between young, healthy volunteers and healthy, elderly 
participants. No previous data are available regarding age and 
the number of CFVs of S. aureus in the noses of persistent 
carriers. From the Rotterdam Study (3851 persons), the high 
numbers of CFUs (median geometric mean, 2.8) in elderly per-
sistent carriers are confirmed (data not shown), but the under-
lying mechanisms of this finding remain to be elucidated. The 
differences in the number of CFVs in persistent carriers in both 
cohorts will have affected the performance of the derived culture 
rule in the validation cohort. When applying this culture rule to 
other patient populations, it will need to be validated in the 
specific population first, when possible. 
Combining qualitative results with quantitative data is, in 
our opinion, conceptually the best choice. Incorporating quan-
titative data makes it possible to refine associations between 
potential determinants and S. aureus nasal carriage because not 
only carriers are compared with noncarriers, but carriers with 
low CFUs can also be compared with carriers with high CFVs 
in their anterior nares. Incorporating quantitative data will also 
make it possible to refine associations between carriage state 
and morbidity and mortality. However, in large-scale epide-
miologic studies, simplicity will often prevail because of logis-
tic reasons and resources. It is therefore reassuring that, in the 
validation cohort, the simple qualitative culture results per-
formed as well as the more complicated culture rule. 
Thus, 2 nasal swab culture of samples obtained at a I-week 
interval can indeed provide sufficient information to adequately 
predict the S. aureus nasal carriage state. The use of only 1 
nasal swab culture to predict the carriage state, as is often done, 
cannot be recommended on the basis of our data because it 
will lead to misclassification of the carriage state. On the other 
hand, the addition of a third or fourth quantitative nasal swab 
culture only minimally improved test performance. Of impor-
tance, no persons whose first 2 culture results were positive 
were found to be non carriers. The finding of 2 negative screen-
ing culture results in 1 person with subsequent positive culture 
results is difficult to explain but may be attributable to sample 
handling mistakes or laboratory error. These results were in-
cluded in the evaluation, however. One negative screening cul-
ture result virtually excludes persistent carriage. Predicting the 
noncarrier state from 2 nasal swab cultures is more difficult 
because ;;:;7 nasal swab cultures would be needed to distinguish 
intermittent carriers from noncarriers. 
At present, data on determinants of persistent S. aureus nasal 
carriage in elderly patients in the Rotterdam Study are being 
analyzed by means of this culture rule. This is the first study to 
validate the potential of a limited number of nasal swab cultures 
in predicting the S. aureus carrier state. Because the incidence of 
S. aureus infections has increased substantially, and because of 
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the dramatic worldwide increase in antibiotic resistance (meth-
icillin and, recently, even vancomycin resistance) in S. aureus, 
prevention is now more important than ever. Apart from its role 
in the Rotterdam Study, we hope that the presented culture rule 
will prove to be a helpful tool in identifying determinants of S. 
aureus nasal carriage and infections, as well as in identifying high-
risk patient populations and the implementation of new methods 
in the prevention of S. au reus infections. 
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Community-Associated Methicillin-Resistant Staphylococcus 
aureus: The Way to the Wound Is through the Nose 
Clarence BuddV Creech 11,1 Thomas R. Talbot/.3 and William Schaffne~ 
'Division of Pediatric Infectious Diseases, Department of Pediatrics, 'Division of Infectious Diseases, Department of Medicine, and 'Department of Preventive 
Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 
(See the article bV Kuehnert et al.. on pages 172-9.) 
The US microbiologist Theobald Smith is 
credited with the view that "disease is an 
accident occurring in the development of 
the parasitic state" [1, p. 2], This per-
spective can certainly be applied to the 
staphylococcus, an organism replete with 
strategies to establish harmony with its 
host in the form of nasal colonization. In 
this issue of the Journal of Infectious Dis-
eases, Kuehnert et al, [2] provide the first 
large population-based assessment of na-
sal colonization with Staphylococcus aureus 
and, more importantly, with methicillin-
resistant S, aureus (MRSA). As the fre-
quency of community-associated MRSA 
infections continues to increase, investi-
gation into the dynamics of nasal colo-
nization will be valuable in the creation of 
plausible strategies for controlling this 
emerging pathogen, 
It is well established that, at any given 
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time, -30% of all persons are colonized 
with S. aureus, with the anterior nares 
serving as its critical niche [3], Although 
colonization typically precedes infection, 
relatively few colonized individuals de-
velop staphylococcal infections. There 
are, undoubtedly, a variety of host-or-
ganism interactions that playa role in this 
symbiosis; yet, much of what is known 
has been derived from the study of per-
sons with clinical disease, not those in 
the asymptomatic carrier state. 
Using the sample provided by the 2001-
2002 National Health and Nutrition Ex-
amination Survey (NHANES), Kuehnert 
et aJ. assessed S, aureus nasal carriage in 
all participants ;;.1 year old. Nearly 10,000 
participants were enrolled; 2964 (32.4%) 
were colonized with S. aureus, of whom 
only 75 (0.8% of the total) harbored 
MRSA, These findings translate into 
weighted estimates of 89.4 and 2.3 mil-
lion persons being colonized with S. au-
reus and MRSA, respectively, in the 
United States in 2001-2002. Thus, al-
though the proportion of the US pop-
ulation colonized with MRSA was low, 
the absolute number of MRSA-colonized 
persons was already quite large in 2001-
2002. Risk factors for MRSA colonization 
were age ;;;.60 years and being female; 
however, when the analysis was limited 
to community-associated MRSA (as de-
termined by the presence of the staph-
ylococcal cassette chromosome mec IV 
gene), younger children and non-His-
panic black persons were found to be at 
increased risk. 
Kuehnert et al, also sought to under-
stand the microbiological and molecular 
epidemiologic character of the coloniza-
tion isolates from their study population. 
Their antibiotic-susceptibility data suggest 
what other investigators have reported for 
community-associated MRSA-namely, fa-
vorable resistance profiles for such agents 
as trimethoprimlsulfamethoxazole, rif-
ampin, gentamicin, and vancomycin, as 
well as the variable presence of an in-
ducible resistance phenotype for clinda-
mycin. This information becomes in-
creasingly germane to practitioners whose 
empirical choices of therapy for com-
munity-associated staphylococcal infec-
tions have moved away from the {:Hac-
tams. In addition, results of the analysis 
of the toxin repertoire were substantially 
different from what would be expected 
from simple extrapolation of data from 
invasive isolates; for example, although it 
appears that the genes for the cytolyt-
ic toxin Panton-Valentine leukocidin are 
found in the majority of clinical isolates 
of community-associated MRSA [4], its 
presence was less common (8.0% of MRS A) 
among the carriage strains in Kuehnert 
et aJ.'s population-based study, a finding 
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corroborated by subsequent local inves-
tigations [5, 6J. 
The carriage estimates produced by 
Kuehnert et al. must be interpreted in their 
historical context. Their results from in-
vestigation of a large, national population 
are quite consistent with the results oflocal 
investigations completed at the same time. 
In 2001, colonization studies from geo-
graphically diverse institutions found a 
similar frequency of MRSA nasal car-
riage. Studies from Chicago, IL; Nash-
ville, TN; Charlottesville, VA; and San 
Francisco, CA, suggested that a small but 
noteworthy reservoir of MRSA carriage 
existed in these areas, at prevalence rates 
ranging from 0.6% to 2.8% [7-12J. Be-
cause these data very closely match Kueh-
nert et al.'s results from the NHANES 
population, it would seem that they were 
not simply local phenomena; rather, it 
would seem that geographically specific 
colonization data are important harbin-
gers that signal trends in staphylococcal 
epidemiologic patterns. 
All of these studies were conducted be-
fore the widespread emergence of com-
munity-associated MRSA infection, which, 
in some areas, now accounts for up to 
75% of all community-associated staph-
ylococcal infections in children [13 J. In 
addition, the increased frequency of com-
munity-associated MRSA infection has 
been associated with reports of increased 
morbidity and mortality-specifically, a 
longer duration of fever, prolonged hos-
pitalization, a higher incidence of pul-
monary complications along with bone 
and joint infections, and the reemer-
gence of a severe staphylococcal sepsis 
syndrome [14-16J. In 2004, to assess 
whether a change in the MRSA nasal col-
onization rate accompanied the increase 
in disease frequency, our group studied 
500 healthy children [5J. Using the same 
methods that we had used in 2001, we 
found that 46 (9.2%) of the 500 children 
were colonized with MRSA. This per-
centage represented a >lO-fold increase 
in the MRSA nasal colonization rate in 
the same community from 2001 to 2004 
[5, lOJ. Similarly, Pan et al. studied >300 
homeless youths in the San Francisco 
area in 2004 and found that 6.2% of the 
enrolled subjects were colonized in the 
nares with MRSA [17J. Last, Alfaro et al. 
recently reported that -22% of children 
admitted to Driscoll Children's Hospital 
in Corpus Christi, TX, in 2005 were col-
onized with MRSA [lSJ. The times-
along with MRSA colonization rates-
are, indeed, changing. 
The question remains: To what extent 
does colonization with S. aureus (and with 
MRSA, in particular) confer increased risk 
to the host? If we are to understand the 
implications of Theobald Smith's asser-
tion that disease is accidental, then we 
must understand just how "accident 
prone" the circulating strains of com-
munity-associated MRSA are. A recent 
study of US soldiers by Ellis et al. helps 
to clarify this issue [6J. Of 812 soldiers 
who were enrolled at the start of ba-
sic training, 24 (3%) were colonized 
with community-associated MRSA. Nine 
(3S%) of the 24 soldiers developed soft-
tissue infections during the 2-month 
study period. This rate was significantly 
higher than that (i.e., 28%) observed 
among the 229 participants colonized 
with methicillin-susceptible S. aureus, of 
whom only S (3%) developed clinical 
staphylococcal infections (relative risk, lO.7 
[95% confidence interval, 4.6-25.2]). In a 
similar vein, Pan et al. [17] have sug-
gested that, among community-asso-
ciated MRSA, there are distinct pop-
ulations that are successful colonizers, 
successful pathogens, or both. What fac-
tors govern these distinctions remain 
largely unknown. 
These studies highlight the changing 
epidemiologic profile of MRSA in the 
community and suggest that commu-
nity-associated MRSA may have acquired 
2 properties that are of particular con-
cern: first, it has the ability to colonize 
effectively, even in the absence of anti-
microbial pressure-and potentially via 
mechanisms that allow them to outcom-
pete other staphylococcal strains in the 
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nares; second, it possesses a variety of 
virulence factors necessary to cause an 
array of disease, from simple, uncom-
plicated furunculosis to deep abscesses, 
osteomyelitis, necrotizing pneumonia, and 
sepsis [13-16, 19J. This combination of 
factors demonstrates the profound adapt-
ability of the staphylococcus. 
In light of the increasing frequency of 
community-associated MRSA infection, 
new antimicrobials are needed, particu-
larly given the emergence of glycopeptide-
resistant strains. Yet, new antimicrobials 
will remain fingers in the proverbial dike 
until a more-definitive solution can be 
found. Can staphylococcal colonization be 
prevented? If not, can we develop a strat-
egy to prevent invasion and establishment 
of infection? For the better part of a cen-
tury, scientists have considered the com-
position and application of a staphylo-
coccal vaccine, refined over time via an 
improved understanding of the virulence 
factors specific to staphylococci. Now, 
stimulated by the successes that Hae-
mophilus injluenzae type b (Hib) vaccine 
and pneumococcus conjugate vaccine 
have had in both eliminating the carriage 
state (a particular success for the con-
jugate Hib vaccine) and preventing in-
fection, several major pharmaceutical 
manufacturers have turned their atten-
tion to the creation of a staphylococcal 
vaccine. The appropriate components of 
such a vaccine (such as capsular poly-
saccharides, surface-exposed proteins, and/ 
or extracellular toxins) remain an area of 
active research, but early successes con-
firm that the vaccine-based approach is 
a viable undertaking. For example, the 
persistent reduction of S. aureus bacter-
emia 40 weeks after vaccination of pa-
tients with end-stage renal disease who 
are undergoing dialysis highlights the 
potential of a vaccine-based approach to 
the prevention of staphylococcal disease 
[20J. Whether such a vaccine should be 
used universally-or whether it should 
be targeted to those with risk factors for 
disease or administered in persons un-
dergoing certain medical procedures that 
confer a high risk of staphylococcal wound 
infections-remains to be determined. 
Studies of the ecological patterns of S. 
aureus colonization in the us population, 
such as the study conducted by Kuehnert 
et aI., will continue to be important as we 
attempt to understand the evolution of 
antimicrobial resistance, the risk factors 
that predict the carriage state, and the mo-
lecular characteristics of circulating strains. 
Ultimately, it is hoped that such studies 
will provide a measure of the impact that 
staphylococcal vaccination has on colo-
nization in the population. 
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Predicting the Staphylococcus aureus Nasal Carrier 
State: Derivation and Validation of a ((Culture Rule" 
Jan L. Nouwen,'.2.3 Alewijn Ott.1" Marjolein F. O. Kluytmans-Yandenbergh.1 Heh~ne A. M. Soelens.1 Albert Hofman.3 
Alex van Selkum.l and Henri A. Yerbrugh1 
Departments of 'Medical Microbiology and Infectious Diseases and 'Medicine, Infectious Diseases Section, and 'Department of Epidemiology 
and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands 
Background. To study determinants and risks of Staphylococcus aureus nasal carriage, adequate differentiation 
between the different S. aureus carrier states is obligatory. We set out to develop a "culture rule" capable of 
differentiating between persistent and intermittent or noncarriers that uses a minimum of nasal swab cultures. 
Methods. In 51 healthy volunteers (derivation cohort), 12 quantitative nasal cultures were performed to 
establish S. aureus nasal carriage states. Persons with 11 or 12 cultures positive for S. aureus were classified as 
persistent carriers, and those with negative results of all cultures were classified as noncarriers. All other persons 
were classified as intermittent carriers. By means of logistic regression and receiver operating characteristic (ROC) 
curves, a culture rule was derived. This culture rule was subsequently validated in 106 participants of an ongoing 
study in 3882 elderly persons, again with the use of 12 quantitative nasal cultures. 
Results. In both cohorts, the positive predictive value of 2 consecutive positive culture results for persistent 
carriage was 79%. The model best differentiating between persistent and intermittent or noncarriers used the 
number of positive culture results combined with the amount of S. aureus in these cultures. By using the outcome 
of 2 cultures, the areas under the ROC curves were 0.981 (95% confidence interval [CI], 0.949-1.0) for the 
derivation cohort and 0.936 (95% CI, 0.881-0.990) for the validation cohort. 
Conclusions. Combining qualitative and quantitative results of 2 nasal swab cultures accurately predicted the 
persistent S. aureus carriage state with a reliability of 93.6%. Thus, this culture rule can be used in studies of 
determinants and risks of S. aureus nasal carriage. 
Staphylococcus aureus nasal carriage is a major risk fac-
tor for both community-acquired and nosocomial in-
fections [1-7], and the anterior nares are the primary 
reservoir of S. aureus in humans [8-10 J. Three S. aureus 
nasal carriage patterns can be discerned: persistent car-
riage, intermittent carriage, and noncarriage [11-22]. 
However, no consensus has been reached on how to 
exactly identify these different states, but most studies 
use findings from 10-12 weekly nasal swab cultures 
[23J. 
The number of colony-forming units (CFUs) of S. 
aureus isolated from the anterior nares are higher in 
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persistent than in intermittent carriers [24, 25J, re-
sulting in more extensive dispersal of staphylococci in 
the environment [25J and in an increased risk of S. 
aureus infection [26-28J. Bacterial variability (i.e., the 
number of S. aureus genotypes isolated in repeated cul-
tures from one individual) is lower for persistent than 
for intermittent carriers [15, 22, 29 J, indicating that the 
underlying mechanisms determining persistent and in-
termittent carriage differs. Adequate differentiation be-
tween.persistent and intermittent carriage is thus rel-
evant for epidemiological studies. 
At present, a large study of S, aureus nasal carriage in 
a population aged ;;:;.60 years is being conducted at Eras-
mus Medical Center (Rotterdam, The Netherlands). The 
main objectives are to study determinants and risks of 
S, aureus nasal carriage. This is part of the Rotterdam 
Study, a population-based prospective study of chronic 
diseases in the elderly population. The Rotterdam Study 
started in 1990 with 7983 persons and has just finished 
its third phase, in which >4000 persons have been in-
cluded. In this large survey, an efficient and reliable way 
to assess S. aureus nasal carriage was obligatory. It would be 
impossible to perform 10-12 weekly nasal swab cultures in all 
participants. Thus, we developed a "culture rule" to discrim-
inate reliably between persistent carriage and noncarriage or 
intermittent carriage, with a minimum of nasal swab cultures. 
Our main questions were as follows: (1) how many quan-
titative nasal swab cultures are needed to accurately predict 
persistent carriage in a cohort of healthy adult volunteers, and 
(2) does the derived culture rule correctly predict persistent 
carriage in the elderly cohort of the ongoing Rotterdam Study? 
PATIENTS AND METHODS 
Patient Cohorts and Microbiological Investigations 
Derivation cohort. In 1988, a cohort of healthy volunteers 
(staff members of the departments of medical microbiology 
and infectious diseases and virology at Erasmus Medical Center) 
was formed to investigate bacterial and human factors associ-
ated with S. aureus nasal carriage [231. During the period of 
September 1995 through March 1996, a total of 51 volunteers 
agreed to participate in this study. Nasal swab cultures were 
performed weekly for 12 weeks. All nasal swab samples were 
obtained for culture by one study physician (M.F.Q.K.-V.), ac-
cording to the protocol below. 
Validation cohort. On the basis of the results of the der-
ivation cohort, 2 quantitative nasal swab cultures of samples 
obtained at I-week intervals were performed in 3882 partici-
pants of the Rotterdam Study. While this study was ongoing, 
106 participants entering the study during the period of Oc-
tober 1997 through April 1998 agreed to be included in the 
validation cohort. Persons with 2 positive or 2 negative nasal 
swab culture results were oversampled to estimate the predictive 
value of these cultures for persistent carriage and noncarriage, 
or for intermittent carriage. One trained research assistant vis-
ited the participants at home and performed 10 additional nasal 
swab cultures at I-week intervals, according to protocol. 
The study was approved by the Medical Ethics Review Com-
mittee of the Erasmus Medical Center, University Medical Center, 
Rotterdam. Informed consent was obtained from all participants. 
Definitions 
S. aureus nasal carriage state was assessed by means of the results 
of nasal swab cultures 3-12, as follows: persistent carrier, 9 or 
10 of 10 cultures were positive for S. aureus; noncarrier, no 
positive culture results; and intermittent carrier, all intermediate 
numbers of positive culture results. 
Microbiological Procedures 
Nasal swab cultures were performed according to a standard 
operating procedure, as described elsewhere [231. Nasal swabs 
specimens were obtained with sterile cotton-wool swabs (Tran-
swab; Medical Wire and Equipment). Both the left and right an-
terior nares were swabbed by rubbing the swab 4 times around 
the inside of each nostril while applying an even pressure and 
rotating the swab without interruption. The swabs were im-
mediately placed in Stuart transport medium and kept at 4°C 
until inoculation (within 24 h). 
Swabs were then cultured quantitatively on phenol-red man-
nitol salt agar (PHMA) and in phenol red mannitol salt broth 
(PHMB). The flasks with transport media containing the nasal 
swab were vortexed for IS s. The swab was then pressed firmly 
against the wall of the flask with a sterile pincette and cultured 
in 8 mL of PHMB. Subsequently, 500 J.'L of the remaining 
bacterial suspension was inoculated evenly onto a large PHMA 
culture plate (diameter, 14 em). Another PHMA culture plate 
(diameter, 8.5 em) was divided into 3 sectors, which were in-
oculated with 10 J.'L of the original bacterial suspension, 10 J.'L 
of a I: 10 diluted bacterial suspension, and I J.'L of the I: 10 
diluted bacterial suspension, respectively. The PHMB was in-
cubated at 37°C for 7 days; the PHMA culture plates were 
incubated at 37°C for 48 h and at room temperature for 5 days. 
Both were interpreted after 7 days of incubation. If, after 7 
days, no S. aureus had grown on the PHMA but the PHMB 
demonstrated a yellow color, a PHMA culture plate (diameter, 
8.5 em) was inoculated with 10 J.'L of PHMB and incubated 
as before. Culture results were recorded as 0 (no S. aureus), I 
(S. aureus only on the PHMB culture plate), 2 (2-9 CFU), 3 
(10-99 CFU), 4 (100-999 CFU), or 5 (;::.1000 CFU). 
Identification of S. aureus was based on colony morphology 
on the PHMA culture. Suspected colonies were cultured over-
night on Columbia blood agar plates (Becton-Dickinson). A 
catalase test lind a latex agglutination test (Staphaurex Plus; 
Murex) were then performed. All S. aureus isolates were stored 
at -70°C in glycerol-containing liquid media. 
Statistical Analysis 
Percentages and continuous data were compared using Fisher's 
exact test and the Mann-Whitney test, respectively. Logistic 
regression was performed, and receiver operating characteristic 
(ROC) curves were constructed for different tests and com-
binations of tests (number of positive cultures, IOI0g-trans-
formed CFUs ['Olog {CFU + Il J and the geometric mean CFUs 
of;::.2 cultures [e.g., {3 1/21) to study their ability to discriminate 
between persistent carriage and noncarriage or intermittent car-
riage [301. Culture results of the derivation cohort were added 
as independent covariates to a logistic regression model with 
our "gold standard" diagnosis of persistent carriage or not (de-
rived from 10 consecutive cultures) as binary outcome variate. 
The right side of the regression equation was [{:lO+{:ll X num-
ber of positive cultures + {:l2 X geometric mean of CFUs I. Fitting 
the model gave us {30 to {32. Then we calculated the odds of 
persistent carriage for all persons of the validation cohort by 
adding their respective culture outcomes in the formula: odds = 
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[e(/30+/31 x number of positive cultures +/32 X geometric mean 
of CFUs)]. Subsequently, the probability of persistent carriage 
was obtained by [odds/(l + odds)]. We choose the midpoint 
between 0 and 1 as the cut point. Areas under the ROC curves 
(AUC) and the corresponding SE were estimated by a non-
parametric method (2-sample Wilcoxon test) [31,32]. Differ-
ences between AUCs of the different test combinations were 
compared by the method of Hanley and McNeil [33]. 
RESULTS 
Fifty-one persons were included in the derivation cohort (19 
men [37%] and 32 women [63%]), with a mean age 29 years 
(range, 20-52 years). Twenty (39%) participants were classified 
as non carriers, 16 (31 %) were classified as intermittent carriers, 
and 15 (29%) were classified as persistent carriers (derivation 
cohort; table 1). Positive predictive values for persistent car-
riage, derived from regression models that included the results 
of cultures 1 and 2, ranged from 0.79 in a model containing 
the qualitative outcome only, to 0.88 in a model including both 
qualitative and quantitative results (figure lA). The use of the 
results of only 1 culture (either 1 or 2) produced a positive 
predictive value of only 0.69. 
The validation cohort consisted of a subset of 106 partici-
pants of the Rotterdam Study cohort (44 men [42%] and 62 
women [58%]), with a mean age 73 years (range, 62-89 years). 
For the present study, persons with 1 positive and 1 negative 
culture result were less informative. Two positive culture results 
could either indicate persistent or intermittent carriage. Pos-
sibly, the number of CFUs of S. aureus cultured could differ-
entiate between persistent and intermittent carriage. Persons 
with 2 negative culture results could help to assess the predictive 
value for true non carriage. Therefore, after initial random in-
clusion of participants, we decided to oversample persons with 
2 positive or 2 negative screening culture results. Fifty-seven 
participants (54%) were classified as noncarriers, 17 (16%) were 
classified as intermittent carriers, and 32 (30%) were classified 
as persistent carriers (validation cohort; table 1). In 1 partic-
ipant, both screening culture results were negative, and the 
results of cultures 3-12 were all positive. The most probable 
explanation for this would be either sample handling mistakes 
or a laboratory error. Because exclusion of this person did not 
significantly alter the data, and because mistakes happen in real 
life, it was decided not to exclude this person's data from analy-
sis. The positive predictive value derived from regression mod-
els that included the results of cultures 1 and 2 was 0.79 in a 
model containing the qualitative outcome only, as well as in a 
model including also the quantitative results (figure lB). The 
use of the results of only 1 culture (either 1 or 2) produced a 
positive predictive value of 0.74. 
The numbers of CFUs of S. au reus were significantly higher 
in the validation than in the derivation cohort (figure 2). The 
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Table 1. Classification of the Staphylococcus aureus nasal car-
rier state based on results of the first 2 cultures. compared with 
results of cultures 3-12. for derivation and validation cohorts. 
Results of cultures 1 and 2 
Both 1 Positive Both 
Cohort negative and 1 negative positive Total 
Derivation cohort 
Noncarrier 19 1 20 
Intermittent carrier 7 5 4 16 
Persistent carrier 15 15 
Total 26 6 19 51 
Validation cohort 
Noncarrier 53 4 57 
Intermittent carrier 7 2 8 17 
Persistent carrier 31 32 
Total 61 6 39 106 
NOTE. Data are no. of subjects. S. aureus carrier status is based on results 
of cultures 3-12. For the validation cohort. persons for whom the results of 
both culture 1 and 2 were positive or negative were oversampled (see Patients 
and Methods). Therefore. the distribution of the different carrier states does 
not represent the population prevalence. 
median geometric mean in intermittent and persistent carriers 
were 1.4 (range, 0.3-3.3) and 3.6 (range, 1.9-3.9) in the validation 
versus 1.0 (range, 0.3-2.0) and 1.8 (range, 0.9-3.2) in the der-
ivation cohort (P = .001 and P< .001), respectively. Persistent 
carriers had significantly higher numbers of CFUs of S. aureus 
in their positive nasal swab cultures than did intermittent carriers 
(figure 2): 1.8 CFUs (range, 0.9-3.2 CFUs) versus 0.98 CFUs 
(range, 0.30-2.0 CFUs; P = .001) in the derivation cohort and 
3.6 CFUs (range, 1.9-3.9 CFUs) versus 1.4 CFUs (range, 0.30-
3.3 CFUs; P< .001) in the validation cohort (figure 2). 
In the derivation cohort, logistic regression showed that the 
model best differentiating between persistent carriage and non-
carriage or intermittent carriage used qualitative culture results 
in combination with quantitative data. The model that used 
the results of 2 cultures performed significantly better than a 
model that used the results of only 1 culture. Adding the results 
of a third or fourth culture did not significantly improve the 
model. Results from the ROC analysis showed that all tests 
used had good performance (all AUes were >0.9), with the 
combined model being slightly-but not significantly-better 
than the qualitative result of 2 nasal swab cultures (figure lA). 
In the validation cohort, 2 qualitative culture results (positive 
or negative) discriminated similarly between persistent carriage 
and noncarriage or intermittent carriage as the combined qual-
itative and quantitative results. All logistic regression models 
were significantly improved by adding data on a third culture. 
However, in the ROC analysis, the differences between the 
models were small. Adding data on a third (but not a fourth) 
culture only significantly improved the model when both qual-
itative and quantitative culture results were used (figure 1B). 
The AUes that used the combination of qualitative culture 
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Figure 1. A, Receiver operating characteristic (ROC) curve illustrating the predictive value of different tests for the persistent Staphylococcus 
aureus nasal carrier state in the derivation cohort. *Area under the ROC (AUC) of 2 versus 1 cultures (P< .05). B, ROC curve illustrating the predictive 
value of different tests for the persistent S. aureus nasal carrier state in the validation cohort. * AUC of 3 versus 2 cultures in the combined test 
(P< .05). PVt. positive predictive value; PV-. negative predictive value. 
results and the geometric mean CFUs of 2 cultures were 0.981 
(95% CI, 0.949-1) for the derivation cohort and 0.936 (95% 
CI, 0.881-0.990) for the validation cohort, respectively (figure 
1). The logistic regression equation that uses the combination 
of qualitative culture results and the geometric mean of CFUs 
from 2 cultures could be written as follows: probability of per-
sistent S. aureus nasal carriage = e({30 + {31 X number of posi-
tive cultures + {32 X geometric mean of CFUs)11 + e({30 + (31 X 
number of positive cultures + {32 X geometric mean of CFUs). 
In the derivation cohort, the respective values of {30, {31, and 
{32 were -20.171, 9.341, and 1.661. In the validation cohort 
these values were -4.572, 2.563, and 0.274, respectively. 
When a cutoff of 0.50 was used, above which probability 
persons were classified as persistent carriers, it followed from 
the logistic regression equation from the derivation cohort that 
a person was a persistent carrier only if both cultures were 
positive with a geometric mean of ;;;'0.9 (-8 CFUs per culture). 
This culture rule, when applied to the validation cohort, had 
a positive predictive value of 0.78, a negative predictive value 
of 0.96, and an AUC of the corresponding ROC curve of 0.936 
(95% CI, 0.881-0.990). 
DISCUSSION 
We examined the diagnostic value of2 weekly quantitative nasal 
swab cultures to predict the S. aureus nasal carriage state and 
developed a culture rule to enable adequate differentiation be-
tween persistent carriage and intermittent carriage among those 
individuals with 2 positive screening culture results. 
We used logistic regression and ROC analysis to derive a cul-
ture rule under ideal laboratory circumstances in a cohort of 
healthy adult volunteers. Strictly speaking, the derivation cohort 
actually was more of an exploratory data set to help select the 
variables in the model, but not the actual predictions. The culture 
rule was subsequently validated under real-life conditions in a 
subset of elderly participants of the Rotterdam Study. 
In the derivation cohort, the best test combined qualitative 
culture results (number of positive culture results) with quan-
titative data (geometric mean number of CFUs of S. aureus in 
nasal swab cultures). In the validation cohort, however, the 
simple qualitative culture result when data on 2 cultures were 
used performed as well as the more complicated culture rule. 
The culture rule performed slightly less well in the validation 
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of Staphylococcus aureus in positive cultures in intermittent versus persis-
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intermittent carriers, derivation versus validation cohort (P == ,001); §, per-
sistent carriers, derivation versus validation cohort (P < ,001 J, 
cohort (AVC, 0.981 in the derivation and 0.936 in the vali-
dation cohort, respectively). In the ideal laboratory situation, 
one trained physician performed all nasal swab cultures in a 
cohort of healthy individuals. In the real-life situation of large-
scale epidemiologic surveys, misclassification of the carrier state 
could have occurred for a variety of logistic reasons, such as 
differing nasal culturing techniques of study physicians, sample-
handling mistakes, and laboratory errors. In theory, many of 
these "errors" are preventable but can never be totally eradi-
cated. The fact that in the validation cohort the first 2 cultures 
were obtained at the Rotterdam Study research center by var-
ious study physicians, whereas cultures 3-12 in the validation 
cohort were performed by one trained person, certainly affected 
culture results: when cultures 3 and 4 of the validation cohort 
were used, instead of cultures 1 and 2, the AVC was increased 
from 0.936 to 0.996. 
Misclassification of the carrier state could also have occurred 
because of factors associated with individual participants of the 
Rotterdam Study. Culture results will potentially have been in-
fluenced by the use of medication (recent courses of antibiotic 
therapy), institutionalization (recent hospital admissions), and 
underlying diseases, as well as other unknown determinants. 
We confirm earlier data that showed that the number ofCFUs 
of S. aureus in the anterior nares was higher in persistent carriers 
810 • eID 2004:39 (15 September) • Nouwen et al. 
than in intermittent carriers [24, 25). We also found a striking 
difference in the amount of S, aureus in the nose of persistent 
carriers between young, healthy volunteers and healthy, elderly 
participants. No previous data are available regarding age and 
the number of CFUs of S. au reus in the noses of persistent 
carriers. From the Rotterdam Study (3851 persons), the high 
numbers of CFUs (median geometric mean, 2.8) in elderly per-
sistent carriers are confirmed (data not shown), but the under-
lying mechanisms of this finding remain to be elucidated. The 
differences in the number of CFVs in persistent carriers in both 
cohorts will have affected the performance of the derived culture 
rule in the validation cohort. When applying this culture rule to 
other patient populations, it will need to be validated in the 
specific population first, when possible. 
Combining qualitative results with quantitative data is, in 
our opinion, conceptually the best choice. Incorporating quan-
titative data makes it possible to refine associations between 
potential determinants and S. aureus nasal carriage because not 
only carriers are compared with noncarriers, but carriers with 
low CFUs can also be compared with carriers with high CFUs 
in their anterior nares. Incorporating quantitative data will also 
make it possible to refine associations between carriage state 
and morbidity and mortality. However, in large-scale epide-
miologic studies, simplicity will often prevail because of logis-
tic reasons and resources. It is therefore reassuring that, in the 
validation cohort, the simple qualitative culture results per-
formed as well as the more complicated culture rule. 
Thus, 2 nasal swab culture of samples obtained at a I-week 
interval can indeed provide sufficient information to adequately 
predict the S. aureus nasal carriage state. The use of only 1 
nasal swab culture to predict the carriage state, as is often done, 
cannot be recommended on the basis of our data because it 
will lead to misclassification of the carriage state. On the other 
hand, the addition of a third or fourth quantitative nasal swab 
culture only minimally improved test performance. Of impor-
tance, no persons whose first 2 culture results were positive 
were found to be non carriers. The finding of 2 negative screen-
ing culture results in 1 person with subsequent positive culture 
results is difficult to explain but may be attributable to sample 
handling mistakes or laboratory error. These results were in-
cluded in the evaluation, however. One negative screening cul-
ture result virtually excludes persistent carriage. Predicting the 
non carrier state from 2 nasal swab cultures is more difficult 
because ~7 nasal swab cultures would be needed to distinguish 
intermittent carriers from non carriers, 
At present, data on determinants of persistent S. aureus nasal 
carriage in elderly patients in the Rotterdam Study are being 
analyzed by means of this culture rule. This is the first study to 
validate the potential of a limited number of nasal swab cultures 
in predicting the S. aureus carrier state. Because the incidence of 
S. aureus infections has increased substantially, and because of 
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the dramatic worldwide increase in antibiotic resistance (meth-
icillin and, recently, even vancomycin resistance) in S. aureus, 
prevention is now more important than ever. Apart from its role 
in the Rotterdam Study, we hope that the presented culture rule 
will prove to be a helpful tool in identifying determinants of S. 
aureus nasal carriage and infections, as well as in identifying high-
risk patient populations and the implementation of new methods 
in the prevention of S. aureus infections. 
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IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE 
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK 
JUDY NIELD, ) 
) 
Plaintiffs, ) 
) 
vs. ) 
) 
POCATELLO HEALTH SERVICES, INC. ) 
a Nevada Corporation d/b/a POCATELLO) 
CARE AND REHABILITATION ) 
CENTER and JOHN DOES I-X, acting as ) 
agents and employees of POCATELLO ) 
HEALTH SERVICES, INC. d/b/a ) 
POCATELLO CARE AND ) 
REHABILITATION CENTER, ) 
) 
Defendants. ) 
) 
Case No. CV-09-3869-PI 
MEMORANDUM IN SUPPORT OF 
PLAINTIFF'S MOTION TO STRIKE 
THE AFFIDAVIT OF DR. COFFMAN 
COMES NOW Plaintiff, by and through the undersigned counsel, and submits this 
Memorandum in Support of Plaintiffs Motion to Strike the Affidavit of Dr. Coffinan. 
I. INTRODUCTION 
In support of Defendant's motion for summary judgment, Defendant offered the Affidavit 
of Dr. Coffinan. As will be asserted in greater detail in the remainder ofthis Memorandum, ~~ 12, 
14,22,23,24,25,26, and 27 of Dr. Coffinan's affidavit must be stricken or, in the alternative, not 
considered by the Court in determining Defendant's motion for summary judgment. 
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II. STANDARD OF REVIEW 
IRCP 56(e) provides, in pertinent part, as follows: 
Supporting and opposing affidavits shall be made on personal knowledge, shall set 
forth such facts as would be admissible in evidence, and shall show affirmatively 
that the affiant is competent to testifY to the matters stated therein. 
The question of admissibility of affidavits under Rule 56( e) is a threshold question to be 
analyzed before reviewing motions for summary judgment, and a court must look at the affidavit to 
determine ifit alleges facts, which if true, would render the testimony admissible. Foster v. Traul, 
145 Idaho 24, 28, 175 P.3d 186, 190 (2007). 
Expert testimony offered in a medical malpractice case, "like any other case, is governed by 
the rules of evidence regarding the opinion testimony oflay witnesses and experts under Idaho Rules 
of Evidence 701 and 702." IRE 702 provides: "If scientific, technical, or other specialized 
knowledge will assist the trier of fact to understand the evidence or to determine a fact in issue, a 
witness qualified as an expert by knowledge, skill, experience, training, or education, may testifY 
thereto in the form of an opinion or otherwise. 
However, expert testimony that is based on speculation, is not admissible under Rule 702. 
Speculation, as it relates to expert testimony is defined as "the-art of theorizing about a matter as to 
which evidence is not sufficient for certain knowledge." Karlson v. Harris, 140 Idaho 561, 564, 97 
P.3d 428,432 (2004). 
An expert opinion that is speculative or unsubstantiated by facts in the record is 
inadmissible because it would not assist the trier of fact to understand the 
evidence or determine a fact that is at issue. Expert opinion that merely 
suggests possibilities would only invite conjecture and may be properly excluded." 
Id. [Emphasis added][Internal citations omitted]. See also Jones v. Crawforth, 147 Idaho 11,205 
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P .3d 660 (2009)( expert opinions are only admissible if they assist the trier of fact in understanding 
the evidence or determining an issue of fact); Weeks v. E. Idaho Health Servs., 143 Idaho 834, 838, 
153 P.3d 1180,1184 (2007)(expertopinion that is speculative, conc1usoryorunsubstantiated by facts 
in the record does not assist the jury and is inadmissible). 
III. AGRGUMENT 
1. Paragraph 12 is conclusory and lacks foundation. 
Paragraph 12 of Dr. Coffinan's affidavit, specifically, the portions stated on page 4, Dr. 
Coffinan does not identifY how he is trained or has experience in how a technician "does not culture 
every micro-organism from a wound or fluid culture" and makes this conclusion that in every case, 
a technician does not perform a complete culture. This assertion is speculation, especially due to the 
fact that Dr. Coffinan does not endeavor to contact the technician or obtain facts to support his 
unsubstantiated conclusion. 
2. Paragraph 14 is inadmissible speculation. 
Dr. Coffinan again asserts supposition in concluding, in the last sentence of Paragraph 14 that 
carries over from page 4, to page 5, in his statement that "it appears" that Dr. Zimmerman's 
reference in his discharge summary of Judy Nield, to a negative MRSA screen refers to the culture 
taken, "and not an actual MRSA screening based on the lack of any MRSA screen report." Dr. 
Coffinan goes on to speculate, "it is fair to assume that a MRS A screen was not performed." Again, 
Dr. Coffinan speculates, and does not endeavor to produce any facts to ascertain whether a screen 
and culture were done. 
Dr. Coffinan goes on to conclude: "If Ms. Nield was not screened for MRSA, it is not 
possible to determine if she was MRSA colonized at the time she was admitted to Pocatello Care and 
MEMORANDUM IN SUPPORT OF PLAINTIFF'S MOTION IN STRIKE THE AFFIDAVIT OF DR. COFFMAN - PAGE 3 
522 
Rehab on August 25, 2007." This is again supposition and conclusory speculation. Dr. Coffman's 
speculation is evident by his use of "If' indicative of his conclusory speculations. 
3. Paragraph 22 is inadmissible speculation. 
Dr. Coffman again speculates as to whether Judy Nield was MRSA or pseudomonas 
colonized at the time of her admission at PCRC. Dr. Coffinan's speculation is again based on his 
unfounded conclusion that the technicians did not properly screen or culture Judy's wounds. 
4. Paragraph 23 is based on speculative "possibility." 
Dr. Coffinan, again, concludes, based on his speculation, whether each of Ms. Nield's 
wounds were cultured, leading to his conclusion, the wound culture "does not rule out the possibility 
Ms. Nield was colonized or infected with MRSA or pseudomonas." Dr. Coffman goes on to 
speculate, "[i]t is possible Ms. Nield had MRS A and/or pseudomonas in one or more, but not all of 
her wounds ... it is possible the swab was taken from one of the wounds in which she did not have 
MRSA and/or pseudomonas." The inadmissible nature of these statements is self-evident by Dr. 
Coffinan's continuous use of "possible" , which he uses several times. Again, this is speculative and 
conclusory, entirely void of any facts. 
5. Paragraph 24 is also based on speculation. 
Dr. Coffinan speculates that "[i]t is possible ... the culture did not grow out and identify 
[MRSA or pseudomonas] resulting in a false negative." This conclusion is based on no facts. 
Again, Dr. Coffinan does not endeavor to ascertain any facts to support this or his final conclusion, 
"It is very possible MRSA and/or pseudomonas were present in the wound that was cultured ... but 
were not dominant microorganisms and were not grown out." This is again inadmissible 
speculation. 
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6. Paragraph 26 is inadmissible speculation. 
Dr. Coffinan concludes, without any factual bases, that Judy was potentially exposed to 
MRSA or pseudomonas when she had visitors. Lacking in this conclusory statement is any evidence 
the visitors were MRSA or pseudomonas colonized or infected. 
7. Paragraph 27 is inadmissible speculation. 
Dr. Coffinan again asserts it is not possible to determine whether Judy's pseudomonas 
infection on November 9, 2007 was related to her right hip infection. Again, Dr. Coffinan's 
admission that "it appears" Judy's infection was resolved by antibiotics and that "it appears" Judy 
had two different strains of pseudomonas are nothing but speculation. 
Finally, Dr. Coffinan's affidavit must be tempered by his admission that "it is not possible to 
determine whether or not Ms. Nield was MRSA or pseudomonas colonized as of the time she was 
admitted to [PCRC]. This conclusion speaks volumes to support that Dr. Coffinan offers nothing 
but speculation, which is not admissible on summary judgment. 
CONCLUSION 
Based on the foregoing, Plaintiff respectfully requests that the Court grant her Motion to 
Strike the Affidavit of Dr. Coffinan. 
DATED this 29th day of November, 2010. 
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CERTIFICATE OF SERVICE 
I HEREBY CERTIFY that on this 29th day of November, 2010, I served a true and correct 
copy of the above and foregoing document to the following person(s) as follows: 
Keely Duke 
Chris D. Comstock 
HALLF ARLEY OBERRECHT &BLANTON 
P.O. Box 1271 
Boise, ID 83701 
[1 
[ ] 
f} 
U.S. Mail/Postage Prepaid 
Hand Delivery 
Overnight Mail 
Facsimile /208-395-8585 
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STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK 
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POCATELLO HEALTH SERVICES, INC., 
a Nevada corporation, d/b/a 
POCATELLO CARE AND 
REHABILITATION CENTER, and 
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Case No. CV-09-3869-PI 
MOTION TO CONTINUE HEARING 
ON SUMMARY JUDGMENT OR IN 
THE ALTERNATIVE ADDITIONAL 
TIME TO SUPPLEMENT THE 
RECORD 
COMES NOW Plaintiff Judy Nield, by and through the undersigned counsel, and pursuant 
to I.R.c.P. 56(f), requests the Court either continue the hearing on Defendants' Motion for Summary 
Judgment, or allow, pursuant to I.R.c.P. 6(b), additional time in which to allow Plaintiffto 
supplement the record so she can procure the affidavit of Suzanne Frederick, one of her experts 
disclosed and identified in this case, additional time to procure and file with the Court the deposition 
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of Derrick Glum, a former administrator at Defendants' facility, and additional time to obtain an 
affidavit from her expert, Dr. Shockley. 
This Motion is supported by the record herein and the Affidavit of Javier L. Gabiola in 
Support of Plaintiffs' Motion to Continue the Hearing on SUITl.!!1ary Judgment filed concurrently 
herewith. 
Oral argument is requested. 
DATED this J2!L day of November, 2010. 
COOPER & LARSEN, CHARTERED 
CERTIFICATE OF SERVICE 
I HEREBY CERTIFY that on this ~7 day of November, 2010, I served a true and correct 
copy of the above and foregoing document to the following person(s) as follows: 
Keely E. Duke 
Chris D. Comstock 
Hall, Farley, Oberrecht & Blanton 
P.O. Box 1271 
Boise, ID 83701 
ff U.S. Mail/Postage Prepaid 
[] Hand Delivery 
[ ] Overnight Mail 
~ Facsimile: 208-395-8585 
/~ 
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IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE 
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK 
JUDY NIELD, 
Plaintiff, 
vs. 
POCATELLO HEALTH SERVICES, INC., 
a Nevada corporation, d/b/a 
POCATELLO CARE AND 
REHABILITATION CENTER, and 
JOHN DOES I-X, acting as 
agents and employees of POCATELLO 
HEALTH SERVICES, INC., d/b/a 
POCATELLO CARE AND 
REHABILITATION CENTER, 
Defendants. 
) Case No. CV-09-3869-PI 
) 
) 
) MEMORANDUM IN SUPPORT OF 
) PLAINTIFF'S MOTION TO 
) CONTINUE HEARING ON SUMMARY 
) JUDGMENT OR IN THE 
) ALTERNATIVE ADDITIONAL TIME 
) TO SUPPLEMENT THE RECORD 
) 
) 
) 
) 
) 
) 
) 
) 
) 
COMES NOW Plaintiff Judy Nield, by and through the undersigned counsel, and submits 
this Memorandum in Support of Plaintiff s Motion to Continue Hearing on Summary Judgment. 
ARGUMENT 
Plaintiff requests a continuance on Defendants' Motion for Summary Judgment, pursuant 
to I.R.C.P. 56(f). Rule 56(f) provides as follows: 
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When affidavits are unavailable in summary judgment proceedings. Should 
it appear from the affidavits of a party opposing the motion that the party 
cannot for reasons stated present by affidavit facts essential to justify the 
party's opposition, the court may refuse the application for judgment or may 
order a continuance to permit affidavits to be obtained or depositions to be 
taken or discovery to be had or may make such other order as is just. 
Plaintiffhas made several attempts to obtain an affidavit from Suzanne Frederick, one of her 
experts in this matter. See Affidavit of Javier L. Gabiola in Support of Plaintiff's Motion to Continue 
Hearing on Summary Judgment ("Gabiola AjJ. ''). For an unknown reason, Ms. Frederick has not 
been available, nor has she been reached by Plaintiff or her attorneys to procure her affidavit to file 
in support of Plaintiffs opposition to Defendants' Motion for Summary Judgment. Id. 
Additionally,on November 1&,2010, Plaintiffs counsel took the deposition of Defendants , 
former administrator, Derrick Glum, in St. George, Utah. On November 24 th, 2010, Plaintiffs 
counsel was notified for the first time that they would not be allowed to obtain an electronic 
transcript by email from the reporting firm that reported Mr. Glum's deposition without first paying 
for and ordering the transcript. See Gabiola Ajf., Exh. 1. On November 26 til, 2010, Plaintiff s 
counsel sent a request to the reporting firm that reported Mr. Glum's deposition requesting that an 
e-transcript of that deposition be provided as soon as possible. See Gabiola AjJ., Exh. 2. 
Additionally, Plaintiff requests a continuance, or in the alternative, additional time to 
supplement the record with the affidavit of her infectious disease expert Dr. Shockley. Plaintiffs 
counsel has been working diligently to procure an affidavit from Dr. Shockley since approximately 
October 29th, 2010. Gabiola AjJ., ~ 4. Due to a miscommunication, Dr. Shockley's assistant did not 
provide him with appropriate documents for his review in order to prepare an affidavit and submit 
his opinions in opposition to Defendants' Motion for Summary Judgment. Id. 
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Pursuant to Rule 56(f), Plaintiff requests the Court to continue the hearing or allow Plaintiff 
to supplement the record with the affidavits of Ms. Frederick and Dr. Shockley and deposition 
testimony transcript of Derrick Glum in order to more fully and completely respond and support 
Plaintiffs opposition to Defendants' Motion for Summary Judgment. 
DATED this ~ day of November, 2010. 
COOPER & LARSEN, CHARTERED 
~~-By' ~ ----. REEriw.LRSEN 
CERTIFICATE OF SERVICE 
I HEREBY CERTIFY that on this pJy day of November, 2010, I served a true and correct 
copy of the above and foregoing document to the following person(s) as follows: 
Keely E. Duke 
Chris D. Comstock 
Hall, Farley, Oberrecht & Blanton 
P.O. Box 1271 
Boise, ID 83701 
[--r--
[ ] 
[ ] 
[--}---
U.S. Mail/Postage Prepaid 
Hand Delivery 
Overnight Mail 
Facsimile: 208-395-8585 
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IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE 
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK 
JUDY NIELD, 
Plaintiff, 
vs. 
POCATELLO HEALTH SERVICES, INC., 
a Nevada corporation, d/b/a 
POCATELLO CARE AND 
REHABILITA TION CENTER, and 
JOHN DOES I-X, acting as 
agents and employees of POCATELLO 
HEALTH SERVICES, INC., d/b/a 
POCATELLO CARE AND 
REHABILITATION CENTER, 
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ST ATE OF IDAHO ) 
: ss. 
County of Bannock ) 
) Case No. CV-09-3869-PI 
) 
) 
) AFFIDAVIT OF JAVIER L. GABIOLA 
) IN SUPPORT OF PLAINTIFF'S 
) MOTION TO CONTINUE HEARI~ 
) ON SUMMARY JUDGMENT OR IN 
) THE ALTERNATIVE ADDITIONAL 
) TIME TO SUPPLEMENT THE 
) RECORD 
) 
) 
) 
) 
) 
) 
) 
) 
JAVIER L. GAB lOLA, being first duly sworn upon oath, deposes and states as follows: 
1. I am one ofthe attorneys representing Plaintiffin this matter and make this Affidavit 
upon my own personal knowledge and information. 
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2. My office and its staff have been attempting and trying to obtain an affidavit from 
Suzanne Frederick, one of Plaintiffs healthcare and nursing experts, disclosed in this matter. Since 
November 8, 2010, I and my staff have been attempting to contact Ms. Frederick to obtain her 
signature on an affidavit, a copy of which is attached hereto as Exhibit 1, to file in opposition to 
Defendants' Motion for Summary Judgment. As of the date of this affidavit, for unknown reasons, 
neither I nor my office staff have been able to contact or get a hold of Ms. Frederick; 
3. Attached hereto as Exhibit 2 is a copy of an email my paralegal received from the 
deposition firm that reported the deposition of Derrick Glum, the former administrator at 
Defendants' facility, which was taken on November 16th, 2010. On November 24h, 2010 I was first 
informed that an e-transcript of Mr. Glum's deposition would not be available until it was ordered 
and paid for. Thereafter, on November 2~, 2010 I sent a request to the reporting firm that reported 
Mr. Glum's deposition, providing a credit card to obtain an e-transcript of Mr. Glum's deposition. 
See Exhibit 3 attached hereto; 
4. On approximately October 28th, 2010 I endeavored to obtain and procure an affidavit 
from Dr. Shockley an infectious disease expert that I wanted to retain on behalf of Plaintiff, and to 
obtain opinions to submit to the Court in opposition to Defendants' Motion for Summary Judgment. 
The documents that Dr. Shockley would need to review to prepare his opinions and affidavit, due 
to a miscommunication between my office and Dr. Shockley's assistant, Dr. Shockley was not given 
documents to review until November 19th, 2010. Based upon this, I was unable to obtain any 
affidavit or opinions from Dr. Shockley to file an opposition to Defendants' Motion for Summary 
Judgment. 
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FURTHER SAITH AFFIANT NAUGHT. 
DATED this..2:1.- day of November, 2010. 
COOPER & LARSEN, CHARTERED 
"~// - / BY:~~L 
. A VIER L. GABIOLA 
SUBSCRIBED AND SWORN TO before me this:J 'i ~day of November, 2010. 
NOTARY PUBLIC FOR IDAHO 
Residing at Pocatello 
My Commission Expires: \ l- J. /., - 13 
CERTIFICATE OF SERVICE 
I HEREBY CERTIFY that on this ~ day of November, 2010, I served a true and correct 
copy of the above and foregoing document to the following person(s) as follows: 
Keely E. Duke 
Chris D. Comstock 
Hall, Farley, Oberrecht & Blanton 
P.O. Box 1271 
Boise, ID 83701 
M [ ] 
~ 
U.S. MaillPostage Prepaid 
Hand Delivery 
Overnight Mail 
Facsimile: 208-395-8585 
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IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE 
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK 
JUDY NIELD, ) 
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) 
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POCATELLO HEALTH SERVICES, INC., ) 
a Nevada corporation, d/b/a ) 
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STATE OF TEXAS ) 
: ss 
County of ) 
Case No. CV -09-3869-PI 
AFFIDA VIT OF SUZANNE 
FREDERICK 
I, SUZANNE FREDERICK, being first duly sworn on oath, depose and state as follows: 
1. That I am over the age of 18 and am competent to testify as to the facts set forth 
below. 
EXHIBIT 
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2. That I am a Registered nurse licensed in the State of Texas. I have been practicing 
as a registered nurse since 1983. Attached hereto is a copy of my CV. 
3. Attached hereto is a copy of my reports dated April 19,2010, and June 10,2010. 
Said reports are incorporated by reference. Attached thereto is a list of all the documents I reviewed 
in preparing my opinions in this matter. 
4. It is my opinion that Pocatello Nursing and Rehabilitation Center nursing staff, as 
well as the Director of Nursing and Administrator, acted negligently and recklessly with regard to 
Mrs. Nield and were indifferent to her health and well-being. The nursing staff knew that their 
failure to meet the standards of care put Mrs. Nield at extreme risk ofharrn and that their failure to 
meet the standards would likely cause injuries to Mrs. Nield but despite this knowledge, Pocatello 
Nursing and Rehabilitation Center and its nursing staff still failed to meet the standard of care which 
caused her to develop MRS A which caused her many subsequent injuries and prolonged suffering. 
5. From my review ofthe records, the records show that Mrs. Nield did not have MRS A 
or Pseudomonas when she entered Pocatello Care and Rehabilitation Center. Mrs. Nield was seen 
at the Wound Care & Hyperbaric Center on November 8, 2008. A physician's note on November 
20, 2007 showed that a wound culture taken November 13, 2007 was positive for MRSA and 
pseudomonas. 
6. It is also my opinion that Pocatello Nursing and Rehabilitation Center failed to follow 
proper infection control procedures to prevent Mrs. Nield's MRSA and pseudomonas infection. As 
stated above, Mrs. Nield did not have MRSA and pseudomonas when she was admitted to Pocatello 
Nursing and Rehabilitation Center on August 25,2007. However, the records clearly show that she 
did develop MRS A and pseudomonas while she was a resident of Pocatello Nursing and 
Rehabilitation Center. 
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7. It is my professional nursing opinion that Mrs. Nield's contraction of MRSA and 
pseudomonas was caused by substandard nursing practice regarding infection control. 
FURTHER SAITH AFFIANT NAUGHT. 
DATED this __ day of November, 2010. 
SUZANNE FREDERICK 
SUBSCRIBED AND SWORN TO before me this __ day of November, 2010. 
(SEAL) NOTARY PUBLIC FOR TEXAS 
Residing at: 
My Commission expires: 
CERTIFICATE OF SERVICE 
I HEREBY CERTIFY that on this day of November, 2010, I served a true and correct 
copy of the above and foregoing document to the following person(s) as follows: 
Keely E. Duke 
Chris D. Comstock 
Hall, Farley, Oberrecht & Blanton 
P.O. Box 1271 
Boise, ID 83701 
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( ] 
[ ] 
[ ] 
[ ] 
U.S. Mail/Postage Prepaid 
Hand Delivery 
Overnight Mail 
Facsimile: 208-395-8585 
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Liz 
From: 
Sent: 
To: 
Sherry Longo [sherry@toddolivas.com] 
Wednesday, November 24, 2010 11 :11 AM 
Liz 
Subject: Deposition of Derrick Glum 
Attachments: DepoOrderForm_O+1.pdf 
Good morning Liz, 
I have received the final transcript of the above mentioned deponent in my office for production. I have 
attached an order form if you would like to fill out the order form and return it to me signed I will be happy 
to forward you an e-transcript right away. 
Best regards, 
Sherry Longo 
Todd Olivas & Associates. Inc. 
41690 Enterprise Circle North 
Suite 200CC 
Temecula, CA 92590 
(951) 296-0114 Main Line: 
(951) 848-0789 Fax 
http://www.toddolivas.com 
sherrv@toddolivas.com 
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IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE 
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK 
JUDY NIELD, 
Plaintiff, 
vs. 
POCATELLO HEALTH SERVICES, INC., 
a Nevada corporation, d/b/a 
POCATELLO CARE AND 
REHABILITATION CENTER, and 
JOHN DOES I-X, acting as 
agents and employees of POCATELLO 
HEALTH SERVICES, INC., d/b/a 
POCATELLO CARE AND 
REHABILITATION CENTER, 
Defendants. 
) Case No. CV-09-3869-PI 
) 
) 
) MEMORANDUM IN OPPOSITION TO 
) DEFENDANTS' MOTION FOR 
) SUMMARY JUDGMENT 
) 
) 
) 
) 
) 
) 
) 
) 
) 
) 
) 
) 
COMES NOW Plaintiff Judy Nield ("Judy"), by and through the undersigned counsel, 
submits this Memorandum in Opposition to Defendants Pocatello Care and Rehabilitation Center's 
(PCRC) Motion for Summary Judgment. 
INTRODUCTION 
Judy is a 68 year old long-time resident of Chubbuck. For over three years, Judy has been 
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bed bound, as she has no leg below her left knee, nor does she have any right hip bone below her hip. 
Judy's situation is entirely due to PCRC's negligence and breach ofthe standard of care. PCRC's 
conduct is best described as reckless and a gross violation of the type of care a health care giving 
facility should have given Judy, which PCRC did not do. PCRC infected andlor colonized Judy with 
Methicillin-Resistant Staphylococcus Aureus ("MRSA") and pseudomonas aeruginosa ("P A"). It 
is not disputed that prior to her admission to PCRC, Judy tested negative for MRSA and P A. 
Apporixmately 3 months after her admission, Judy contracted MRSA and P A, based on tests done 
November 9th, 2007. Judy was infected andlor colonized with MRSA and P A at PCRC as a result 
of its negligent, reckless conduct and its breach of the standard of care in failing to prevent the spread 
of MRS A and P A to Judy. 
PCRC's request for summary judgment is improper, as it based on speculation, nothing more. 
PCRC asserts Judy could have been a carrier of MRS A or P A or that someone other than PCRC may 
have exposed her to MRSA and P A and that there is no evidence Judy contracted MRSA or P A due 
to PCRC"s negligence or breach of the standard of care. The lynchpin of PCRC's speculative 
motion is their expert, Dr. Coffman, who, in his deposition testified, when asked whether he could 
rule out Judy contracted MRSA at PCRC: "I can't rule out where she got it from" and "Well, 1 
don't think we can tell." Dr. Coffman also, as to P A, concluded he does not know where, when or 
how Judy acquired it. 
On the other hand, Judy's treating physician and expert, Dr. Hugh Selznick, opined that to 
a reasonable degree of medical probability, Judy contracted MRSA and P A from PCRC. Dr. 
Selznick concluded "the etiology of [Judy's MRSA infection] was poor infection control measure 
by the staff at Pocatello Care & Rehabilitation Center. . . and it is my opinion Ms. Nield also 
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sustained left lower extremity pseudomonas wound infection while hospitalized at Pocatello Care 
& Rehabilitation Center as evident per 1119/07 culture results." Further, Judy's other experts, 
reviewed this matter, Sid Gerber, an expert in healthcare administration, as well a residential care 
nurse, Suzanne Frederick, both opined that Judy contracted MRSA and PA due to PCRC's breach 
of the standard of care from its failure to prevent the transmission of disease and infection. Mr. 
Gerber characterized PCRC's conduct as "gross violations", "reckless" and "unjustifiable." Further 
Ms. Frederick concluded PCRC's failures to provide adequate care and prevent the spread of MRS A 
and PA to Judy "increas[ ed] the risk of harm, causing injury and unnecessary pain and suffering to 
Mrs. Nield, as well as MRSAlPseudomonas infection." 
PCRC is not entitled to summary judgment, as there is a genuine issue of material fact Judy 
contracted MRSA and P A due to the negligence and breach of the standard of care committed by 
PCRC. 
STATEMENT OF FACTS 
1. On August 21 S\ 2007, Judy was taken to the ER department at PortneufMedical Center 
("PMC"). At the time, Judy was suffering from four open wounds on her left leg, as well as 
cellulitis, and other medical conditions. See Affidavit 0/ Reed W Larsen ("Larsen Aff. 'j, Exhibit 
A {history and physical/rom PMC}. While at PMC, Judy was tested for MRSA and PA, and the test 
results were negative for those infections. Larsen £lff., Exh. B. (Test results August 21-23, 2007). 
2. Judy was admitted to PCRC on August 25 th, 2007, to recuperate enough to have surgery 
as her medical providers planned to operate on her hip so that she could have a hip replacement, as 
well as other prosthetic procedures done. Larsen £lff., Exh. C (PCRC admission records). 
3. Upon admission to PCRC, PCRC' s wound care nurse knew Judy's physician ordered that 
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Judy have daily wound assessments. Larsen Af[., Exh., D (PCRC record-Maxfield). Despite this, 
PCRC's nurses did not do daily skin assessments Larsen Af[., Exh. E (weekly skin assessment and 
ulcer pressure sore sheets). PCRC's medical staff generated cryptic medical records, which did not 
identify or document accurately Judy's four open wounds in her left leg. Larsen Af[., Exh. F 
(Suzanne Frederick 4-19-1 0 Report, pp. 9-13; Affidavit o/Sid Gerber~~ 4-5, Gerber Report, pp. 6-7. 
In fact, Judy's weekly skin assessments, which certainly were not daily, were started upon her 
admission and then ended on September 18th, 2007, such that all documentation on two of Judy's 
wounds stopped at that time, and the largest wound on her left leg stopped on October 22nd, 2007, 
three weeks prior to her being positively cultured for MRS A and P A. Larsen Af[., Exh. F (Frederick 
Report, pp. 9-10; Gerber Report, p. 7, ~ 3. This deficiency was admitted to by one of Judy's 
wound care nurses, Joyce Maxfield, who testified Judy's wound care records could have been more 
accurate. Larsen Af[., Exh. G (Joyce Maxfield Deposition), p. 77, ll. 12-22. 
4. On November 13th , 2007, Judy's left leg wounds were cultured. Larsen Af[., Exh. H 
(November 13, 2007 test reports). The test results showed Judy was positive with infections of 
MRSA and PA. Id. This was a trivial matter, to PCRC's former administrator, Derrick Glum, who 
testified that "it was not warranted" for PCRC to conduct an investigation as to how Judy acquired 
MRSA and P A while she was at PCRC. 1 
5. PCRC did not do any testing or screening for MRSA or P A of Judy prior to her admission 
to its facility, nor during her stay there. 
6. PCRC had in place, while Judy was a resident, an "Infection Control Policy and Procedure 
lJudy has requested a copy of Mr. Glum's deposition transcript, from his deposition on 
November 16, 2010, which will be produced to the Court upon receipt. 
PLAINTIFF'S MEMORANDUM IN OPPOSITION TO DEFENDANT'S MOTION FOR SUMMARY JUDGMENT 4 
544 
Manual (Manual)." Larsen Aff., Exh. 1. However, not everyone at PCRC was given a copy of the 
policy, which PCRC's directors of nursing and staff developer admitted. Larsen Aff., Exh. G 
(Maxfield Depo.), p. 21, ll. 18 to p. 22, I. 2; Exh. J (LaRee Dunn Deposition), p. 26, I. 10-15. 
PCRC's manual required that its staff do a self evaluation to insure its employees were following 
policies regarding infection control practices. Larsen Aff., Exh. L p. 992. Further, PCRC's manual 
had "Compliance Rounds Forms" which were to be filled out to monitor universal precautions and 
documentation of infections. Id., pp. 1118-1119. However, the Director of Nursing during Judy's 
residency, testified that she "did not recall" using the Compliance Rounds Forms at PCRC and 
"didn't recall ever seeing this [compliance rounds forms] before." Larsen Aff., Exh. K (Marjorie 
Brim Deposition),p. 25, l. 21 to p. 26, I. 5. Further, as to the staffselfevaluation form PCRC's staff 
were required to perform every six months, the Director of Nursing testified those forms did not look 
familiar to her. Id., Exh. K,p. 26, l. 12-19. PCRC's Director of Nursing was in charge of monitoring 
its staff to ensure they complied with its infection control prevention procedures. Id., Exh. K, p. 24, 
I. 22 to p. 25, I. 1. 
7. PCRC's failure to monitor its medical caregivers, to see if they were following basic 
infection prevention procedures, such as handwashing, is evident from the testimony of Ms. 
Maxfield, one of Judy's nurses who provided wound care, who admitted that she did not wash her 
hands prior to gloving, itself a violation of PCRC's manual. PCRC's manual required that, to 
prevent the spread of infection, the caregiver was first required to obtain gloves, open the package, 
without touching the gloves, and wash hands and then put on the gloves. Larsen Aff., Exh. L p. 991. 
Ms. Maxfield did not do this, which the Department of Health and Welfare documented in its survey 
on January 24,2008. LarsenAff., Exh. M (January 24,2008 survey o/PCRC). In that report, DHW 
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documented nurse, LN(A), which was Ms. Maxfield, prior to putting on her gloves, did not wash her 
hands, did not remove contaminated gloves, did not wash a wound guide prior to treating a resident 
who had MRSA. Id., Exh. G (Maifzeld Deposition), p. 46, I. 20, I. 25; p. 49, I. 14 to p. 50, I. 5; p. 
53, l. 13 to p. 55, I. 20; Exh. M, p. 82-86. DHW found PCRC failed to follow its policies on 
preventing infection and the spread of infection.Id., Exh. M, p. 85. Further, DHW sent a letter to 
PCRC's then adminstrator, Derrick Glum, notifYing him PCRC was cited for improper infection 
control, for failure to provide proper wound care using proper clean technique and universal 
precautions on a resident who had MRSA. Larsen AjJ., Exh. N (DHW 2-19-10 Letter to Derrick 
Glum), p. 3. PCRC did not follow its own hand washing policy, which it characterized as "the most 
important single procedure for preventing nosocomial infections." Larsen AjJ., Exh.I, p. 1002. 
8. Judy testified in her deposition that her room was not clean, smelled of urine, there was 
mold in the bathroom, and feces in the bed and sink, for weeks. Larsen AjJ., Exh. 0 (Judy Nield 
Deposition), p. 127, I. 21 to p. 128, 1.13. Judy also witnessed the nurses failing to wash their hands, 
and did not have gloves on, before they came into her room. Id., p. 131, 1.14 to p. 132, I. 9. The 
nurses admitted to Judy that it was too hard to put on gloves or wash their hands, and Judy witnessed 
that 60% of the time, the nurses were not washing their hands or putting on gloves. Id., p. 131, I. 
10 to p. 132, l. 9. [Emphasis added]. 
9. Judy testified she was housed next to a resident who had MRSA, and witnessed him 
walking in the hallway. Id., p. 139, I. 3-p. 140, I. 12. Judy was also told by CNAs at PCRC that 
PCRC was "working us to death" and that "[t]here's not even enough of us to cover." Id., p. 161, 
ll. 18 to 21. Judy also recounted that she would be left in a wheelchair for eight straight hours to get 
a pain pill. Id., p. 161, I. 22 to p. 162, I. 17. 
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10. Judy's observations of the MRSA resident are confinned by the DHW 2-19-2008 letter 
it sent to Mr. Glum. Larsen AjJ., Exh. N, p. 3, '3. That letter confinned, by PCRC's admission, that 
while Judy was at PCRC, there were residents diagnosed with MRSA. See also, Affidavit of Dr. 
Selznick, September 19, 2009 report, p. 13, , 5. 
11. Further, as for PA, the DHW 1-24-2008 survey report noted that in August of 2007, 
there was a patient at PCRC who was treated for wound care and "pseudomonas cellulitis of both 
knees." Larsen AjJ., Exh. M, p. 32; Affidavit of Dr. Selznick, September 17, 2009 report, p. 13, , 
4. [Emphasis added]. 
12. Judy's observation, and the PCRC nurses saying that they did not always wash or glove 
is copacetic with PCRC's expert, Dr. Coffinan's opinion that: 
And when it's [hand washing] done-it's interesting, when people do self-evaluation, 
self-reporting on hand washing, it's always close to 100 percent. But when they're 
actually observed doing it, yeah, 70, 72 percent, 60 percent, at some facilities 
50 percent. 
Larsen AjJ., Exh. P (Dr. Coffman Deposition),p. 64, II. 17-22 [Emphasis added]. 
13. More telling from Dr. Coffinan is that, during his deposition testimony, he admitted that 
he could not rule out where Judy contracted MRSA. Specifically, Dr. Coffinan testified: 
Q. So ifPCRC didn't follow infection control procedure, how are you able to rule out 
that Judy Nield did not contract MRSA at PCRC? 
*** 
A. Well, I don't think we can tell .... And we don't know where it came from. It 
had a susceptibility pattern that was sort of more consistent with the community-
acquired strain than a hospital strain. So it makes you think it might have come from 
outside. But we just don't know. 
Q. Well, if PCRC is being cited for not following infection control procedure, so I 
mean they didn't follow that, would you be able to rule out that Judy didn't 
contract MRSA from PCRC? 
A. I can't rule out where she got it from. 
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Larsen AjJ., Exh. P (Dr. Coffman Deposition), p. 69, t. 18 to p. 3. [Emphasis added]. Further, Dr. 
Coffinan's own affidavit amplifies that he cannot determine when Judy contracted MRS A or PA: 
"[IJt is not possible to determine when, where or how Ms. Nield became infected with MRSA 
or pseudomonas." See Affidavit of Thomas J. Coffman, MD in Support of Defendant Pocatello 
Health Services, Inc. DBA Pocatello Care and Rehabilitation Center's Motion for Summary 
Judgment, ,-r 28. 
14. On the other hand, Dr. Hugh Selznick, Judy's treating physician, opined that, to a 
reasonable degree of medical probability, Judy contracted MRSA and P A from PCRC. Dr. Selznick 
concluded "the etiology of [Judy's MRSA infection] was poor infection control measure by the staff 
at Pocatello Care & Rehabilitation Center ... and it is my opinion Ms. Nield also sustained left lower 
extremity pseudomonas wound infection while hospitalized at Pocatello Care & Rehabilitation 
Center as evident per 1119107 culture results." Affidavit of Hugh Selznick, September 17, 2009 
Report, p. 17, 3rd and 4th Paragraphs. 
15. Further, Judy's other experts who have reviewed this matter, Sidney Gerber, an expert 
in healthcare administration, as well as Suzanne Frederick, a residential care nurse, both opined that 
PCRC failed to comply with state and federal regulations and standard of care to prevent the 
transmission of disease and infection, leading to Judy's contracting of MRS A and PA. Both Mr. 
Gerber and Ms. Frederick reviewed the January 24th, 2008 survey ofPCRC by the Department of 
Health & Welfare, which found that the staff at PCRC failed to follow proper infection control 
prevention procedures, such as hand washing, which was the result of PCRC failing to properly 
instruct and train its employees on infection control and prevention measures. Larsen AjJ., Exh. Q 
(1-24-10 Survey report from the Idaho Department of Health and Welfare, pp. 82-86); Exh. R 
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(Suzanne Frederick 4-19-10 & 6-10-10 Reports, pp. 9-13; Affidavit o/Sid Gerber" 4-5, Gerber 
Report, pp. 6-7. Further, Ms. Frederick concludes that the January 24th, 2008 Department of Health 
& Welfare review established that the nurses at PCRC, during wound care failed to follow the 
professional practice standards and facility policies to prevent infections, as nurses repeatedly failed 
to wash their hands at appropriate times during wound care procedures and follow proper precautions 
with a resident that had MRSA. See Larsen Ajf, Exh. R, pp. 10-11. Mr. Gerber also concluded that 
PCRC failed to provide an adequate and sufficient, in addition to competent, nursing staff to provide 
necessary care to prevent Judy from contracting MRSA and P A from PCRC. According to Mr. 
Gerber, the nursing staff at PCRC "were not compliant with the ordinary standard of care and 
protocols established to prevent the spread of infection and in [Mr. Gerber's expert opinion], were 
reckless in not complying with essential and fundamental precautions established universally when 
nursing staff are in physical contact with all patients or residents i.e. routine had washing regardless 
of predisposition or risk factors involving MRSA." See Affidavit o/Sid Gerber, Gerber Report, p. 
8. Mr. Gerber further characterized PCRC's conduct as 
[G]ross violations and significant deviations from the standard of care that 
they were responsible and obligated to provide to Ms. Nield, .. resulting in 
Ms. Nield's injuries and causing her deterioration and needless suffering .... 
Furthermore, under these circumstances, such conduct in my opinion is 
unjustifiable. 
Gerber Ajf, Gerber Report, p.9. 
Ms. Frederick further opined that 
[T]he Director of Nursing and nursing staff of Pocatello Nursing and Rehabilitation 
Center and its owners, managers, and agents failed to adhere to applicable standards 
of care and violated state and federal nursing home regulations in addition to facility 
policies and procedures in their care and treatment of Mrs. Nield thereby increasing 
the risk of harm, causing injury and unnecessary pain and suffering to Mrs. Nield, as 
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well as MRSA infection. 
Larsen AjJ., Exh. R, p. 10-11. 
16. Additionally, Dr. Selznick concluded that due to PCRC's actions and omissions in 
transmitting MRSA and P A to Judy, Judy had to have her left legmnputated below the knee, surgery 
on her right hip. See Dr. Selznick AjJ., ~~ 4-10. 
ARGUMENT 
A. JUDY CONTRACTED MRSA AND PA FROM PCRC THEREBY 
PRECLUDING SUMMARY JUDGMENT. 
1. Standard of review in medical malpractice cases. 
Pursuant to IRCP 56( c), summary judgment is appropriate, "if the pleadings, affidavits, and 
discovery documents on file with the court, read in a light most favorable to the nonmoving party, 
demonstrate no material issue of fact such that the moving party is entitled to a judgment as a matter 
oflaw." Cramer v. Slater, 146 Idaho 868, 873, 204 P.3d 508,513 (2009)(citation omitted). "The 
burden of proving the absence of a material fact is upon the moving party. Id. All disputed facts are 
to be construed liberally in favor ofthe nonmoving party, and all reasonable inferences that can be 
drawn from the record are to be drawn in favor of the nonmoving party. Id. (Citation omitted). "If 
reasonable people might reach a different conclusion from conflicting inferences based on the 
evidence then the motion must be denied." Id. "If the evidence is conflicting on material issues or 
supports conflicting inferences, or if reasonable minds could reach different conclusions, summary 
judgment must be denied." !d. (Citation omitted). 
As to the issue of proximate cause, the court in Cramer, supra, a medical malpractice case, stated 
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the following: 
The question of proximate cause is one of fact and almost always for the jury .... 
[P]roximate cause is one of fact to be submitted to the jury and not a question of law 
for the court; if, upon all the facts and circumstances, there is a reasonable 
chance or likelihood of the conclusions of reasonable (people) differing, the question 
is one for the jury. 
Cramerv. Slater, supra, 146 Idaho at 875, 204 P.3d at 515 (2009(citing, Sisters a/the Holy Cross, 
126 Idaho 1036, 1041,895 P.2d. 1229, 1234 (Ct. App. 1995)). 
A plaintiff is not required, in a medical malpractice action, to prove proximate cause beyond 
a reasonable doubt or that such must be proven by expert testimony. As stated by the court in 
Sheridan v. St. Luke's Reg 'I Med. Ctr., 135 Idaho 775, 25 P.3d 88 (2001) 
Unlike the elements of duty and breach of duty, there is no statutory requirement 
explicitly stating proximate cause in medical malpractice cases must be shown 
by direct expert testimony. Therefore, testimony admissible to show proximate 
cause in a medical malpractice case, like any other case, is governed by the rules 
of evidence regarding opinion testimony by lay witnesses and experts under Idaho 
Rules of Evidence 701 and 702. 
Sheridan, supra. Further, the court held: 
Furthermore, according to our precedent, proximate cause can be shown from 
a "chain of circumstances from which the ultimate fa<:::! required to be 
established is reasonably and naturally inferable. 
* * * 
[A plaintiff] was not required to prove his case beyond a reasonable doubt, nor 
by direct and positive evidence. It was only necessary that he show a chain of 
circumstances from which the ultimate fact required to be established is 
reasonably and naturally inferable. "If the rule oflaw is as contended for by 
defendant and appellant, and it is necessary to demonstrate conclusively and 
beyond the possibility of a doubt that the negligence resulted in the injury, it would 
never be possible to recover in a case of negligence in the practice of a profession 
which is not an exact science. [Internal citations omitted]. 
Sheridan, supra. 
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2. Judy can and has established she did not have MRSA or P A prior to her 
admission to PCRC. 
As the expert opinions of Dr. Selznick, Dr. Gerber, and Suzanne Frederick clearly establish, 
Judy contracted MRSA and PA from PCRC. As a reminder, summary judgment is not appropriate 
where there are affidavits or opinions from which reasonable minds could conclude or reach different 
conclusions. Further, under the summary judgment standard, the court is precluded from weighing 
the evidence and is to accept all facts offered by Judy, as well as the opinions from her experts, as 
true, and to look at the facts posed by and opinions held by PCRC experts as not true. Given that 
Judy's treating doctor and expert, Dr. Selznick, concluded that Judy contracted MRS A and PA from 
PCRC, PCRC is not entitled to summary judgment. 
3. PCRC's motion is based on speculation as to whether Judy "could" have been 
MRSA or PA positive/carrier when she was admitted to its facility, that she may 
have had the infections in her wounds or contracted it from another source 
PCRC offers the speculative opinions from their key expert, Dr. Coffinan, who testified that 
he could not rule out where Judy contracted MRSA, and in his affidavit that he did not know when, 
where or how Judy acquired MRSA and P A. Summary Judgment is not allowed based on the 
supposition of Dr. Coffinan.2 
PCRC offers no evidence showing it they tested Judy to determine ifshe was colonized with 
MRSA or P A prior to or during her stay at its facility. PCRC offers no evidence to show that the 
screening done prior to her admisstion to its facility "may" have proven a false negative or fails to 
show that each wound was tested. PCRC fails to offer any evidence in the record to support its 
supposition that Judy "could" have acquired MRSA or PA from a visitor or from PortneufMedical 
2Judy incorporates herein by reference her Memorandum in Support of Motion to Strike 
Affidavit of Dr. Coffman, filed concurrently with this Memorandum. 
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Center. Again, PCRC certainly had the ability to screen or test Judy to rule out whether she was 
MRS AlP A colonized or positive upon her admission to its facility but did not do so. 
It is axiomatic that the defendant asserting an affirmative defense has the burden of proving 
the defense. See, Chandler v. Hayden, 147 Idaho 765, 771, 215 P.3d 485, 491 (2009)(nonmoving 
defendant has the burden of supporting a claimed affirmative defense on a motion for summary 
judgment). Further, as IRCP 56(e) requires evidence be admissible before the court can consider 
such in deciding a motion for summary judgment. IRE 401 and 402 preclude the Court's 
consideration ofPCRC's speculation and supposition. IRE 401 provides: 
"Relevant Evidence" means evidence having any tendency to make the existence 
of any fact that is of consequence to the determination of the action more probable 
or less probable than it would be without the evidence. 
Further, IRE 402 requires the exclusion of irrelevant evidence: 
All relevant evidence is admissible except as otherwise provided by these rules or 
by other rules applicable in the courts of this state. Evidence which is not relevant 
is not admissible. 
Here, PCRC asserts its affirmative defense, albeit based on pure speculation, that Judy may have 
been MRSA/P A positive or colonized or acquired MRSA and P A from other people or entities. 
PCRC offers no evidence Judy was MRSA or P A colonized prior to her admission there, nor any 
evidence Judy acquired the infections elsewhere. PCRC's administrator admitted in deposition that 
PCRC did not do an investigation as to how Judy acquired MRSA or P A. PCRC did not test Judy 
at any time prior or during her stay. All ofthis was confirmed by PCRC' s own expert, Dr. Coffinan, 
who admitted he cannot determine "when, where or how Judy became infected with MRSA or 
pseudomonas. " 
The evidence in the record, as concluded by Dr. Selznick and Mr. Gerber and Ms. Frederick 
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supports the conclusion Judy contracted MRSA and P A due to PCRC's conduct and/or omissions. 
Her preadmission testing showed her to be negative for MRSA and P A. The evidence shows PCRC 
and its nursing staff did not follow proper infection prevention procedures. The evidence shows 
Judy was housed near MRSA and P A infected residents while she was there. At the very least, 
summary judgment is not appropriate. 
Again, taking as true what Judy and her experts' facts and opinions are, which the court must 
do under summary judgment, it is clear summary judgment should not be allowed. It is up to the jury 
to decide the issue ofwhether Judy contracted MRSA and PA from PCRC and as a result ofPCRC's 
negligence and breach of the standard of care. 
B. JUDY HAS ESTABLISHED SHE WAS INFECTED AND/OR COLONIZED 
WITH MRSA AND PA DUE TO PCRC'S NEGLIGENCE AND BREACH OF 
THE STANDARD OF CARE. 
Again, as all of Judy's experts opined, Dr. Selznick, Mr. Gerber, and Ms. Frederick, Judy 
contracted MRSA and P A from PCRC. See Dr. Selznick Affidavit, September 18, 2009 report, pp. 
13-18; Gerber AfJ., Gerber Report, pp. 6-9, and Frederick Reports, Exhibit R to the Larsen AfJ., pp. 
9-13. Mr. Gerber and Ms. Frederick concluded, PCRC failed to provide adequately trained staff, and 
an adequate number of staff, which resulted in Judy contracting MRSA and P A from PCRC. Again, 
Judy's initial requirements at peRC were to have daily wound assessments. PCRC did them weekly 
and also incompetently as they failed to properly document the size of the wound, what the wound 
looked like, and any other identification of the wound and in the weekly skin assessments and the 
ulcer sore sheets. PCRC completely stopped documentation of two of the wounds on September 18, 
2007, and the largest wound on October 22,2007, a few weeks prior to Judy testing positive for 
MRSA and P A. Furthermore, PCRC was found in violation of state and federal standards by the 
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Department of Health and Welfare on January 24, 2008. The Department of Health and Welfare 
found that the staff at PCRC could not demonstrate proper infection control policies and procedures 
when handling patients that had MRSA. Moreover, there is evidence Judy was housed in a room 
next to a patient that had MRS A and that there was a P A infected patient at PCRC while Judy was 
there. Larsen Affidavit, Exhibits M and N. Judy also testified that she witnessed nurses exiting the 
MRSA patient's room without any gloves on or washing their hands. Larsen AjJ., Exh. 0, p. 127, 
l. 21 top. 128, t. 13;p. 131, t.14 top. 132, t. 9; p.131, l.10top. 132, l. 9. Asaresult,summary 
judgment must be denied. 
C. DR. SELZNICK OPINED JUDY'S PA INFECTION RESULTED IN HER 
RIGHT HIP INFECTION. 
Contrary to PCRC's unfounded conclusion, Judy has retained experts, more specifically her 
treating physician, Dr. Hugh Selznick, who unequivocally opined that she contracted MRSA and P A 
from PCRC. Also, Dr. Selznick concluded that Judy's pseudomonas infection resulted in her right 
prosthetic hip infection requiring surgery in May and June of 2008. In that regard, Dr. Selznick 
concluded: 
It is also my opinion that the right hip joint aspiration confirms pseudomonas which 
is also related to Pocatello Care & Rehabilitation Center. It is my opinion 
that the colonization of pseudomonas took place during her hospitalization and stay at 
Pocatello Care & Rehabilitation Center. It is my opinion the aspiration confirmed 
pseudomonas infection of the right hip was indeed related as well to 
pseudomonas colonization during her hospitalization at Pocatello Care & 
Rehabilitation Center. Again, the 1119/07 left lower extremity would cultures 
did grow out moderate pseUdomonas aeruglnosa. It is my opinion that her right hip 
two-stage revision surgery should be attributed to Pocatello Care & Rehabilitation 
Center hospitalization, colonization and subsequent infection with pseudomonas. 
After the two stage revision, she developed recurrent prosthesis right hip infection 
and all of that treatment for that condition should be related to her stay and 
subsequent infection while at Pocatello Care & Rehabilitation Center. 
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Affidavit of Dr. Selznick, ~ 6. As a result, PCRC is not entitled to summary judgment. 
D. JUDY HAS PRESENTED EXPERT TESTIMONY ESTABLISHING CAUSATION. 
PCRC asserts it is entitled to summary judgment because Judy has no expert testimony from 
an infectious disease expert to show PCRC' s conduct or omissions caused her to contract MRSA and 
P A. PCRC cites to no case supporting this unfounded position that Judy needs expert testimony 
from an infectious disease expert. As stated earlier by the court in Sheridan v. St. Luke's Reg 'I Med. 
Clr., 135 Idaho 775, 25 P.3d 88 (2001) 
Unlike the elements of duty and breach of duty, there is no statutory requirement 
explicitly stating proximate cause in medical malpractice cases must be shown 
by direct expert testimony. Therefore, testimony admissible to show proximate 
cause in a medical malpractice case, like any other case, is governed by the rules 
of evidence regarding opinion testimony by lay witnesses and experts under Idaho 
Rules of Evidence 701 and 702. 
Sheridan, supra. [Emphasis added]. Further, the court held: 
Furthermore, according to our precedent, proximate cause can be shown from 
a "chain of circumstances from which the ultimate fact required to be 
established is reasonably and naturally inferable. 
*** 
[A plaintiff] was not required to prove his case beyond a reasonable doubt, nor 
by direct and positive evidence. It was only necessary that he show a chain of 
circumstances from which the ultimate fact required to be established is 
reasonably and naturally inferable. "If the rule of law is as contended for by 
defendant and appellant, and it is necessary to demonstrate conclusively and 
beyond the possibility of a doubt that the negligence resulted in the injury, it would 
never be possible to recover in a case of negligence in the practice of a profession 
which is not an exact science. [Internal citations omitted]. 
Sheridan, supra. 
Additionally, there is no requirement that Judy have an infectious disease expert. See, Fosler 
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v. Traul, 145 Idaho 24,29, 175 P .3d 186, 191 (2007)(there is no requirement that an expert witness 
be board-certified in the same specialty as the defendant in a malpractice action)). 
PCRC's position is belied by the fact that Dr. Selznic~a medical physician who has been 
practicing in Idaho since 1993, concluded Judy contracted MRSA and PA from PCRC. PCRC's 
position is also ironic, since its expert, Dr. Coffman concluded he does not know where Judy 
contracted MRSA or P A and admitted he could not rule out where she got it. The record shows that 
Judy has met her burden on summary judgment, and that PCRC's motion should be denied. 
CONCLUSION 
Based on the foregoing, plaintiff Judy Nield respectfully requests the Court deny PCRC's 
Motion for Summary Judgment. 
DATED thiSci1f- day of November, 2009. 
COOPER & .!".A~E;;J ,CHARTERED 
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Reed W. Larsen, ISB # 3427 
Javier L. Gabiola, ISB # 5448 
COOPER & LARSEN, CHARTERED 
151 North 3rd Avenue, 2nd Floor 
P. O. Box 4229 
Pocatello, ID 83205-4229 
Telephone: (208) 235-1145 
Facsimile: (208) 235-1182 
Attorneys for Plaintiff 
IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE 
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK 
JUDY NIELD, 
Plaintiff, 
vs. 
POCATELLO HEALTH SERVICES, INC., 
a Nevada corporation, d/b/a 
POCATELLO CARE AND 
REHABILITATION CENTER, and 
JOHN DOES I-X, acting as 
agents and employees of POCATELLO 
HEAL TH SERVICES, INC., d/b/a 
POCATELLO CARE AND 
REHABILITATION CENTER, 
Defendants. 
STATE OF IDAHO ) 
: ss 
County of Bannock ) 
) Case No. CV-09-3869-PI 
) 
) 
) 
) 
) AFFIDAVIT OF REED W. LARSEN IN 
) SUPPORT OF PLAINTIFF'S 
) OPPOSITION TO DEFENDANTS' 
) MOTION FOR SUMMARY 
) JUDGMENT 
) 
) 
) 
) 
) 
) 
) 
) 
I, REED W. LARSEN, being first duly sworn on oath, depose and state as follows: 
1. I am Plaintiff Judy Nield's attorney and make this affidavit upon my own personal 
knowledge and information. 
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2. Attached hereto as Exhibit A is a copy of Judy Nield's discharge summary and 
medical records from PortneufMedical Center from August 21 to 25,2007. 
3. Attached hereto as Exhibit B is a copy of wound cultures and tests taken of Judy 
Nield at PortneufMedical Center on August 21,2007. 
4. Attached hereto as Exhibit C is a copy of Pocatello Care and Rehabilitation Center's 
records of admission. 
5. Attached hereto as Exhibit D is a copy of Resident Care Plan Skin Integrity, Actual 
or Potential records from Pocatello Care and Rehabilitation Center. 
6. Attached hereto as Exhibit E are Non-Pressure Ulcer Site Sheets and weekly skin 
assessment records of Judy Nield from Pocatello Care and Rehabilitation Center. 
7. Attached hereto as Exhibit F is a copy ofthe reports of Suzanne Frederick dated April 
19,2010, and June 10,2010. 
8. Attached hereto as Exhibit G is a copy of the transcript of the deposition of Joyce 
Maxfield. 
9. Attached hereto as Exhibit H is a copy cultures tests from PortneufMedical Center 
dated November 9,2007. 
10. Attached hereto as Exhibit I is a copy of Pocatello Care and Rehabilitation Center's 
Infection Control Policy and Procedure Manual. 
11. Attached hereto as Exhibit J is a copy of the deposition transcript of LaRee Dunn. 
12. Attached hereto as Exhibit K is a copy ofthe deposition transcript of Marjorie Brim. 
13. Attached hereto as Exhibit L is a copy of excerpts from the Department of Health and 
Human Service's survey dated January 24, 2008. 
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14. Attached hereto as Exhibit M is a copy of a letter from the Idaho Department of 
Health and Welfare to Derrick Glum, former Administrator of Pocatello Care and Rehabilitation 
Center dated February 19,2008. 
15. Attached hereto as Exhibit N is a copy of a deposition transcript of Judy Nield. 
16. Attached hereto as Exhibit 0 is a copy of a deposition transcript of Dr. Jeffrey 
Coffman. 
FURTHER SAITH AFFIANT NAUGHT. 
------" 
SUBSCRIBED AND SWORN TO before me this J.1if day of November, 2010. 
(SEAL) NOTARY PUBLIC FOR IDAHO 
Residing at: t3cvvvvu-ti. C-o 
My Commission expires: t I - 0. Is, , 13 
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Chris D. Comstock 
Hall, Farley, Oberrecht & Blanton 
P.O. Box 1271 
Boise, ID 83701 
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Hand Delivery 
Overnight Mail 
Facsimile: 208-395-8585 
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PT NAME: NIELD, JUDY 
PT DOB: 
ADMIT: 08/21/2007 
DISCH: 08/25/2007 
ATTN PHYS: JONATHAN 
5;52 0 
PORTNEUF MEDICAL CENTER 
651 Memorial Drive 
Pocatello, Idaho 83201 
(208) 239-1000 
DISCHARGE SUMMARY 
PT AGE: 65Y 
CREE, M.D. 
ROOM: 
MR: 
ACCT: 
DD: 
TD: 
DT: 
ATTENDING PHYSICIAN: DR. DAN JONES; DR. JONATHAN CREE 
PRIMARY CARE PHYSICIAN: None. 
DISCHARGE DIAGNOSES 
1. Left lower extremity cellulitis. 
2. Right hip pain. 
3. Left hip dislocation. 
4. Newly diagnosed diabetes. 
5. Hypothyroidism. 
6. Hypertension. 
PAST MEDICAL HISTORY 
1. DVT one year ago in the left leg. 
2. Bilateral hip replacements. 
ALLERGIES 
No known drug allergies. 
DISCHARGE MEDICATIONS 
MS-0003-1 
125192 
3865462 
08/25/2007 
1235 
08/27/2007 
1. Colace 100 mg p.o. two times daily for constipation. 
2. Synthroid 0.05 mg p.o. daily for hypothyroidism. 
3. Lovenox 40 mg subcutaneously daily for DVT prophylaxis. 
4. Naprosyn 500 mg p.o. two times daily p.r.n. pain. 
5. Lantus 20 units subcutaneously every night for diabetes. 
6. Cephazolin 1000 mg IV every 8 hours times six weeks for cellulitis. 
7. Morphine 2 to 4 mg IV every 2 hours p.r.n. pain. 
8. Phenergan 6.25 mg IV every 4 hours p.r.n. nausea. 
9. Metformin 500 mg p.o. every night for diabetes. 
FOLLOWUP INSTRUCTIONS 
Orthopedics consult for applying definitive management of prosthetic 
joints. M.D. will call. 
CONSULTATIONS 
Dr. Newhouse, Orthopedics 
PROCEDURES 
Fluoroscopic-guided right hip arthrocentesis. 
EXHIBIT 
CONTINUED A 
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NAME: 
ADMIT: 
NIELD, JUDY 
08/21/2007 
CONTINUED 
DIAGNOSTIC TESTS 
DISCHARGE SUMMARY 
MR: 125192 
DD: 08/25/2007 
DT: 08/27/2007 
PAGE 2 
X-ray AP pelvis and lateral right hip show shallow acetabular 
configuration with uncovering of the lateral stent component 
arthroplasty. No acute fracture or dislocation involving right hip. AP 
film which also reveals a fracture dislocation involving the left hip 
with superior dislocation of the femoral component and displacement at 
the level of the acetabular fracture. 
HISTORY OF PRESENT ILLNESS 
This pleasant 65-year-old Caucasian female presents to the Emergency 
Room with worsening oozing and redness of her left lower extremity. She 
had a history of a DVT in this left leg approximately one year ago. She 
states that she had an ulceration over this leg and that she had popped 
it approximately three months ago. Apparently this leg is swollen at 
this time, but it is normally swollen seconaary to this history of DVT 
that she had. The patient took Coumadin for six months and then stopped 
for treatment of DVT. The patient denies any fevers or chills. She 
basically has no pain in this area, but she attributes that to she has 
no feeling in the left lower extremity at alL secondary to her hip 
replacement in the past. She also does report a little bit of back 
pain, but this is nothing new. 
HOSPITAL COURSE 
The patient was admitted to Med-Surg overflow and placed on contact 
isolation in case she had MRSA. She was placed on IV antibiotics and 
improved considerably. She had her pain controlled with morphine and 
Naprosyn. Wound culture of the left lower extremity grew out klebsiella 
sensitive to Ancef; this is the IV medication that she will be placed on 
long-term for this infection. Also, an aspiration of the right hip 
showed only white blood cells but did not grow any bacteria. Blood 
cultures were negative for any organisms times two. The patient had a 
hemoglobin Ale that showed an elevated level of 6.6%. I did start her 
on Lantus and a mild sliding scale of NovOLog, and her sugars improved. 
I believe that she is an undiagnosed diabetic and will start her on 
metformin for her time over at the skilled nursing facility. I believe 
Lantus and metformin will be a good combination for her to control her 
blood sugars. She does need to have her left and right hip 
arthroplasties revised as they are unstable, and actually her left hip 
is completely dislocated. She is non-weightbearing at this time, and 
she does need revision of these types of arthroplasties at the 
University of Utah as we are not able to do those here. 
564 
DISCHARGE SUMMARY 
NAME: NIELD, JUDY 
ADMIT: 08/21/2007 
CONTINUED 
MR: 125192 
DD; 08/25/2007 
BT: 08/27/2007 
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We will get a hold of Orthopedics here to help us to make this referral 
happen. f'V(\S P; S ~~d1'.re.. 
\ : lh /: 374 
JOB: 278354 
fx; KENNETH E. NEWHOUSE, M.D. (00975) 
> 
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3:36 08/£2/2007 
POFTNEUF MEDICAL CENTER 
651 Memorial Drive 
Pocatello, Idaho 83201 
(208) 239-1000 
HISTORY AND PHYSICAL 
-----------------------------------------------------------------------PT NAME: NIELD, JUDY 
ADMIT: 08/21/2007 
DISCH: 
ATTN PHYS: JONATHAN CREE, M.D. 
PT DOB: PT AGE: 65Y 
CHIEF "COMPLAINT 
Left leg infection. 
HISTORY OF PRESENT ILLNESS 
PT 
FOOM: MS-0003-1 
MR: 125192 
ACCT: 3865462 
TYPE: I 
DD: 08/21/2007 
TD: 1924 
DT: 08/22/2007 
The patient is a 65-year-old female with a previous history of DVT with 
.chronic edema and some ulceration in her left lower extremity as well as 
being insensate from the knee down, who presents to the Emergency Room 
with worsening oozing and redness in her left lower extremity. The 
patient reports that approximately three months ago, she had a clear 
blister posteriorly of her distal lett lower extremity. They popped the 
ulceration, and since then that araa has been getting progressively 
worse and has proceeded to move around toward the front. The patient 
reports that her leg is normally incredib,ly swollen. Today it is much 
better as she was on her back with per leg elevated all day yesterday. 
The swelling has been going on since the DVT she had approximately one 
year ago in this left leg. The patient was on Coumadin for six months 
and then requested not to be on it any longer. The patient denies any 
fevers. The patient has no pain in this area, so denies any pain. 
Again she has no feeling, so no numbness or tingling in that area. The 
patient denies any weakness, any weight changes. The patient has a 
bilateral hip prosthesis and does report increased pain in her right hip 
prosthesis and that is why she was actually on her back yesterday was 
because of the pain in this right hip. 
The patient has been having Home Health come for the last week or so to 
help with dressing changes and the patient reports that approximately 
four to five weeks ago, she was on antibiotics for a few days. They 
were leftover antibiotics that she had from a dental procedure 
previously. 
PAST MEDICAL HISTORY 
Remarkable for the DVT as stated above, hypothyroidism, and the patient 
has had bilateral hip replacements. The patient has not had any 
colonoscopies or colon cancer screening. 
SOCIAL HISTORY 
The patient is widowed. She lives alone. She has about a 15 pack/year 
history of tobacco in the distant past and has occasional alcohol use. 
CODE STATUS 
DNR/DNI. 
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HISTORY AND PHYSICAL 
MR: 125192 NAME: NIELD, JUDY 
ADMIT: 08/21/2007 
DISCH: 
DD: 08/21/2007 
DT: 08/22/2007 
CONTINUED 
MEDICATIONS 
The 
1. 
2. 
3. 
patient is on. 
Hydrocodone 10/325 p.o. every 4 hours p.r.n. 
Diclofenac 50 mg p.o. every day for pain. 
Levothyroxine 50 mcg p.o. daily. 
FAMILY HISTORY 
PAGE 2 
pain. 
No blood clots in the family history. The patient reports that her 
mother had colon cancer in her mid-30's. 
ALLERGIES 
No known drug allergies. 
REVIEW OF SYSTEMS 
The p\atient has been in a wheelchair for approximately the last three 
months due to the swelling and pain and difficulty walking due to the 
feel~ng in this left leg and weakness and pain in the right leg. The 
patient denies any weight changes. The patient denies any night sweats, 
any weakness, any chest pain, any shortness of breath, no cough. 
/ 
PHYSICAL EXAMINATION 
VITAL SIGNS; Temperature 98.8, pulse 96, blood pressure 165/83, 
respirations 20 and the patient was satting 95% on room air. 
GENERAL: The patient is in no acute distress. She is awake, alert, and 
oriented. She is pleasant and cooperative during the exam. 
HEENT: Pupils are equal, round, and reactive to light and 
accommodation. Sclerae and conjunctivae are normal. Mouth and pharynx 
are without lesions or exudate. Tympanic membranes were unable to be 
visualized bilaterally due to cerumen. Hearing to finger rub was 
intact. 
NECK: Soft and supple, no lymphadenopathy, no thyromegaly, no carotid 
bruits. 
HEART: Regular rate and rhythm, no murmurs, rubs, or gallops. 
LUNGS: Clear to auscultation, no wheezes, rales or rhonchi. 
ABDOMEN: Abdomen appeared to be mildly distended, was nontender, no 
peritoneal signs. 
EXTREMITIES; The patient had trace pitting edema in the left lower 
extremity. The patient was insensate from approximately the knee down. 
The patient from the mid-shin down had erythema, but no warmth. There 
was superficial ulcerations around much of the distal lower leg. The 
largest being posteriorly, approximately 6 to 7 cm. There was 
granulation tissue and vascular tissue on all of these. There were some 
areas of oozing and it was a clear to yellowish serous discharge. 
Pulses were present bilaterally at the posterior fibula and posterior 
tibia and dorsalis pedis. Sensation was intact everywhere other than 
this left lower extremity. 
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PCRC000161 
NAME: 
ADMIT: 
DISCH: 
NIELD, JUDY 
08/21/2007 
CONTINUED 
LABORATORY 
HISTORY AND PHYSICAL 
MR: 125192 
DD: 08/21/2007 
DT: 0 8 /22/2 007 
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White count was 7.6, hemoglobin 13.7, hematocrit 40.6, platelets 229. 
BMP revealed a glucose of 177, creatinine 1.0, and electrolytes were 
fine. The patient's albumin was a little bit lbw at 3.1. The rest of 
her liver function tests were otherwise normal. 
The patient had a venous and arterial ultrasound of her left extremity. 
The arterial ultrasound showed an abnormal wave form consistent with 
proximal arterial disease, likely at the iliacs or distal abdominal 
aorta. The venous ultrasound showed disease in the common femoral vein 
.consistent with a chronic DVT. 
ASSESSMENT AND PLAN 
1. Left lower extremity cellulitis. I believe that there is a 
cell~litic component to the patient's infection. However, I believe 
tha~ is not the greatest component. The patient has chronic edema 
ulcerations on and off, most recently-for the last three months. 
The patient has arterial and venous disease and so this is more of a 
picture of arterial and venous disease. However, given the 
pat{ent's poor circulation, she is at high risk for infectious 
disease and I suspect that there is some component of infectious 
disease here. The patient also has elevated sugar, so it is a worry 
that the patient may be a diabetic or borderline diabetic and also 
has bilateral artificial hips. Given all of this, I feel that it 
would be in the patient's best interest to be admitted for IV 
antibiotics at least until cultures are back. We will admit the 
patient on Primaxin 500 mg every 8 hours IV, as well as Vancomycin 1 
gram every 24 hours IV. Wound and blood cultures were sent in the 
Emergency Room. The patient h~s been seen in the past by 
hyperbarics. Hyperbarics will be consulted for further evaluation 
of this wound and in preparation for further outpatient treatment. 
2. Right hip pain. It is unlikely being that the patient is afebrile 
and has a normal white count that the patient has seeded one of the 
artificial joints. However, I will check an ESR and a CRP. If 
these are normal. that will be very reassuring. I will also check 
an x-ray of this right hip to look for any signs and symptoms of 
inflammation or instability there. 
3. Elevated sugars. If the patient had more signs of this being a 
systemic infection, could easily be ascribed to that. However, 
those were not present. If the ESR is normal, it makes these sugars 
more worrisome. I will check a hemoglobin Alc and check a fasting 
glucose in the morning with a BMP for further evaluation of this. 
4. Hypothyroidism. The patient will continue on her outpatient dose 
and a TSH will be checked in the a.m. 
5. Hypertension. The patient does not have a diagnosis of 
hypertension, but had blood pressure up to 165/83. This will 
continue to be followed in the hospital and if it continues to be 
plpVA~prl ~hp "Ain will likplv npprl ~n hp A~Ar~prl nn An 
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PCRC000161 
NAME: NIELD, JUDY 
ADMIT: 08/21/2007 
DISCH: 
CONTINUED 
HISTORY AND PHYSICAL 
MR: 125192 
DD : 0 8 /21 / 2 007 
DT : 0 8 /22 / 2 0 07 
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antihypertensive at discharge or possibly with fol10wup as an 
outpatient. 
6. Prophylaxis. The patient is at high risk for deep venous thrombosis 
havi~g had a previous deep venous thrombosis and has poor flow in 
this left leg. The patient will be given Lovenox 40 mg subcu daily. 
The patient is low risk for gastrointestinal prophylaxis, so a 
proton pump inhibitor will not be prescribed. 
\ : arb 
\, 
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PT NAME: NIELD, JUDY 
PT DOB: 
ADMIT: 08/21/2007 
DISCH: 
15:04 Oo,G3/2007 
POR'l'NEUF MEDICAL CENTER 
651 Memorial Drive 
Pocatello, Idaho 83201 
(208) 239-1000 
CONSULTATION REPORT 
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PT AGE: 65Y 
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KP .. : :.25192 
ACCT .. : 3865462 
PT TYPE: ~ 
DD: 08/23/2007 
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CONSULTING PHYSICIAN: KENNETH E. NEWHOUSE, M.D. 
REQUESTING PHYSICIAN: 
_ .. ___ ._ . .DATE OJ" CONSULTATIObJ: 08123/2007 
IDENTIFICATION 
A 65-year-old female. 
" 
CHIEF'COMPLAINT 
Cellulitis and right hip pain. 
HISTO~Y 
The patient does have a fairly long complicated history in .which she h.c..d 
bilateral total hip replacements done! approximats~.y.: 1.3. yea.rs age done by 
Dr. William Mott, now deceased. ., .... 
The patient evidently had some sort of sciatic nerv~ injury to the left 
hip at or around the time of surgery and since the time of surgery she 
has had difficulty with feeling in her left leg and moving her ankle up 
and down. 
The patient was ambulatory until about two years ago when she evidently 
Iell coming out of a grocery store. She was at that point seen and 
evaluated by Dr. B.J. Blair. The patient states she had radiographs of 
her spine. She is not $ure if she had radiographs of her hip but was at 
any rate given a reasonably clean bill of health and did reasonably well 
until about three month$ ago when, without any type of insult or ir.jury 
whatsoever, she lost che ability to ambulate. 
She has evidently been dealing with chronic cellulitis in he= lower 
extremities, treated with hyperbarics, p.o. antjbiotics and the like. 
She presented to the hospital approximately 36 hours ago with increasipg 
pain and soreness in her right hip as well as increasing ce!l~~itis. 
She was admitted to the hospital and started on IV antibiotics. I was 
consulted approximately 21 hours after her admission b¢cause of right 
hip pain. Radiographs had been obtaineo (they were not evaluated by a 
clinician at that point). I waS asked to see her, wondering whether or 
not her right hip could be infected. 
The patient'~ past medical history is well documented in the clinic 
notes but from an orthopedic standpoint again, she says she has not 
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ambulated for approximately three months and she states she really is 
not having no pain at all in her left leg. 
Examination of her left leg shows the left leg is at least 2 inches 
shorter contrary to her right leg and general range of motion causes her 
very little discomfort. She has a fair amount of cellulitis and open 
blistering of her left lower extremity. It should also be noted she has 
essentially no sensation in her left foot and calf area. 
Examination of the right leg shows she is grossly neurovascular intact. 
She has much less cellulitis and open areas on the right leg but has 
fair amount of pain both laterally and anteriorly with range of motion 
of her hip. 
Radiographs were reviewed. The radio~raphs consist of an AP pelvis. The 
patient has a fracture dislocation of her left total hip replacement. 
The cup has been disassembled from the native acetabulum and there is a 
central acetabular fracture. The hip is dislocated with the femoral 
h~d slttlng at least two~nches proximal to the native acetabulum. 
There also appears to be some loosening of the right hip acetabular 
component but the hip is grossly~located, the cup is somewhat vertical. 
This is a difficult problem that I believe the patient has what appears 
to be a Charcot left leg and at least a chronic dislocation and intury 
to this w[thout any evidence of trauma whatsoever. 
The patient could also have seeded both of her hips, the left and the 
right, with her cellulitis and is now complaining of pain and loosening 
of the right hip. On the other hand, she simply could have a loose 
acetabulum which could be causing her discomfort. 
Antibiotics are started prior to any type of aspiration and therefore 
any aspiration studies we get are equivocal. 
On a positive note, the patient is not septic at this point. 
I think medical management at this point should consist of continuing 
with antibiotics but I have recommended last evening, when I saw the 
patient, aspiration of her hip. At the time of this dictation this 
still has not been done yet. This is scheduled. 
Unfortunately the results of this aspiration are going to be compromised 
because of starting the antibiotics. However, if we obtain a 
considerable amount of white blood cells we can assume that the hip is 
infected. 
Unfortunately, if the hip is infected I think the only option would be~ 
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the other side and the fracture is noted in the disassembly of the 
components, this would basically give her no lower extremity on which 
she can stand. 
with respects ~o operative treatment for the left leg this would be 
difficult. Revision could be performed but given the fact that she has 
a Charcot leg she very likely may end up with similar circumstances in 
the future. 
In any event, I think this should probably be done by a total joint 
revision specialist. We will await the aspiration results and discuss 
this further. 
I have discussed this case at length with Dr. Routson as well as Dr. 
Zimmerman and they concur wi th this plan. " 
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~Thite count was 7.6, hemoglobin 13.7, hematocrit 40.6, platelets".229. 
aMP revealed a glucose of 177, creatinine 1.0, and £lectrol~te~ we~e 
fine. The patient's albumin was a little bit l'ow at 3.1. The res.t c:': 
her liver function tests were otherwise normal. 
The pati£nt had a venous and arterial ultrasound of her left e~tremity. 
The arterial ultrasound showed an abnormal wave form consistent with 
proximal arterial disease, likely at the ~liacs. or distal abdominal 
aorta. The venous ul trasound Showed disease .in the .common :: ell'~l': '.l ~ .. . . 
.. consistent with a chronic DVT. . .- ... -." 
ASSESSMENT AND PLAN 
1. Left lower extremity cellulitis. I believe that there 'is a 
cellulitic component ~(l the patient's infection. How·eve'!··; I :;:"e::'ie'le 
that is not the grea~est component. The patient has chronic edema 
ulcerations on and off, most recently for th.e last three months. 
The patient has arterial and venous disease and so this is more of a 
picture of arterial and venous disease. However, given the 
patient's poor circulation. she is at high risk for infectious 
disease and ! suspect that there is some component of infectious 
disease here. The patient also has clevated sugar, so it is a wo~~y 
that the patient may be a diabetic or borderline diabetic and e~so 
has bilateral artificial hips. Given all of this, I feel that it 
would be in the patient's best interest to be admitted for IV 
antibiotics at least until cultures are back. We will admit the 
patient on Pr.imaxin 500 mg every 8 hours IV, as well as vancomycin 1 
gram every 24 hours IV. Wound and hlood cultures we=e sent in :h~ 
Emergency Room. The patient has been seen in the pes.:: by 
hyperbarics. Hyperbarics will be consulted fo::: fu:::!::he.r ~val\l.<!t.:'~,: 
of this wound and in preparation for further outpatient treatment. 
2. Right hjp pain. it is unlikely being that the patient is afebrile 
and hus it normal white count that the patient has seeded one of the 
artificial joints. However, I will check an ESR and a CRP. If 
these are normal, that will be very reassuring. I will also check 
an x-ray of this right hip to look for any signs and symptoms of 
inflammation or instability there. 
3. Elevated sugars. If the patient had more signs of this being a 
systemic infection, could casi.1y be ascribed t.o that. However, 
those were not prosent. 2f the ESR is normal, it makes these sugars 
more worrisome. I will check a hemoglobin Alc and check a fasting 
glucose in the morning with a BMP for further evaluation of this. 
4. Hypothyroidism. The patient will continue on her outpatient dose 
and a TSH will be checked in the a.m. 
5. Hypertension. The patient does not have a diagnosis of 
hyp~Ttension, but had blood pressur~ up to 165/83. This will 
continue to be followed in the hospital and if it contin~es ~c ~e 
elevated, the pain will likely need to be started on a~ 
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antihypertensive at discharge or possibly with followl.:p as a:'. 
ou tpa tient. 
6. Prophylaxis. The patient is at high risk for deep venous thrombosis 
having had a previous deep venous thrombosis and has poor flow in 
this left leg. The patient will be given Lovenox 40 mg subcu daily. 
The patient is low risk for gastrointestinal prophylaxis. so a 
proton pump inhibitor will not be prescribed. 
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N!ELD, JUDY 
-_ ... ~-.- 5126142 F 065 8/21/07 
Faculty Admit/Progress Note mllillmU 3865462 
Dale: .. n'?ij';;2·· Time: Z J; n . ,l:.m. ,Hl.m; CREE. JONATHAN 
Attending: L :" " 4-1-<.r-s--:... IlilllmllmB 00 125192 
~~~de!11. ;' M,~dc.ot:J ._. 
~E. tI~r AUf. i4.k.:::.I.o~,'t!:. O'(61/I.':rkJIQ .i)(A A.'. I fiJI 1.;, t?'-4-. 
.. 
Interval History (1·3 LicrncnlS ior 221/2.22, 4" eI~ments ior W'oradtnll) 
~r~ f, (~ I '(lcv.Jt." ~""'I1s{ Wkr '", '& &t!I.c-Ir ~·~~~5.~(;:A.-.: 
e/JI'.."LI ..... ,.;: .J,;t)ljJ&- ct:s:d~ 4Jt- CrrdJ.i.... !--..4. 
~.·t 1~/N:ff. ,,20 of,!..; l,itP·_'4d. .ci)..R.vr l.,... ~_ ;:- , .. "., ",/l. 
/f .. , ... A'AIe-l.U", ".>;.~ Ji,,"C f &.- ~~,,-'" ·""f.ietI..~7/Y..l!A'Y ~ kJ/ 
PFSH (dnc lor 223. PMHx for admit) A .. ·. :S'~~I-<' ~dy &,... r< #J.:.:-'..!.'f- Nt4 ( /"'w A'.Ir ..P'~? r"'-.(L'-
~", 7" • </ 
• ( /,4 L .4 '1:'~ '* 2Y~ V £.6) t. . ._ 
ROS: Check if not ~n isstfe, Circle if problematic, lOne Sf$l~m for m,T9s)'$'~ for 223) 1[ii1{esident admit notl' 
Ceneral EfChflls o Poor ae~ite . 0'Weal<ncss review~:...--=--____ 
Ef Cbesl Pain '0 piaEhoresis Cardiac o Pal[!itations 
-
L 
Pulmonary ~~ o Wheezing E1 Labored breathinr, IE!' Concur with resident -GI o Diarrhea Ef AbE3in . Fam Hx. Soc H.x & ROS 
Psychi3tric Cl Depression o Anxiety Cllnsomnia .' .. , \,' ." 
Other: /.11.$ A:,L ,/. r~;' J~ &) ,..... J<:k-, Be, ' i ,. 
r?fi~ I PHYSICAL EXAM: Check findings ot make note. (221-1-5,222 ==6-11.223 = 12 +) .' .. 
Vitals: T 1"10 IF dCr' !BP 1/1 / ?, IRR 60 ~ wt. 11/0 I 
Ceneral 
.At:> .e!~ ; ADDfTfONAL FINDINGS : 
Head tFNormocePh~lic D No lnIumalic wuund/aepitis I 
,Eyes LJ PEltRL er EOMll!n:onullclivae clear 
· an' ~l ~1ruC1ures well iotmed o EACs/TMs clear : 
.J NOI'IlIill teeth/lips/gUlWl Ja'PImynx pink .. moist , 
· 
Neck [J Supple/lvll ROM l!l' iiod~/tbYtoid JWI cnl~rged " .~. I 
Back CJ Nomlal CW'~atUte S-SVA/SP UDaHendlll' t 
Lungs ~ "T ........ ~ CfC'IIISiDn '6 o.ar dUle U Clear pcrcu:iS 
· 
· CV JiiMtklt 0 Normal $1. ~. 110 M/C/R 0 Neck valIS Ilat '; 
Ab ~rl COlltoUr 6" Active IlS liiI't:onlerll sol\fnoll-leOder 
GU PNonDaI_ em Inspeetion Ll No wuS$elI/lImdcmcs. ! 
Ext J t'UII!tOM 0 No edema U Nfl pulSe5/perfllSinn 
. {A/t:( >,,,,,,,,tur - ~.r.c.r ",,"I-~,x..d ... , 
Skin o No rash or im::ak.iown o W.1rm~ dry ; ., (I P' .,., , 
Neuro U DT.!t~ 1.;. Isym o MOLIH' SIS ,.I.;; A",~ ._ ..... -. .;!t//-l ! ._
,-
M5 pariCllt~'II. J:3 Er Appropriale "ffeet U ~'Il ~ itell15 fI1 S min i ! 
IMAGING EKe LABS t..>1t:: 1. '-, Col ... I??, ~u""....e. 
C,.U If'.'f, erA!. r ~ . 
231 - ReSJlftll\ling to rut. ZlZ - !'oot re:Jl!/minur COm!!lic:aliollS. 2.U - Unst.lble/nlalor euml!!icalionsl 
Problems & Plans 
I. c.~"" //J./L_ ~. 
• rAm-~ ~ ~':'" .w '-";"""" ~;;= ..... "''''; I I t /(.)/.. ',. ...... 1 - ,,.: "" I}", '.'A .ir. :..-L .~ ~ • ~l$.. ~::u .. 
., . 
, .' -:: r , 
I !'", (h I eY''T1"'" ;;; fiIN t)" Z" ... ~ cV' /1"':!M II ....g~ -,." , " . : 
1) VTE prophylaxis . -----, 
2) Stress ulcer prophylaxis 
~ .. 
, 
, 
'-
E&M 
ISU STUDENT ED 
WORKSHEET 
I 
: 
...----: I 
: 
\. 
I 
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PT TYPE: I 
ATTN PH N CREE, M.D. DD: 08/21/2007 
TD: 1924. PT DOB: PT AGE: 65Y 
CHIEF COMPl,A:tNT 
Left leg infection. 
HISTORY OF PRESENT ILLNESS 
DT: 08/22/2007 
',' 
The patient is a 65-year-old female with a previous history of DVT with 
chronic edema and some ulceration in ber left lower extremity' as "/el: as 
being insensate from the knee down. who presents to the Emergency th)pm 
with worsenipg oozing and redness in ber. left lower extrem:ty, The 
patient reports that app.oximately three months ago. she had e clea= 
blister posteriorly of her distal left lower extremity. They popp~d the 
ulceration, and since tben that area has been getting progressive~y 
worse ana. has proceeded to move around toward the front. The patient 
reports that her leg is normally incredib~swollen. Today it is muer. 
better as she was on her back with her leg elevated all day yesterday. 
The swelling has been going on since the DVT she had approximately one 
year ago in this left leg. The patient was on Coumadin for six months 
and then requested not to be on it any longer. The patient denies any 
fevers. The patient has no pain in this area, so denies any pain. 
Again she has no feeling, so no numbness or tingling in that area. The 
patient denies any weakness. any weight changes. The patient has a 
bilateral hip prosthesis and does report increased pain in her right hip 
prosthesis and that is why she was actually on ber back y~sterday was 
because of the pain in this right hip. 
The patient has been having Home Health come for the last week 0= so to 
help with dressing changes and the patient reports that approximately 
four to five weeks ago, she was 00 antibiotics for a few days. -:'.hey 
were leftover antibiotics that she had from a dental procedu~€ 
previously. 
PAST MEDICAL HISTORY 
Remarkable for the DVT as stated above. hypothyroidism. and the patient 
has had bilateral hip replacements. The patient ha~ not had any 
colonoscopic~ or colon cancer screening. 
SOCIAL HISTORY 
The patient is widowed. She lives alone. She has about a 15 pack/yca= 
history of tobacco in the distant past and has occasional alcohol use. 
CODE STATUS 
DNR/DN1. 
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The 
1. 
2. 
3. 
Hydrocodone'10/325 p.o. every 4 hours p.r.n,. pain. 
Diclofenac SO mg p.o. every day for pain:.:"', " 
Levothyroxifie 50 mcg p.o. daily. ~~ ~ 
:. ,':: ':;..:; 
FAMILY HISTORY 
No b).ood clots in the family history. The patient reports that her 
mother had colon cancer in her mid-30's. 
ALT..ERGIES 
No known drug allergies. 
REVIEW OF SYSTEMS 
The patient has been in a wheelchair for approximately the last three 
months due to the swelling and pain and difficulty walking diie to ,th-s 
feeling in this left leg and weakness and pain in the right leg. The 
patient denies any weight changes. The patient denies any night swea~s. 
any weakness. any chest pain. any shortness of breath, no coug~. 
PHYSICAL EXAMINATION 
VITAL SIGNS: Temperature 98.8. pulse 96, blood pressur'e 165/83, 
respirations 20 and the patient was satting 95% on room air. 
GENERAL: The patient is in nO acute distress. She is awake, alert, ana 
oriented. She is pleasant and cooperative during the ~~am. 
HEEN~: Pupils are equal. round, and reactive to light and 
accommodation. Sclerae and conjunctivae are normal. Mouth and pharynx 
are without lesions or exudate. Tympanic membranes were unable to be 
visuali~ed bilaterally due to cerumen. Hearing to fi,nger rub was 
intact. 
NECK: Soft and supple, no lymphadenopathy, no thyromegaly, no carotid 
bruit.s. 
HEART: Regular rate and rhythm. no murmurs. rubs. or gallops. 
LUNGS: Cl~ar to auscultation, no wheezes. rales or rhonchi. 
ABDOMEN: Abdomen appeared to be mildly distended. was nontende~, no 
peritoneal signs. 
EXTREMITIES: The patient had tr~ce pitting edema in the left lower 
extremity. The patient was insensate from approximately the knee dO"'/~. 
The pat.ient from the mid-sh:i.n down had erythema, but no warmtb. The:::-~ 
WaS superficial ulcerations around much of the distal lowe= leg. The 
Itlrgest being posteriorly. approximately 6 to 7 em. The:::"€: was 
granulation tissue and vascular tissue on all of these. ~bere ~e=9 &~~~ 
areas of oozing and it was a clear to yellowish serous dis=har~i. 
Pulses W€re present bilaterally at the posterior fibula a~d pos~eric= 
tibia and dorsalis pedis. Sensation was intact. everywhere other than in 
this left lower extremity. 
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ambulated for. approximately three months and she states she really is 
not having no pain at all in her. left leg. 
Examination of her left leg shows the left leg is at least 2 inches 
shorter contrary to her right leg and general range of motion"" cau.s~s ~e~ 
very little discomfort. She has a fair amount of cellulitis and open 
blistering of heT. left lower extremity, It should also be no~ed ste h~5 
essentially no sensat.ion in her left foot and calf area. 
Examinat.ion of the right leg shows she is grossly neurovascular intact". 
She has much less cellulitis and open areas on the right leg but has 
fair amount of pain both 1a terally and anteriorly wi th range of motion 
of her hip. 
Radi.ographs weX'e reviewed. Th~ radiograph~ consist of an AI' pelvi~:. T~";'i: 
patient has a fracture dislocation of her~left total hip r~placcmR=t. 
The cup has been disassembled from the native acetabul~m a~d there is a 
central acetabular fracture. The hip is dislocated with the =emo=al 
head sitting at least two inches proximal/to the native acetabulum. 
There also appears to be some loosening of the right hip acetabular 
component but the hip is grossly located, the cup is somewhat vertical. 
This is a difficult problem that! believe the patient has what appears 
to be n Charcot left leg and at least a chronic dislocation and injury 
to this without any evidence of trauma whatsoever. 
The patient could also have seeded both of her hips, the left and the 
right. with her cellulit:is and. is now complaining of pain and loosening 
of the right hip, On the other hand; she simply could ha"e a loosg 
acetabulum which. could be causing her discomfort. 
Antibiotics are started prior to Qny type of aspiration a~d theT€f~~e 
any aspiration studies we get a.re equivocal. 
On a positive note, the patient is not septic at this point. 
I think medical management at this point should consist of continuing 
with antibiotics but I hav~ recommended last ev~ning, when I saw the 
patient, aspiration of her hip. At the time of this dictation this 
still has not been done yet. This is scheduled. 
Unfortunately the results of this asoi~ation are going to be compromis~d 
because of starting the antibiotics,- However, if we obtain a 
considerable amount of white blood cells we can assume that the hip i5 
i.nfected. 
Unfortunately, if the hip is infected I think the only option would be a 
two stage exchange. Given the fact that the patient has Charcot h!p o~ 
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the other side and the fracture is noted i.n the disassembly of t!1e 
components. this would basically give her no lower extremi ty on whid: 
she can stand. 
with respects 'to operative treatment for the left leg thi:; would De 
difficult. Revision could be performed. but given the fact that she ;"",5 
a Cha.rcot leg she very likely may end up with similar CirC'I.lffistances in 
the future. 
In any event, r. think this should probably be done by a total joint 
. __ .... _____ .... __ revision specia.list. We will await the aspiration results and d.iscuss 
this further_ 
I have discussed this case CI.t length with Dr. Routson as well as D!:'. 
Zimmerman and they cor-cur with this plan. I, 
~ 
------------_._-- .~(-----
KENNETH E. NEWHOUSE, M.D. 
\ : db /: 97'5 ID: 001409310 
TUrF.: 14.36 JOB: 278063 
fx: KENNETU E. NEWHOUSE, M.D. (00975) 
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ANAEROBE CULTURE 
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COPY TO MEDICAL RECORDS 
PAI"HOLOGlST: 
S.M. SI<OUMAL. M.D 
DOC. NO. LB!XXll1 /lllO6l 
e LITHO PRINTING 
CREE, JONATHAN ~* FINAL** REPORTED: 08/21/2007 23:53 PAGE: 1 
NIELD/JUDY MR 125192 
OS/26j1942(65Y F) BN 3865462 MS 
ORDERED BY: BRADBURY, ANDREW 
COLLECTED ON: 08/21/2007 @ 21:00 ACCESSION: L0847960 
............ 
WOUND CULTURE ACC #: L0847960 
Source: WOUND, LEFT LEG 
Status: FINAL 
GRAM STAIN 
Set-up: 08/21/2007 2345 
1+ WBC1S - 1+ GRAM NEGATIVE RODS 
1+ GRAM POSITIVE COCCI 
RESULTS 
MODERATE GRAM POSITIVE COCCI 
MODERATE COAG-NEG STAPH SPECIES 
MODERATE BETA HEMOLYTIC STREPTOCOCCI, NOT GROUP A,B OR D 
(NO FURTHER IDENTIFICATION) 
LIGHT GRAM NEGATIVE RODS 
LIGHT KLEBSIELLA PNEUMONIAE 
ANTIMICROBICS 
AMOXICILLIN!K CLAVULANATE 
AMPICILLIN 
AMPICILLIN/SULBACTAM 
AZTREONAM 
CEFAZOLIN 
CEFTAZIDIME 
CEFTRIAXONE 
CEFUROXIME 
CIPROFLOXACIN 
ERTAPENEM 
GENTAMICIN 
IMIPENEM 
LEVOFLOXACIN 
PIPERACILLIN/TAZABACTAM 
TETRACYCLINE 
~RIMETHOPRIM/SULFAMETHOX 
KLEBSIELLA PNEUMONIAE 
MIC uG/ML BLD UR 
<-=8(4 S 
16 I 
<=8/4 S 
<=8 S 
<=8 S 
<=1 S 
<=8 S 
<=4 S 
<=1 S 
<=2 S 
<=1 S 
<=4 S 
<=2 S 
<=16 S 
<=4 S 
<=2/38 S 
REPORT CONTINUED ON NEXT FORM 
H-HIGH t·LOW "·SIGNIFICANT CHANGE FROM PREVIOUS RESULT UNK-UNKNOWN NA-NOT APPLICABLE NO-NOT DONE PND·PENDING *·FOOTNarE 
584 
585 
'fiPortneuf 
:ONTINUED REPORT 
MEDICAL CENTER 
NEST CAMPUS EAST CAMPUS 
MEMORIAL DRIVE 777 HOSPITAl WAY 
r~_ATELLO. IDAHO 83701 POCATELLO. IDAHO 83201 
CLINICAL RY ~E S.M. SKOUMA1 .. M.D. 
DOC NO. LBOCOll (111()6) 
C LITHO PRINTING 
CREE, JONATHAN **~~~~ __ ~~~~~~~~/2007 23:53 PAGE: 2 
NIELD,JUDY 
OS/26/1942(65Y F) 
MR 125192 
BN 3865462 MS 
ORDERED BY: BRADBURY, ANDREW 
COLLECTED ON: 08/21/2007 @ 21:00 
WOUND CULTURE 
Source: WOUND, LEFT LEG 
Status: FINAL 
.~. :~;-r: .. '.:: 
ACCESSION: L0847960 
Ace #: L0847960 
Set-up: 08/21/2007 2345 
S=Susceptible I=Intermediate R=Resistant N/R=Not Reported 
BLANK=Drug not advisable BLAC=Beta Lac Pos TFG=Thymidine dependant 
INTERPRETATIONS BASED ON APPROX. ADULT ATTAINABLE BLOOD/URINE LEVELS. 
IB APPEARS IN PLACE OF INTERP W/ORG'S W/KNOWN INDUCIBLE B-LACTAMASES. 
S.aureus and Coag neg Staph species tested for Inducible Resistance 
to Clindamycin, results reported as MIC interpretation 
H·HICH L·LOW #·SlGNlfICANT CHANGE FROM PREVlOUS RESULT UNK·UNKNOWN NA·NOT APPLlCABLE ND-NOT DONE PND·PENDING *·FOOTNOfE 
586 
587 
·Portneuf 
MEDICAL CENTER 
weST CAMPUS EAST CAMPUS 
MEMORIAl. DKIV!: 77 J HOSPITAl. WAY 
.•• ,,1 ellO. IDAHO 03201 POCATELLO, IDAHO 83201 
ATTENDING PHYS: 
CREE, JONATHAN 
CLINICAL LABORATORY 
COLLEGE OF AMERICAN PATHOLOGISTS CERTIFIED 
COpy TO MEDlCAL RECORDS 
PATHOLOGIST: 
S_M_ SKOUMAI., M.D 
DOC NO LB@n (11106 
C LITHO PRINTING 
*~ FINAL** REPORTED: 08/~3/2007 18:47 PAGE: 1 
NIELD,JUDY MR 125192 
OS/26!1942(65Y F) BN 3865462 MS 
ORDERED BY: CREE, JONATHAN 
COLLECTED ON: 08/23/2007 @ 13;30 ACCESSION: L0848712 
MISC FLUID CELL COUNT 
FLUID TYPE 
VOLUME 
APPEARAl~CE 
RBC count 
WBC'S 
** Test performed at: WEST 
SYNOVIAL 
3 
YELLOW, CLOUDY 
10250 
3 
mL 
per uL 
uL 
CLEAR 
(O-25) 
H-HIGH ["·LOW #-SIGNIFICANT CHANGE FROM PREVIOUS RF.5ULT UNK·UNKlIIowN NA·NOT APPLICABLE NO-NOT DONE PND·PENDING *-FOOTNOTE 
588 
589 
'ilPortneuf 
MEDICAL CENTER 
ST CAMPUS EAST CAMPUS 
iMORIAL DmvE 777 IIOSPITAL WAY 
POL ... .! ELLO. IDAHO 83201 POCATELLO, IDAHO 83201 
ATTENDING PHYS: 
CLINICAL LABO RY 
COLLEGE. OF AMERICAN PATHOLOGISTS CERTIFIED 
COpy TO MEDICAL RECORDS 
PATHOI.OGIST; 
S,M. SKOLJMAL, M,D. 
DOC. NO. L8()(:Oll t lI/Q6J 
~ WHO FRINTING 
CREE, JONATHAN ** FINAL** REPORTED: 08/23/2007 06:59 PAGE: 1 
NIELD/JUDY MR 125192 
65Y F} BN 3865462 MS 
ORDERED BY: ZIMMERMANN, RYAN, FP--RES 
COLLECTED ON: 08/23/2007 @ 06:00 ACCESSION: L0848159 
[If[!~;[l:;.:[:I::.'I'~::;,;:?,i' .• '::';:::.:'::'.':::;~:;l::tr~iji&IS~¥?1~~[,1.!,::::·~;;:j:(:",;~;:.;;::;:::::,:i::;:XW::N:;:;i:i:;~;:iij:~~:;,:,.:,:; 
CRP 1 7 . 1 file:?;: mg / dL (0 . 1 - 0 . 9 ) 
The assay used in FMC lab has an extended rarig'e. It is therefore 
useful for assessing both high sensitive CRP (hsCRP) AND 
traditional less sensitive CRP. High sensitivity assays for CRP 
may add to the predictive value of other markers used to assess the 
risk of cardiovascular and peripheral vascular disease. Low 
sensitive CRP may be useful for the detection and evaluation of 
infection, tissue injury, inflammatory disorders and associated 
diseases. . 
Separate reference ranges are listed with hsCRP and CRP·results. 
**- Test performed at: WEST :';:<-
H-H1GH L,LOW a·SIGNIFICANT CHANGE FROM PREVIOUS RfSULT UNK·UNKNOWN NA·NOT APPLICABLE NO·NOT DONE PND-PENDING *·FOOTNOTE 
590 
591 
'8Portneuf 
MEDICAL CENTER 
,ST CAMPUS 
,[MORtAl DRIVE 
po""rEUO. IDAHO R:J201 
EAsrCAMpUs 
117 HOSPITAL WAY 
POCA1ELLO,IDAH083:>01 
ATTENDING PHYS: 
CLINICAL LA RY 
COLLEGE OF AMERICAN PATHOLOGISTS CERTIFIED 
COpy TO MEDICAL RECORDS 
PATHOLOGIST: 
S.M. SKOUMAL. M.D. 
DOC NO l6UOOIl (11!116) 
@ LITHO PRINTING 
CREE, JONATHAN ** FINAL** REPORTED: 08/23/2007 17:38 PAGE: 1 
NIELD,JUDY MR 125192 
OS/26/1942(65Y F) BN 3865462 MS 
ORDERED BY; CREE, JONATHAN 
COLLECTED ON: 08/23/2007 @ 13:30 
BODY FLUID CULTURE 
Source: BODY FLUID, SYNOVIAL 
Status: FINAL 
GRAM STAIN 
ACCESSION: L084870B 
ACC #: L0848708 
Set-up: 08/23/2007 1736 
2+ WBelS - NO ORGANISMS SEEN 
RESULTS 
SOURCE IS RT HIP 
NO GROWTH IN 24 HOURS 
NO GROWTH IN 48 HOURS 
H-HiGH L·LOW '·SlCN1F1CANT CHANGE FROM PREVIOUS RESULT UNK-UNKNOWN NA-NaT APPLICABLE ND·NaT DONE PND-PENDING *-FOOTNOTE 
592 
593 
'8Portneuf 
MEDICAL CENTER 
'EST CAMPUS 
A£MORIAi. Dl'liVF 
PlKATELlO. IDAHO 11,7.01 
EAST CAMPUS 
777 HOSPITAl. WAY 
POO.TE:L~O.IDAHO 83201 
ATTENDING PHYS: 
CLINICAL LABORATORY 
COLLEGE Of AMERICAN PATHOLOGISTS CERTIFIED 
COpy TO MEDICAL RECORDS 
PATHOLOGIST: 
S.M. SKOUMAI.. M.D 
DOC. NO.lB(XX)11111106 
Q LITHO PRINTING 
CREEl JONATHAN ** FINAL** REPORTED: 08/23/2007 17:38 PAGE: 1 
NIELD, JUDY MR 125192 
OS/26/1942(65Y F) BN 3865462 MS 
ORDERED BY: ZIMMERMANN, RYAN, FP--RES 
COLLECTED ON: 08/23/2007 @ 16:05 
ANAEROBE CULTURE 
Source: JOINTIHIP 
Status: FINAL 
RESULTS 
SOURCE IS RT HIP 
ACCESSION: L0848620 
ACC #: L0848620 
Set-up: 08/23/2007 1736 
NO GROWTH ANAEROBICALLY IN 48 HOURS 
I-HIGH L·I.OW "·SICNIFICANT CHANGE FROM PREVIOUS RESULT UNK·UNKl\OWN NA-NOT APPLICABLE NO-NOT DONE PND,PENDING *·FOOTNOTE 
594 
595 
PO 
First Name 
JUDY 
Admit # 1 
Race White 
Address 
260 ADAMS STREET 
City 
CHUBBUCK 
~LLO CARE & REHAB CEN 
Record of Admission 
Middle Last Name 
NIELD 
Gen F BirthDate Age 65 
Phone (208)237-4079 
M/R # 
223538 
M/S M 
ST Zip Code Admit Date ReAdm.i.t Date 
ID 83202 
-
08/25/07 14:00 / / : 
Soc.Sec.1t edicaid 1/ Payor Care 
Date: 08/31/07 
Time: 10 = 53: 15 
Insert 
Photo 
Return Date 
: / / : 
Level 
MEDICARE A Skilled 
PLACE OF BIRTH: PRIOR STAY 
RELIGION OTHER INSURANCE 
OCCUPATION POLICY ft 
ADMIT FROM: AUTHORIZATION It 
PMC 
QUALIFYING STAY MCR PART D 
08/21/2007 - 08/25/2007 
Phone Address City St. Zip_ 
Attending Physician (208)282-4700 465 Memorial Dr Pocatello ID 83201 
JONES, DANIEL F(208) 282-4696 
~ternate Physician 
Hospital 
. 
Funeral Hom.e 
Dentist / 
Pha:rm.acy 
Ambulance 
Prim.ary Contact 
Barbara Larson 
Friend H(208) 232-5320 
Financial Contact 
Judy Nield 260 ADAMS STREET Chubbuck ID 83202 
Self H(208) 237-4079 
Contact 
~dmitting Diagnosis 
682.6 - CELLULITIS OF LEG *** 835.00 - DISLOCAT HIP NOS-CLOSED *** 719.7 -
DIFFICULTY IN WALKING *** 250.00 - DIABETES MELLITUS WITHOUT MENTION OF 
COMPLICATION, *** 244.9 - HYPOTHYROIDISM NOS *** V57.1 - PHYSICAL THERAPY NEC *** 
VS7.21 - ENCNTR OCCUPATNAL THRPY *** 
Allergies ." EXHIBIT 81 
NKDA '9 !3 
6 C, ~ 
PDP Carrier: I w 
a. 
PDP Plan: 
Building: Memorial Floor:Floor 1 Hall:Hall A Room: Room 01 Bed: Room 01a 
596 
: 
/ 
POCATELLO CARE & dAB Page: 28 
Resident Diagnosis Listing Date: 12127/2007 Time: 09:30:27 
~~a~m~e~:~J_U_D_Y __ N_IE_LD ______________ ~R~M~/~B_E~D __ I __ ~A~D~M~#_1~~ ______ M~.~R~.#~22_3_5_38 ____ ~) 
ICD9: 682.6 Type: Admission Date: 08/25/2007 PIS Primary 
Description: CELLULITIS OF LEG 
ICD9: 835.00 Type: Admission Date: 08/25/2007 PIS Secondary 
Description: DISLOCAT HIP NOS-CLOSED 
ICD9:719.7 Type: Admission Date: 08/25/2007 PIS 
Description: DIFFICUL TV IN WALKING 
ICD9: 250.00 Type: Admission Date: 08/25/2007 PIS 
Description: DIABETES MELLITUS WITHOUT MENTION OF 
COMPLICATION, 
ICD9: 244.9 Type: Admission Date: 08/2512007 PIS 
Description: HYPOTHYROIDISM NOS 
ICD9: V57.1 Type: Admission Date: 08/2512007 PIS 
Description: PHYSICAL THERAPY NEC 
ICD9: V57.21 Type: Admission Date: 08/2512007 PIS 
Description: ENCNTR OCCUPATNAL THRPY 
597 
Resolved: 09/2412007 
Resolved: 09/1212007 
A_",. s<:;'r.F l",~_. _______ _" 
I T: en ~ p \(Q (RegL Ir~:g _) R-llo- SiP ..J1ll...J.1.O... Weis;ht 1<i(p H:igh:: .:L~.!l in 
""At:encin.;:pr.,/sici3nr,otifiedCfaCr.1issicn:{1Yc5 [[No lir.-,e 1400 Ai\A/PM Data: tl~"()7 
;.lIergies (with r=ac~icnl: Mccica,icr,s 
-------------------------------------------Allergies: Focc ___ \'...,l""D .... N..,....L::..-___________________________ _ 
Othar ________________ _ 
Oat: of last c~cst x·ray or P?D: __ , ___ , __ P.esults fer 18: [ I Positive ( I Ne~a:il/e 
Skin Condition: Indicac.; c-eiow all tocy marks such as oCe or recant scars (Surgical am! ether) bruises. 
disc%rations. a~rasions. pressure ulcers cr ar.'1 C;l!es:jGr.a~/e r;-;arkin~s. Ir.cica~e si:e. ce:;th (ir.t. Crtis). color and 
crair.a~e. . 
.... . ,-.. 
R:C;1I1 V.::}' La:: ,C OI7.r.1elits:_ (~ \\tf~Jr . ~ '; ~' ~. ~~ , : ,..~. '~J 
. 1.1 ~ ;' d,sll)u, So~ciar li:atr:-.erits e. Fr~ce~ur;s: 
:Ufl 1 ,. iloU
t 
\\ .: \ )je;.~Je4 5RDD ~e $ to O~!{> Q,,~5 o.,:~.-. l.J. l?,wvC \£:5 ~ }P1)1:: -
'1 . . 11 .\::l.. 3,. 5t--'" <\C-'" J 7 ~ -q ~t.-..,.:;2.0<"'-
Ger.era~kjn Ccncitjcn: [ l Recccr.ed [J Fale [ I Jaur:ciced r I Cya;;ctic ( J Ashen [.(Dry [ I Mcist [ I 
Oily. [-1 Warm f J Cold [ ! Ecema { J Site cfE~er..a . , 
Paraly.sistPar.asis: site: _______________________ --:-______ _ 
Cont.act!1re: site:-:-______________________________ _ 
Con~e:-jtat a:lCmOlieS~. _________________ ___: ____________ _ 
Prcs:hesis: ( I Glasses r I Dentures - Upr:;er { I Dentures - Lower r I Hearin; Aice r I 
Other. _____ ...;..;~_ 
Functional Status 
Trarysf~rs:. -:: a.ble to ti3r.sfer 
r ! Inc~::er.C entty 
{ I 1: perscn assis: 
( ! 2 perscr. assisi 
[.{Total assis! 
':',:nt·ula:icn - a::'/~ 10 ar.:bv(a::: 
[ llnd=p-enCer.tly 
[ I I ;:;.erscn assis. 
( I:;: p~;sc:r. assis: 
{. I ' .... ,en d':'/lc::. _____ . 
( I It'lha;lc:-.air on Iy 
( I \."!r.=-=-lch::irlr-·ror.::.I<: s::.ff (4c~-;=s:-'" ~-'- ~. 
9t~ Y2u!.c!,";,3·pO~/J 
W=!~ht bearing - able to c-:;a. 
[ I Full weight 
r I Par:iaf wei~r.t 
(r(c"01i~wej~ht bearing 
( I Etas.ic has; 
( I 8~d cradle 
( I Shce;:·sr:in 
! I Ha:-.d rells 
[ I Siing 
Tra::icr.: :N'r.i:f:: 
'/'Jh~;; 
[ I Footbcarc 
{ I ;.,ir martr~ss 
( I E;,; crat~ 
r I Tra~€:; 
-------
------
o:~;~· ______________ _ 
598 
R •• d.nts N,meo JI!.~ Nidd 
Admitting Physician: D~ ~'mmtrf1\4f\ 
Attending Physician: -1'.D.LC~ • ...I.~WQ.D_..u.s .. .. " ____ _ 
Primary Diagnosis: 1_)::::U=O=I4i=w::;..'n:....:...· \1...-____ _ 
Secondary Diagnosis: 1.) Q't\.ip ch:l>lpadt'o VI ~ 
®~p PCVO'"' 
Admit to: Skilled I~tl~~f'f. O(·~ 
Certificatio Facility Standing Orders 
I certify that post-hospital skilled nursing services ·2 Step PPD Test 
are required to be given on an inpatient basis are • Pneumovax on admission if indicated 
required because of the above named patient's • Annual influenza vaccine 
need for skilled nursing care on a continuing basis • Follow Bowel and Bladder protocol 
for the condition(s) for which he/she was receiving • Follow Skin protocol 
inpatient hospital services prior to hislher transfer • Follow facility protocol 10 discontinue orders for 
or discharge to the facIY' medication or treatments not used in 60 days. 
l!;D:;a::le;,;.: ~~d!.!.::;..:;M::.: ..:::D.;;..:S::::i:.l!gn:.::a::lu~r.::e.;;;: ~~~$==!!eJ. DentalNision/Podiatry consults PRN 
Rehab Potential: X. Good 
Diet: D\~-b~. 
Allergies: rJ '-OA 
CPR Status: 0 N Ii. I I 
Fair · Poo~ 
Labs: ____ o-; _________ _ 
Oxygen at (i lPM 
Nasal canCa Mask Other 
• Tylenol 325 1-2 tabs every four hours PRN for mild 
post-op chronic pain: moderate or severe pain use 
other pain meds per M.D. 
• May go off premises with Family and/or Staff 
Associated Diagnosis: 
Dressing Changes: Left /..oww- fKft<..ms'!J 
Type of Dressing: ------------.. f.J~fU_iQl~~..u.:::lL.!:-=t:.....J,~....rt::~~-.:=_r_f'.~. 
Treatments: Associated Diagnosis: 
Therapy (please check all applicable therapies) 
~ PT Eval & Tx wt bearing status MW,& i- OT Eval & Tx . 
o ST Eval & Tx 
o Swallow Evaluation 
'rf~ -M.-O'-Si-gn-at-ure-: =:=::~~~~;:::::: 
Date: ------:A.------f-\--- ---
599 PCRCOOQ11 
